

AUTHOR INDEX

VOLUME 37

Abdalla, Salah, 138
 Abe, Shigeru, 228
 Acharya, Gopal, 2418
 Adam, D., 1620
 Adkinson, N. Franklin, Jr., 1463
 Agacifdan, Ali, 1746
 Aggarwal, Sunil K., 818
 Agrawal, Krishna C., 818
 Aguado, J. M., 2490
 Aguirre, Tania, 580
 AIDS Clinical Trials Group
 Virology Committee
 Resistance Working Group, 1095
 Ajiki, Yoko, 1749
 Akahane, Kazumi, 1764
 Akalin, H. E., 1637
 Akalin, H. Erdal, 1831
 Akao, Mitsutaro, 1313
 Akashi, Akira, 287, 1826
 Akova, M., 1637
 Akova, Murat, 1831
 Aksnes, Arne, 2024
 Alam, N. H., 1572
 Alcouloumre, Marcia S., 2628
 Alder, Jeffrey, 864, 1329
 Aldridge, Kenneth E., 1986
 Aliu, Yusuf O., 1050
 Allard, J. P., 2239
 Allegre, Carmen J., 1227
 Allen, S. D., 1696
 Allen, Stanley D., 2716
 Allouch, P., 737
 Alos, Ignacio, 2059
 Alpert, Nathaniel M., 1270, 2144
 Alteri, Enrica, 2087
 Althaus, Irene W., 1127
 Amicosante, Gianfranco, 1324
 Amirault, Pascal, 1790
 Amsterdam, Daniel, 896
 Anaissie, Elias J., 51
 Anderson, Kevin P., 1945
 Andremont, A., 1432
 Andrews, Charla, 178
 Aoki, Hiroyuki, 2173
 Aoki, Yuhko, 2656, 2662
 Appelbaum, P. C., 1649
 Arai, Sumio, 287, 1826
 Arakawa, Yoshichika, 984
 Arduino, Jean-Marie, 1095
 Argenson, Jean Noel, 1214
 Arika, Tadashi, 363, 785
 Arisawa, Mikio, 2656, 2662
 Arison, Byron, 1737
 Aristoff, Paul A., 1127
 Arlet, Guillaume, 2020
 Armstrong, Donald, 398, 2323
 Aronovitz, Gerson H., 159
 Artaza, M. A., 1587
 Arthur, Michel, 78, 1563
 Arts, Eric J., 1305
 Ashdown, Leslie R., 905
 Ashtekar, Dilip R., 183
 Ashton, Sarah H., 393
 Ateshkadi, Arasb, 2650
 Atzori, Chiara, 1492
 Averett, Devon R., 441
 Awan, Aftab R., 2478
 Aymard, M., 2239
 Azad, Raana F., 1945
 Babich, John, 2144
 Babst, Anna F., 1552
 Bachelier, Lee T., 2606
 Back, Arthur F., 1552
 Bader, John P., 754
 Baginski, Rainer, 750
 Bajaksouzian, Saralee, 1799
 Bakken, Johan S., 1171
 Balfour, Henry H., Jr., 357, 835
 Ballet, Jean-Jacques, 889
 Ballow, Charles H., 1065, 1073
 Baltaiyan, Manik, 1614
 Balzarini, J., 332
 Balzarini, Jan, 2540
 Bamberger, David M., 203
 Bando, Kaori, 957
 Baqar, Shahida, 2688
 Baquero, F., 1982
 Baquero, Fernando, 2059, 2427
 Baquero, Maria-Rosario, 2059
 Barbadora, Karen, 1238
 Barbhaiya, R. H., 1180
 Barbour, Alan G., 1115, 1704
 Bargiggia, Stefano, 2212
 Barker, Patrick J., 84
 Barko, Nir, 2483
 Barluzzi, Roberta, 2422
 Barmada, S., 2678
 Barone, Joseph A., 778
 Barrios, Alcira Angelio, 859
 Barrow, William W., 652
 Barry, A. L., 893
 Barry, Arthur L., 14
 Barry, Beatrix, 1599
 Bartizal, Ken F., 39
 Bartlett, John A., 2449
 Bartlett, Marilyn S., 39, 1543, 2166
 Bartos, Linda, 512
 Barza, Michael, 931
 Barzen, Georg, 1367
 Basco, Leonardo K., 924
 Bastone, Elisa B., 914
 Batra, Kumar K., 1025
 Bauchet, J., 633
 Bauer, Friedrich Eckhard, 2153
 Bauer, Gerhard, 115
 Bayer, Arnold S., 546, 2030
 Bazmi, Hengameh Z., 875
 Beam, Thomas R., Jr., 896
 Beauchamp, Denis, 2727
 Beaudouin, Robert, 1264
 Beck, Francis, 1873
 Becker, S. A. W. E., 2638
 Beckett, Laurel A., 1095
 Beijnen, Jos H., 1426
 Bell, Constance A., 2668
 Beller, Jean-Paul, 1873
 Bellido, J. L. Muñoz, 911
 Benchimol, Marlene, 2722
 Bender, Rudolf, 1659
 Bengtsson, Stellan, 2200
 Bennett, Diane, 613
 Bennett, L. Lee, Jr., 1004
 Bennett, Peter M., 153
 Bennett, Sam, 825
 Bennett, W. M., 347
 Benson, Constance A., 1444
 Benson, John M., 1343
 Bentorcha, Fairouze, 2593
 Berger, L. C., 1713
 Bergeron, Michel G., 2727
 Bergeron, Yves, 2727
 Berggren, Terri, 2033
 Berkowitz, Barry A., 393
 Berlitti, F., 2618
 Bernan, Valerie, 1624
 Bernard, E., 921
 Bernard, Edward M., 398, 2323
 Bertasso, A., 559
 Berti, Marisa, 741
 Bertrand, Kevin P., 1624
 Bethell, Richard C., 1473
 Bethune, Linda, 746
 Betriu, Carmen, 1717
 Beumer, Henriette, 885
 Beveridge, Terry J., 715
 Beyer, Jörg, 1367
 Bhatt, Arun D., 183
 Bhattacharya, M. K., 1197
 Bhattacharya, Prabhat Kumar, 2459
 Bhattacharya, S. K., 1197
 Bienen, E. Jay, 1082
 Bierman, Robert H., 778
 Bilello, John A., 115
 Billard, Lynne, 825
 Billhardt, Uta-Maria, 1659
 Binczewski, Brian, 1238
 Bindra, Rani R., 1360
 Birmingham, Mary C., 1065, 1073
 Biron, Karen K., 19
 Bischofberger, Norbert, 2247
 Bistoni, Francesco, 2422
 Björneklett, Arvid, 2443
 Black, Paul L., 71
 Black, Roberta J., 1095
 Blahy, Olga M., 1576
 Blais, Johanne, 1701, 2571
 Blanchet, Françoise, 1790
 Blasi, Elisabetta, 2422
 Blatter, Marianne, 1971
 Blazquez, J., 1982
 Blazquez, Jesus, 2059
 Blom, Jens, 2550
 Blum, Hubert E., 1539
 Bodeau, Amy L., 2710
 Bodey, Gerald P., 51, 2504
 Bodey, G. P., 729
 Bodmer, Thomas, 2054
 Body, Barbara A., 39
 Bogaki, Mayumi, 839
 Bohm, Rudolf, 1370
 Boivin, Guy, 357
 Bolan, Gail A., 1670
 Bold, Guido, 2087
 Bollen, A., 142
 Bombardelli, Ezio, 1492
 Bond, Lynne, 474
 Bongaerts, G. P. A., 2017
 Bonnay, M., 1432
 Bonnem, Eric, 512
 Bonner, Daniel P., 213, 1289
 Bonnesen, Shari Powers, 1614
 Bonnet, M., 1015
 Bordon, Florence, 1247
 Borin, Marie, 1137
 Borin, Marie T., 2650
 Borner, Klaus, 1835
 Borroto-Esoda, Katyna, 1720
 Borsch, Carina M., 128
 Bosso, John A., 1414
 Bostian, Keith A., 377
 Bouchard, Céline, 1373
 Boucher, Charles, 1390
 Boucher, Charles A. B., 1525, 2231
 Boudinot, F. Douglas, 1343
 Boudjema, Karim, 1873
 Boulerice, François, 1305
 Bourget, Philippe, 54
 Bourneix, C., 1432
 Bouvet, Olivier, 464
 Bouza, Emilio, 1200
 Bova, Carol A., 178
 Bowden, Raleigh A., 1360
 Bowdon, Bonnie J., 1004
 Boyce, Steven T., 1890
 Boyd, Malcolm R., 642
 Boyd, Michael R., 754, 1037
 Bradford, Patricia A., 251, 1989, 2578
 Bradley, Suzanne F., 2003
 Brake, W. B., 1713
 Brandicourt, Olivier, 970
 Brasseur, Philippe, 889
 Bray, Patrick G., 1318
 Brazeau, Gayle A., 246
 Breslin, Barbara J., 2407
 Bressolle, Françoise, 464
 Bril-Bazuin, C., 2318
 Brion, N., 737, 2674
 Broccali, Gianpietro, 2212
 Brockmeyer, N. H., 1010
 Broder, Samuel, 810
 Brogard, J. M., 1488
 Brook, I., 1882
 Brook, Itzhak, 997, 1452, 1531
 Brookshire, Kenneth W., 213
 Brouwer, J. T., 595
 Brown, Barbara A., 1850
 Brown, Prince, 613
 Brown, Richard B., 1
 Brown, Sheldon T., 398, 2323
 Bruch, Suzanne, 2449
 Bruggeman, Cathrien A., 218
 Brumfitt, W., 1558
 Bruneton, Jean, 859
 Brunemann, Sherry R., 93
 Bruno, Antonella, 1492
 Bryskier, André, 1560
 Bubp, Jeff, 1137
 Buckheit, Robert W., Jr., 754
 Burger, David M., 1426
 Burstein, Esther, 2483
 Busch, Janice, 775
 Bush, Karen, 851, 1989
 Bussó, Mariano, 1127
 Butler, T., 1572
 Butler, Thomas, 2418
 Buu-Hoi, A., 2159
 Byrnes, Vera W., 947, 1576
 Cacalano, Grace, 667
 Cahill-Feehan, Carol, 1693

Cal, Stanley X., 1869
 Caliendo, Angela M., 1480
 Callahan, Ronald J., 1270
 Callaway, James E., 1614
 Calvat, Sylvie, 281
 Cambau, Emmanuelle, 1247
 Cameron, Janet, 1390
 Cameron, Janet M., 2231
 Cameron, Miriam L., 2449
 Cammack, Nick, 1390, 2231
 Cammarata, Catherine, 1986
 Campbell, D. A., 1180
 Campbell, Lee Ann, 8
 Canfield, Craig, 1417
 Cannon, Deborah L., 875
 Cantin, Line, 1993
 Canton, Rafael, 2059
 Cantoni, Lavinia, 2527
 Carbon, Claude, 1790, 2466
 Carelli, Maria, 2527
 Carey, Patrick M., 2650
 Carias, Lenore L., 610, 1061, 2760
 Garret, G., 1685
 Cars, Otto, 2200
 Carsenti-Etesse, H., 921
 Carter, Stephen G., 144
 Cartwright, Frank D., 1726
 Casadevall, Arturo, 1383
 Casetta, A., 2159
 Cassileth, Peter A., 474
 Cataldo-Caputza, Lucille, 1556
 Cavalieri, Stephen J., 1171
 Cavé, André, 859
 Cekleniak, Natalie, 1624
 Cercenado, E., 1604
 Cercenado, Emilia, 1200
 Cesana, M., 2545
 Cesana, Marina, 2298
 Chachaty, E., 1432
 Chamberland, Suzanne, 1701, 1993, 2571
 Chambers, Henry F., 1144
 Chan, Chor-Bun, 2007
 Chan, C. Y., 1001
 Chan, Marion Man-Ying, 1909
 Chandrasekar, P. H., 1927
 Chapelky, Martha, 775
 Chaplain, C., 737
 Chastre, Jean, 281
 Chavalitszewinkoon, Porntip, 403
 Cheeseman, Sarah H., 178
 Chen, Ming, 2550
 Cheng, A. F. B., 1001
 Cheng, Yung-chi, 1420
 Chichino, Guido, 1492
 Chimata, Minoru, 229
 Chimiri, A., 1497
 Chin, Nai-Xun, 566
 Chio, Li-Chun, 1914
 Chiodini, Rodrick J., 1645
 Chopra, Ian, 153
 Chow, Andrew T., 1468
 Chow, Joseph W., 134, 1187, 2474
 Chow, Yung-Kang, 1480
 Christensen, Søren Brøgger, 2550
 Chu, Chung K., 875
 Chuah, See Kean, 1711
 Chuard, Christian, 625
 Citron, Diane M., 1150
 Clanton, David J., 754
 Clark, Nancye C., 2311
 Clarkson, Allen B., Jr., 1082
 Clavier, Francoise, 970
 Clecner, Bya, 1373
 Cleeland, Roy, 2144
 Clement, Jacob, 864, 1329
 Clemons, Karl V., 1177, 2224
 Clewell, Don B., 134, 2474
 Coates, Jonathan A. V., 1473
 Cochereau-Massin, I., 633
 Coen, Donald M., 19
 Coene, Marie-Claire, 2101
 Coffey, Tracey J., 1938
 Cohen, Louise G., 2187
 Cohen, Michael A., 2563
 Cohen, Myron S., 950
 Cohen, Yves, 692
 Colaizzi, John L., 778
 Cole, Stewart T., 414
 Coleman, Ruth A., 2027
 Colina, F., 2490
 Coll, Ramon, 868
 Collatz, Ekkehard, 1247
 Collins, Linda, 2009
 Collins, Linda A., 598, 1364
 Colturani, F., 2545
 Comodi-Ballanti, M. R., 2618
 Condra, Jon H., 947, 1576
 Conejo, Carmen, 187
 Conly, J. M., 574
 Connally, Michele C., 2247
 Connor, Edward, 532
 Connor, James, 532
 Conway, Anthony J., 2033
 Cook, James A., 393
 Cooke, N. J., 804
 Cooksey, Robert C., 1348, 2311
 Cookson, Barry, 681
 Cooley, Timothy P., 1480
 Cools, Willy, 2101
 Cooper, Brian W., 234
 Cooper, Chester R., Jr., 2407
 Coorenman, M. P., 1506
 Corbett, Anita H., 2599
 Corey, Lawrence, 975
 Correa-Coronas, Rafael, 474
 Correia, John A., 1270, 2144
 Cory, Michael, 2668
 Cosgrove, Yvonne T., 8
 Costa, Yannick, 1896
 Costa-Perira, Rabi, 183
 Costerton, J. W., 2000
 Coudron, Philip E., 1447
 Courvalin, Patrice, 78, 1456, 1563, 1896, 2093, 2119
 Cowser, Lex M., 171
 Cox, H., 1924
 Cozens, Robert, 2087
 Craig, William A., 2650
 Crane, Deborah D., 357
 Crawford, Jack T., 1348
 Cretton, Erika M., 1816
 Crooke, Rosanne M., 1945
 Cruceyra, Antonio, 1717
 Crumpacker, Clyde S., 1095
 Cui, X., 2496
 Cunningham, Francesca E., 1343
 Curfs, Jo H. A. J., 276
 Currens, Michael J., 1037
 Curvale, Georges, 1214
 Cynamon, M. H., 2344
 Daffa, Mamadou, 1536
 Dal Bo, Lorenzo, 2212
 Dale, Glenn E., 1400
 Dal Pizzol, Virginia, 2693
 Dalton, Harry, 2193
 Damiani, Aldo, 106
 Dan, M., 293
 Dandekar, Kishor A., 1160
 D'Aquila, Richard T., 1095, 1480
 Davidson, Ross J., 1154
 Davies, Julian, 2379
 Davis, Michelle, 19
 Day, C. A., 2506
 Day, D. F., 2506
 Dayer, P., 2132
 Dazer, Maureen E., 2563
 de Anta, Teresa Jimenez, 138
 de Aquino Almeida, João Carlos, 2722
 de Beco, Virginie, 281
 Debysier, Zeger, 2540
 des Cespèdes, Gilda, 2593
 Decker, William D., 754
 De Clercq, E., 332
 de Clercq, Erik, 218, 2540
 de Graaff, J., 1184
 de Jonge, Boudewijn L. M., 342
 de la Coussaye, Jean-Emmanuel, 464
 de Lalla, Fausto, 2693
 Delbos, Françoise, 2593
 del C. Ceinos, Maria, 1728
 Delehaney, John, 975
 Dellamonica, P., 921
 Delouis, Christine, 54
 Del Valle, O., 1587
 Demain, Arnold L., 84
 DeMuria, Deborah, 2187
 Denaro, Maurizio, 741
 Denny, William, 403, 991
 De Rosa, Franco, 1679
 Derouin, Francis, 2371
 De Sarro, A., 1497
 De Sarro, G. B., 1497
 Desmyter, Jan, 2540
 De Souza, Wanderley, 580, 2722
 DeStefano, M. S., 2344
 Dever, Lisa L., 1115, 1704
 DeVore, Kimberly M., 1480
 Dhindsa, Harinder S., 2754
 Diasio, Christopher R., 1771
 Diaz, M. Dolores, 1200
 Dieck, Harold A., 1082
 Digranes, Asbjørn, 2024
 Dijkstra, Jan, 2293
 Dionne, Gervais, 130
 DiPiro, Joseph T., 1343, 1463
 Doherty, Catherine, 123
 Doherty, Patrick, 1737
 Domagala, John M., 2563
 Dombret, Marie-Christine, 281
 Donabedian, Susan, 134
 Donabedian, Susan M., 2474
 Donowitz, G. R., 2261
 Donta, I., 308
 Doury, Jean-Claude, 924
 Downey, Kathleen M., 1127
 Downs, Mary Beth, 71
 Drancourt, Michel, 1214
 Dreyer, Geoffrey B., 71
 Driver, Vickie B., 1945
 Drusano, George L., 115, 483
 Drusano, G. L., 2496
 DuBois, J., 574
 Dubois, Jacques, 1373
 Ducharme, Murray P., 2706
 Duchateau, V., 1860
 Dudley, Michael N., 1723, 1756
 Dueweke, Thomas J., 1127
 Dullenkopf, Klaus, 1367
 Dumas, J. C., 1232
 Duncanson, F. P., 1580
 Dunn, David L., 357
 Dunne, W. Michael, Jr., 2522
 Dupeyron, Jean-Pierre, 501
 Dupont, Marie-Ange, 1536
 Duport, Catherine, 962
 Durack, David T., 903
 Durant, J., 921
 Dutko, Frank J., 297
 Dutta, P., 1197
 Duval, Jean, 78, 789, 1896, 2119, 2466
 Dworin, R., 2678
 Dykstra, C. C., 1713
 Dykstra, Christine C., 2668
 Dylewski, Joseph, 1373
 Earnhardt, K. I., 2261
 Echols, Roger, 1670, 2193
 Edelstein, Martha A. C., 908
 Edelstein, Paul H., 908
 Edlund, Charlotta, 1665
 Edmonds, Kay, 1799
 Edmund, Michael, 1238
 Edwards, Barbara A., 2754
 Edwards, David J., 2706
 Edwards, Fitzroy F., 398, 2323
 Edwards, John E., Jr., 546, 2628
 Egan, William, 1420
 Ehrett, Stuart, 1630
 Eledjam, Jean-Jacques, 464
 Eling, Wynand M. C., 276
 Eliopoulos, C. T., 366
 Eliopoulos, George M., 507, 598, 1364, 2009
 Eliopoulos, G. M., 366, 1604
 Elliott, T. B., 1882
 Ellner, Jerrold J., 1799, 1807
 Elsea, Sarah H., 2179
 El Solh, N., 2159
 Emge, Thomas J., 1909
 Emini, Emilio A., 947, 1576
 Emori, Masako, 722
 Engel, Lee S., 1856
 Enoxacin Prophylaxis Study Group, 474
 Entenza, J., 921
 Entenza, José, 1971
 Erice, Alejo, 357, 835
 Erickson, John, 810
 Eron, Joseph J., 1480
 Espinel-Ingroff, Ana, 39
 Esteve, Montserrat, 868
 Etter, L., 2432
 Etter, Laura, 1061
 Fabre, David, 464

Fadat, G., 1955
 Faessler, Alex, 2087
 Fagon, Jean-Yves, 281
 Fairley, Terri A., 2668
 Faleschini, E., 2545
 Falkenstein-Paul, Hildegard, 696
 Fallani, Stefania, 2693
 Fantin, Bruno, 2466
 Farinotti, Robert, 281
 Farmer, Susan W., 453
 Farzadegan, H., 360
 Farzadegan, Homayoon, 429
 Fass, Robert J., 2080, 2348
 Faurisson, F., 633
 Feibusch, Evan L., 106
 Ferencz, Nicholas, 818
 Fernandez, Hervé, 54
 Ferraro, Mary Jane, 598, 1364
 Ferraro, M. J., 366
 Fey, P. D., 2432
 Fich, Karen, 2550
 Fichtl, Richard E., 1504
 Field, Hugh J., 2478
 Fields, Marc T., 203
 Fierer, Joshua, 2293
 Figgitt, David, 403, 991
 Filadoro, Francesco, 1958
 Finegold, S. M., 2638
 Finegold, Sydney M., 2509
 Fischman, Alan J., 1270, 2144
 Fishman, Jay A., 1543
 Flaherty, John, 1137
 Flandrois, J. P., 1685
 Flexner, C., 360
 Flor, Soledad C., 1468
 Fluckiger, Ursula, 1971
 Foca, Alfredo, 393
 Focht, Josef, 2298
 Foleno, Barbara D., 301
 Fong, Dunne, 1909
 Foo, Hsin-Hsin, 2500
 Foor, Forrest, 84
 Ford, Harry, Jr., 810
 Ford, Jeanne, 2193
 Forrest, Alan, 1065, 1073, 2187
 Fothergill, Annette W., 2307
 Fouda, Hassan G., 314
 Fournet, Alain, 859
 Fournier, Genevieve, 2020
 Foweraker, J. E., 804
 Fox, Maureen C., 171
 Foy, Jilanna, 1436
 Frachet, B., 2674
 Fraimow, Henry S., 2736
 Francioli, Patrick, 1971
 Francioli, Patrick B., 207
 Franzblau, Scott G., 1997
 Franzini, P., 2545
 Freifeld, Alison, 495
 French, Pamela, 2736
 Fresnadillo, M. J., 911
 Frey, Carrie, 39
 Frick, Lloyd W., 2285
 Fridland, Arnold, 2247
 Friedland, Ian R., 1630
 Froelich-Ammon, Stacie J., 646
 Fromtling, Robert A., 39
 Frost, R. Wayne, 2106
 Fu, K. P., 301
 Fuchs, P. C., 893
 Fuchs, Peter C., 14
 Fujii, K., 67
 Fujisawa, Chiho, 2173
 Fujita, Y., 1043
 Fukasawa, Masatomo, 2743
 Fukatsu, Hiroshi, 2756
 Fukuoka, Takashi, 322
 Fukuoka, Yoshikazu, 384
 Fukutomi, Yasuo, 2265
 Fulton, David R., 1655
 Fung-Tom, Joan, 213, 1289
 Furfine, Eric S., 2285
 Furman, Phillip A., 1720, 2285
 Furudera, Takenori, 1826
 Furuya, Nobuhiko, 675
 Gadgil, Shrikant D., 314
 Gaffar, Maria C., 778
 Galgiani, John N., 39, 2126, 2517
 Galimand, Marc, 1456, 1896, 2093, 2119
 Gallati, Harald, 2418
 Galtier, Marc, 464
 Gálvez, Antonio, 148
 Gamage, Swarna, 403, 991
 Gambertoglio, John, 1137
 Gangeness, David, 1171
 Gao, Qing, 130, 1390
 Garber, Sena, 2606
 Garcia, I., 2490
 García, Isabel, 187
 Garcia, Jesus, 868
 Garcia, M. M., 2638
 García-Rodríguez, J. A., 911
 Gardner, Mark J., 314
 Gargallo-Viola, Domingo, 868
 Garneau, Valérie, 1701
 Garon, Claude F., 46
 Gaspar, Erzsebet, 2593
 Gasser, I., 1587
 Gastañares, Maria-Jose, 2427
 Gatti, Giorgio, 1137
 Gaudébaut, Claude, 970
 Gaudreau, Christiane, 1174
 Geggel, Robert L., 1655
 Gehanno, Pierre, 1599
 Geisel, Janet, 393
 Gelezinius, Romas, 1305
 Gelfusa, Vincenzo, 1190
 George, Robert C., 681
 George, William J., 818
 Georgii, Aletta, 2064
 Georgopapadakou, N. H., 559, 2045
 Gerard, Geoffrey C., 1334
 Gerbaud, Guy, 1456, 2093
 Gerlach, E. H., 1696
 Gerok, Wolfgang, 1539
 Ghaleh, Bijan, 1777
 Ghannoun, Mahmoud A., 546, 2628
 Ghezzi, Maria Cristina, 1958
 Ghezzi, Pietro, 2527
 Ghione, Mario, 1492
 Ghosh, Dilip Kumar, 2459
 Giannarelli, Helen, 308
 Gibert, Claude, 281
 Gikas, Achilleas, 51
 Gilbert, James, 32
 Gilbert, D., 2678
 Gilbert, Deborah, 1723
 Gilbert, Deborah H., 1756
 Gilbert, D. N., 347
 Gilja, Odd Helge, 2024
 Gillespie, S. H., 2493
 Gilliland, Susan S., 436, 1377
 Gillum, J. Gregory, 2193
 Gilman, Thomas M., 93
 Gilmore, James D., 1452
 Giroux, M., 1232
 Glauser, Michel P., 207, 1971
 Gleaves, Curt A., 1360
 Goering, R. V., 2432
 Goetz, Matthew B., 1334
 Goh, Khye Seng, 652, 1560
 Gohara, Yukiko, 287, 1826
 Gold, H. S., 1604
 Goldman, Hy, 1305
 Goldman, Mark E., 947
 Goldstein, Beth P., 741
 Goldstein, Ellie J. C., 1150
 Goldstein, Neil H., 297
 Gollapudi, Sastry V., 1711
 Golub, Lorne M., 592
 Gomez, Maria, 1717
 Gomez, R., 2490
 Gómez-Jiménez, J., 1587
 Gomez-Lus, Rafael, 138
 Gonçalves, Noémia Rodrigues, 2722
 Gong, Yi-Fei, 2247
 Gooch, W. Manford, III, 159
 Gooding, Beth Briggs, 349
 Goody, Roger, 2612
 Goos, M., 1010
 Gootz, Thomas D., 646, 2179
 Gordillo, Manuel E., 1203
 Gorrens, Jos, 2101
 Gorzynski, Eugene A., 896
 Goss, Thomas F., 1073
 Gotlib, Leah, 1576
 Goto, Sachiko, 60
 Govan, John, 123
 Grady, Robert W., 1082
 Graham, Donald J., 1576
 Grasso, S., 1497
 Green, Michael, 1238
 Grewal, Jaswinder, 2645
 Griffith, Jeffrey K., 1253
 Griggs, D. J., 662
 Grill, Susan, 1420
 Grootenhuis, Jessie R., 1655
 Grosset, Jacques, 407, 692, 1690
 Gu, Ligang, 2265
 Gu, Zhengxian, 130, 1390
 Guay, David R. P., 436
 Guay, Gordon G., 191
 Gueret, Dominique, 970
 Guerillot, F., 1685
 Guerra, Isabel, 148
 Guerry, Philippe, 2599
 Guinea, Jesus, 868
 Gulakowski, Robert J., 754
 Gulnik, Sergei, 810
 Gunther, Michael R., 950
 Gupta, Pramod, 864, 1329
 Gupta, Rachna, 882
 Gur, D., 1637
 Gür, Deniz, 1831
 Gutmann, L., 1406
 Gutmann, Laurent, 1247, 1387
 Haag, Jo Jean, 1670
 Hackbarth, Corinne J., 1144
 Hakusui, Hideo, 2173
 Halinen, Sirkka, 592
 Hall, Geraldine, 39
 Hall, J. E., 1713
 Hall, Joseph, 592
 Hall, L. M. C., 1637
 Hall, M. C., 662
 Halstensen, Alfred, 2024
 Halushka, Perry V., 393
 Hamer, Davidson H., 931
 Hamilton, H., 1620
 Hamilton, Robert G., 1463
 Hamilton-Miller, J. M. T., 1558
 Hamzeh, Faye M., 602
 Hancock, Robert E. W., 453
 Hand, Debra L., 2557
 Hand, W. Lee, 2557
 Hansen, Lori M., 2699
 Hansen, Sharon L., 1334
 Hanson, Linda H., 1177, 2224
 Hanssen, Brenda R., 265
 Hara, Kohei, 2762
 Hardie, J. M., 2493
 Harding, G. K. M., 574
 Hare, Roberta S., 2074
 Hare, R. S., 708
 Hariprashad, June, 1504
 Harrington, Joan A., 918
 Harrison, Barbara, 1444
 Harvey, Kevin, 2193
 Harvey, Tracey, 1711
 Hase, Toyoji, 363
 Hasegawa, Takaaki, 1781
 Hasegawa, Takashi, 2217
 Haselbeck, Bob, 1614
 Hashimoto, Nobuo, 901
 Hashizume, Terutaka, 2756
 Hattori, Hiroaki, 839
 Hattox, Susan E., 178
 Häusler, Alex, 84
 Havenith, Mick, 218
 Hawkey, P. M., 804
 Hayakawa, Isao, 2112
 Hayashi, Hideya, 810
 Hayashi, Ryogo, 100
 Hayden, Frederick G., 297
 Hayes, Michael M., 2500
 Hayman, Alan C., 246
 Hayran, Murat, 1831
 Healy, Niamh, 1473
 Heifets, Leonid, 111, 1380, 2364
 Heijink, R. A., 595
 Heikkilä, Elina, 1297
 Heisig, Peter, 696
 Heller, Allen H., 2193
 Hemming, Val G., 1655
 Hendrix, Craig W., 429
 Hengels, K. J., 1506
 Hengge, U. R., 1010
 Henry, N. K., 554
 Herndon, Betty L., 203
 Herrero, J. A., 2490
 Hesse, Werner H., 2622
 Heudes, Didier, 1790
 Hewitt, Ross G., 512
 Heykants, Jos, 2224
 Hickey, Sheila, 1630
 Hidaka, T., 67
 Hidaka, Takayoshi, 722
 Hikida, Muneo, 199
 Hill, Bertha C., 2311

Hill, Craig L., 1707
 Hill, Edgar, 975
 Hill, James M., 1856
 Hille, Heidemarie, 2153
 Hilligoss, Donald M., 314
 Hintermann, Gilberto, 84
 Hiraga, Y., 1043
 Hirakata, Yoichi, 675
 Hiramatsu, Keiichi, 1219, 2278
 Hirata, Michimasa, 2534
 Hirata, Takahiro, 2656
 Hirsch, Martin S., 1480
 Hirsh, Dwight C., 2699
 Hiscott, John, 130
 Hiscox, Steven A., 1473
 Hitchcock, C. A., 1962
 Hitchcock, Michael J. M., 1816
 Hizi, Amnon, 1037
 Hjelm, Ulrika, 1285
 Ho, Chi-Tang, 1909
 Ho, Dah Hsi, 2504
 Ho, May, 2418
 Hoban, Daryl J., 1154
 Hobden, Jeffery A., 1856
 Hocquemiller, Reynald, 859
 Hoepelman, Andy I. M., 885
 Hoffman, Jacob M., 947
 Hoffner, Sven E., 1285
 Høyby, E. Arne, 2024
 Holder, Ian A., 1890
 Holy, A., 332
 Holy, Antonin, 2540
 Honore, Nadine, 414
 Hoogkamer, Johannes F. W., 2622
 Hoogkamp-Korstanje, J. A. A., 2017
 Hook, Edward W., III, 1670
 Hooper, David C., 2588
 Hoosen, Anwar A., 2733
 Hopkins, Sam, 1720
 Horaud, Thea, 2593
 Hori, Satoshi, 2278
 Horii, Toshinobu, 984
 Horiuchi, Sankichi, 2486
 Hoshino, Kazuki, 2112
 Hostetler, John S., 2224
 Houck, Herbert J., 613
 Hougen, Thomas, 1655
 Howell, John M., 2754
 Howells, R. E., 2337
 Howells, Robert E., 1318
 Huang, Hua-Bin, 566
 Huang, Jun-Li, 1370
 Huang, Wai Mun, 457
 Huart, Alain, 1777
 Huband, Michael D., 2563
 Hughes, George S., 2650
 Hughes, Stephen H., 1037
 Hughes, Walter T., 1417
 Huhn, Dieter, 1367
 Huls, Christine E., 1414
 Huovinen, Pentti, 1158, 1297
 Husson, M., 1860
 Ibrahim, Ashraf S., 546, 2628
 Ichiyama, Satoshi, 984
 Iijima, Masako, 322
 Izawa, Yuji, 100
 Ikeda, Yasushi, 384
 Ilksoy, Nurcan, 875
 Imada, Akira, 100
 Imagawa, Yatsuka, 2486
 Imbimbo, B. P., 2545
 Imbimbo, Bruno P., 637, 2212
 Imboden, Paul, 2054
 Imhoff, Tracy, 2030
 Immendoerfer, Ulrike, 2612
 Imtiaz, Uzma, 2438
 Inagaki, Yoshio, 2486
 Inamatsu, T., 1043
 Inciardi, John F., 1025
 Ingman, Tuula, 592
 Inomata, Norikazu, 199
 Inoue, Eiko, 1547
 Inukai, Masatoshi, 980
 Ioannides-Demos, Lisa L., 914
 Irvin, James D., 835
 Isaacs, David M., 301
 Ishida, Hiroko, 2112
 Ishida, Mariko, 2327
 Islam, A., 1572
 Isono, Fujio, 980
 Israel, Debra, 2139, 2193
 Ito, Hideaki, 839
 Itoh, Tomoo, 2327
 Iwagaki, Akitaka, 164
 Iwahashi, Tomoyuki, 100, 769
 Iwasaki, Shigeo, 1313
 Iwatani, Wakao, 785
 Jackson, M. Keven, 2716
 Jackson, W. E., 1882
 Jacobberger, Bernadette, 1873
 Jacobs, Michael R., 1799, 1807
 Jacobs, M. R., 1649
 Jacobs, William R., Jr., 1348
 Jacobus, David P., 1417
 Jacobus, Nilda V., 2270
 Jacoby, George A., 2760
 Jansen, Robert W., 441
 Janssen, David A., 2003
 Jantos, Christian, 846
 Japour, Anthony J., 1095
 Järvinen, Heliä, 1158
 Jarvis, Ken, 1329
 Jarvis, Kenneth, 864
 Jayanetra, P., 2000
 Jeanfavre, Deborah Durham, 1693
 Jefson, Martin R., 646
 Jehl, F., 1488
 Jehl, Francois, 501
 Ji, Baohong, 407
 Jin, Y. F., 662
 Jindrich, J., 332
 Jindrich, Jindrich, 2540
 John, Joseph F., 1334
 Johnson, C. C., 2069
 Johnson, Curtis A., 2650
 Johnson, David E., 483
 Johnson, Elma, 1264
 Johnson, E. M., 1962
 Johnson, James R., 2033
 Johnson, Lance C., 441
 Johnson, Victoria A., 1095
 Jones, R. N., 1696
 Jones, Robert B., 1670
 Jones, Ronald N., 349, 2747
 Jones, S. K., 1713
 Jorgensen, James H., 1115, 1704
 Kaatz, Glenn W., 128, 1086
 Kabir, I., 1572
 Kadurugamuwa, Jagath L., 715
 Kageyama, Seiji, 810
 Kaiser, Allen B., 702
 Kaku, Mitsuo, 2762
 Kakuta, Sachiko, 229
 Källenius, Gunilla, 1285
 Kalvakuntla, Laxman, 729
 Kam, Kai-Man, 2007
 Kanichonwongpaisan, Sumalee, 1108
 Kamide, Ryōichi, 2217
 Kamiyama, Tsutomu, 2656
 Kamwan, Chantana, 2407
 Kaplan, Edward L., 159
 Kaplan, Joan C., 1480
 Kaplan, Sheldon L., 2401, 2522
 Kar, Kalipada, 2459
 Kar, Sujata, 2459
 Karayiannakos, P., 308
 Karlovsky, James A., 1154
 Karp, Judith E., 1847
 Kato, Haru, 957
 Kato, Katsuyoshi, 1781
 Kato, Michiyuki, 1764
 Kato, Naoki, 957
 Kato, Nobuo, 984, 1781
 Katsuta, Mitsuo, 322
 Kauffman, Carol A., 2003
 Kaufhold, Achim, 2740
 Kaul, Sanjeev, 1160, 1816
 Kawada, Harumi, 1749
 Kazanjian, Powel H., 2187
 Keirns, James J., 178
 Kellam, Paul, 1525
 Kenny, George E., 1726
 Kernodle, Douglas S., 702
 Kessler, Joseph A., 144
 Keusch, Gérard, 1056
 Keyhani, Afsaneh, 246, 2584
 Kharazmi, Arsalan, 2550
 Khordori, Nancy, 729, 882
 Kharasany, Ayesha B. M., 2733
 Kibbler, C. C., 2493
 Kidd, Lauren B., 1816
 Kiehn, Timothy E., 2323
 Kierszenbaum, Felipe, 2235
 Killmar, John, 1417
 Kimura, Masashi, 801
 Kimura, Sadao, 2228
 King, Anna, 746
 Kinowski, Jean-Marie, 464
 Kinsman, Oonagh S., 1243
 Kinzig, M., 1860
 Kishimoto, Toshio, 801
 Kishore, Alugupalli R., 240
 Kiso, Yoshiaki, 810
 Kitzis, Marie-Dominique, 1387
 Kleim, Jörg-Peter, 1659
 Klemens, S. P., 2344
 Kleter, G. E. M., 595
 Klietmann, Wolfgang, 2298
 Klimkait, Thomas, 2087
 Klimm, K., 366
 Klopman, Gilles, 1799, 1807
 Klugman, Keith P., 1938
 Knapp, C. C., 1696
 Knapp, Joan S., 1552
 Kobayashi, Teruaki, 2042
 Koehler, Joy M., 905
 Koenig, Bernhard, 2612
 Koeppe, Peter, 1835, 2153
 Kofel, Jean-Claude, 1873
 Koga, Hironobu, 1877, 2762
 Koga, Tetsufumi, 1749
 Koh, Julia G., 778
 Kohlhepp, S., 2678
 Kohlhepp, S. J., 347
 Kohnen, P. W., 347
 Kohno, Shigeru, 1877, 2762
 Kojima, Tsuyoshi, 839
 Koks, Cornelis H. W., 1426
 Kolek, Benjamin, 213, 1289
 Kolenda, Herbert, 1518
 Kondoh, Masumi, 2662
 Kontinen, Yrjö T., 592
 Kopp, U., 224
 Koranyi, Katalin I., 314
 Kort, Jens J., 115
 Kortting, Hans C., 2064
 Kotani, Hitoshi, 2500
 Kotnik, V., 1786
 Koup, Richard A., 178
 Kovacs, Joseph A., 1227, 1674
 Krahenbuhl, James L., 2265
 Krausgrill, P., 1506
 Kreeger, John M., 1645
 Krinke, Alison J., 2454
 Kristensen, Gun, 1665
 Kruse, James A., 1927
 Krusell, Allan R., 1132
 Kubat, Tina, 1171
 Kuebelbeck, Virginia, 835
 Kumar, Ashir, 159
 Kuo, Cho-Chou, 8
 Kurata, Tadashi, 2173
 Kuritzkes, Daniel R., 1095
 Kurtzberg, Joanne, 144
 Kusne, Shimon, 1238
 Kuwahara-Arai, Kyoko, 1219
 Kuwano, Koichi, 287, 1826
 Kuypers, Frans, 1108
 Labia, Roger, 939, 962
 LaBombardi, Vincent J., 1556
 Lachance, Nathalie, 1174
 Lacroix, Jean-Michel, 2037
 Ladizensky, Esther, 2483
 Lafredo, Stephen C., 301
 Lagrange, Philippe H., 2020
 Lahiri, M., 1197
 Lai, Cham-Fai, 2007
 Lai, Jiunu, 1614
 Laizure, S. Casey, 448
 Lalande, Valerie, 407
 Lam, Joseph S., 715
 Lam, K., 2000
 Lam, Patrick Y.-S., 2606
 Lambert, C., 1860
 Lambert, Dennis M., 71
 Lambert, Thierry, 1456, 2093
 Lamer, Christian, 281
 Lamothé, François, 1174
 Lamp, Kenneth C., 605, 1931
 Landman, David, 1904
 Lane, James, 532, 1095, 1127
 Laneelle, Gilbert, 1536
 Lang, Marc, 2087
 Lang, R., 2333
 Lange, Joep M. A., 1525
 Lantero, Marta, 2427

Larder, Brendan A., 1525
 Larrick, James W., 2534
 Larsson, Alison J., 1377
 Last-Barney, Kathleen, 1693
 Lastilla, Marco Gregorio, 1679
 Lavoie, Suzanne R., 1447
 Lawlor, Michael T., 234
 Lawrence, A. Jean, 1869
 Lawrence, Theresa, 896
 Lawrence, William D., 512
 Lazar, Thierry, 692, 1690
 Lazardi, Keyla, 580
 Lazdins, Janis, 2087
 Lazzaroni, Marco, 2212
 LeBlanc, Barbara, 2504
 Le Bras, J., 1955
 Le Bras, Jacques, 924, 970
 Lebsack, M. E., 775
 Leclercq, Roland, 78, 789,
 1896, 2119, 2466
 Lee, Hsi-Ming, 592
 Lee, K., 2638
 Lee, Ving J., 851, 2270
 Lee, Yun-Sang, 2007
 Leemann, T., 2132
 Leggett, J., 2678
 Le Gros, V., 737, 2674
 Lei, Shau-Ping, 1614
 Leibowitch, Jacques, 2206
 Le Jeune, Ludo, 2101
 Lemeteil, Denis, 889
 Lemmich, Else, 2550
 Lentino, Joseph R., 339
 Lépine, Guyalaine, 2037
 Lepoche, H., 1410
 Lerner, Stephen A., 2438
 Lertora, Juan J. L., 818
 Leser, Ulrike, 2612
 Leske, Valeria L., 835
 Lettieri, John T., 2106
 Levin, James M., 1444
 Levison, M. E., 2069
 Levitsky, Sidney, 2106
 Levy, Stuart B., 825, 2699
 Lew, Daniel P., 625
 Lew, D. P., 2132
 Lewin, Clement, 123
 Lewis, Mark G., 71
 Li, Cong, 2030
 Li, M. S. K., 1001
 Li, Ronald C., 371, 523
 Li, Shu C., 914
 Liebman, Howard A., 1480
 Lietman, Paul S., 429, 602
 Lim, Seung T., 1264
 Lima, Viera, 1108
 Lindley, Ivan J. D., 276
 Lindquist, S., 224
 Lindstrom, Terry D., 265
 Lindy, Otso, 592
 Lins, Ulysses, 2722
 Liotta, Dennis C., 875, 1720,
 2206, 2285
 Lipke, Peter N., 1264
 Littlejohn, Tim G., 761
 Liu, Tiepu, 1771
 Liu, Yu-Ying, 2144
 Livermore, David G., 1243
 Livermore, D. M., 1637
 Livni, E., 1270, 2144
 Livornese, L. L., 2069
 Lizasoain, M., 2490
 Lloyd, Robert M., Jr., 875
 Lo, Kuen-Kong, 2007
 Lo, Shyh-Ching, 2500
 Lockwood, Graham, 297
 LoCoco, John M., 301
 Lode, Hartmut, 1835
 Lombardi, F., 2545
 Loncle, V., 2159
 Long, William J., 1576
 Lonks, John R., 1742
 Lopardo, Horacio A., 1728
 Lopez-Berestein, Gabriel, 246
 Lorschneider, Fritz L., 825
 Lortholary, Olivier, 1790
 Louchahi, K., 737, 2674
 Louis, F. J., 1955
 Louis, J.-P., 1955
 Löwdin, Elisabeth, 2200
 Lu, Zhihong, 1771
 Lumbrieras, C., 2490
 Lupia, Raul H., 818
 Lüthy, Ruedi, 1056
 Maass, Gerhard, 2612
 Macalintal, Clarissa, 851
 Maderazo, Eufonio G., 1132
 Maeda, Akio, 1313
 Maeland, Arild, 2443
 Magallanes, Marcus, 2293
 Magnuson, Terry, 1610
 Mahr, Gerhard, 1518
 Majorus, P., 142
 Majumder, Sarmila, 2235
 Malanowski, Gregory J., 598,
 2009
 Maldonado, Rosa A., 1353
 Maldonado, Rosa Amelia, 580
 Malessa, R., 1010
 Maliszewski, Maureen L., 512
 Mallet, D., 1410
 Mallie, Jean-Pierre, 1510
 Mamber, Stephen W., 213
 Mamman, Mohammed, 1050
 Manavathu, Elias K., 2438,
 2645
 Mancini, Carlo, 1958
 Mann, Paul A., 2074
 Mansat, V., 1232
 Mant, Tim G. K., 637
 Mao, Jinghe, 950
 Maqueda, Mercedes, 148
 Maraki, Sofia, 51
 Marceau-Day, M. L., 2506
 Marchan, Edgar, 580
 Marchbanks, C. Randall,
 1723, 1756
 Marchesi, Francine, 2054
 Marco, Francesc, 138
 Marcos, Angeles, 138
 Margolick, Joseph B., 429
 Marichal, Patrick, 2101
 Mariotte, Sophie, 939
 Markham, Richard B., 429
 Markowitz, Sheldon M., 1447
 Marler, J. K., 1122
 Marlin, Steven D., 1693
 Marrakchi-Benjaafar, S., 633
 Marshall, Bonnie, 825
 Marshall, Steven A., 2747
 Marshall, Steven H., 2760
 Martel, A. Y., 574
 Martin, Andrea, 1278
 Martin, David H., 1670, 1986
 Martin, J. Louise, 1720
 Martin, Stephan, 1278
 Martinez, Anthony, 1674
 Martinez, J. L., 1982
 Martínez-Bueno, M., 148
 Martínez-Vázquez, J. M.,
 1587
 Martino, Piero, 1190
 Marutani, Kiyoshi, 2217
 Marx, Gerald R., 1655
 Marzella, Louis, 120
 Mason, Edward O., Jr., 2401,
 2522
 Massidda, Orietta, 1324
 Masuda, Nobuhisa, 322
 Masukawa, Yoshikazu, 199
 Matera, Giovanni, 393
 Materman, E., 1620
 Mathez, Dominique, 2206
 Matsubara, Shuzo, 1826, 2217
 Matsuda, Kouji, 2756
 Matsumoto, Fumio, 2217
 Matsumoto, Keizo, 164
 Matsumoto, Masahiko, 2217
 Mattie, H., 2318
 Matsumoto, Masahiko, 1826
 Mauël, Jacques, 991
 Maurin, M., 1410, 2633
 Maxwell, Anthony, 126
 Mayers, Douglas L., 1095,
 1127
 Mayhall, C. Glen, 1334
 Mazzolla, Rosanna, 2422
 McClure, Harold M., 1816
 McCracken, George H., Jr.,
 1630
 McEntee, M. F., 360
 McGahren, Jim, 1624
 McGlynn, Marion, 1624
 McGrath, Betty J., 1723, 1931
 McGuirk, Paul R., 646, 2179
 McKiel, Joan R., 1756
 McKoy, Judith, 1264
 McLaughlin, Margaret M.,
 178
 McLean, Allan J., 914
 McLinn, Samuel E., 159
 McMahon, James B., 754,
 1037
 McMillan, Angela, 875
 McMurry, Laura M., 2699
 McNally, Eugene J., 1693
 McNamara, Patrick J., 2706
 McQueen, Teresa J., 2584
 McWhinney, P. H. M., 2493
 Mechliński, Witold, 778
 Medeiros, Antone A., 1742
 Meenhorst, Pieter L., 1426
 Mehl, Paul, 2470
 Mehta, Reeta T., 2584
 Meichsner, Christoph, 1659
 Meissner, H. Cody, 1655
 Mellors, John W., 875
 Menard, Robert, 78
 Menck, Sylvia, 1518
 Menninger, John R., 2027
 Merluzzi, Vincent J., 1693
 Merz, William G., 1847, 2407
 Meservey, Mark A., 2563
 Meshnick, Steven R., 1108
 Meyer, A. P., 2318
 Michel-Briand, Yvon, 962
 Mierzwia, Ronald, 2074
 Mikami, Yuzuru, 1313
 Miksits, Klaus, 1367
 Milatovic, D., 1620
 Miller, Carole B., 1847
 Miller, George H., 2074
 Miller, G. H., 708
 Miller, Jeffry, 2139
 Millet, V., 2239
 Milocchi, Fabio, 2693
 Mimoto, Tsutomu, 810
 Minamimura, Masashi, 1547
 Mirabelli, Christopher K., 171
 Mitra, U., 1197
 Mitsuhashi, Susumu, 793,
 1547
 Mitsutake, Kotaro, 2762
 Mitsuya, Hiroaki, 810
 Mitten, Michael, 1329
 Mitten, Mike, 864
 Miyasaki, Kenneth T., 2710
 Miyazaki, Haruko M., 2762
 Miyazaki, Shuichi, 60
 Miyazaki, Yoshitsugu, 2762
 Miyoshi, Akio, 2217
 Mobarakai, Neville K., 1904
 Mobashery, Shahriar, 2438
 Mochizuki, Hidenori, 2412
 Moellering, R. C., Jr., 366,
 1604
 Moellering, Robert C., Jr.,
 507, 598, 1364, 2009
 Mogilevsky, N., 142
 Moland, Ellen S., 260
 Molina, Judith, 1353
 Molinas, Catherine, 78
 Molitoris, Eric, 2509
 Moloo, Shamshudeen K.,
 1163
 Moncada, Jeanne, 1746
 Mondain, V., 921
 Monteil, H., 1488
 Monteil, Henri, 501
 Montgomerie, John Z., 1334
 Moody, Julia A., 2454
 Moore, Carol, 1264
 Mor, Natan, 111, 1380, 2364
 Moreno, E., 2490
 Morgan, U. M., 328
 Morikawa, Keiko, 270, 2684
 Morikawa, Shigeru, 270, 2684
 Morisaki, Naoko, 1313
 Morris, Anne B., 1
 Morrison, Donald, 681
 Morrison, Paul J., 637
 Morrison, Susan, 532
 Morse, Gene D., 512
 Moskowitz, Bruce L., 778
 Mourton, Tracy, 1610
 Moynihan, Melinda, 2179
 Mroczkowski, Tomasz F.,
 1670
 Mueller, Barbara, 2612
 Muffat-Joly, Martine, 1599
 Müller, Hans-Jochen, 1835
 Mulligan, Maury E., 1334
 Mumaw, Nancy, 89
 Munayyer, H., 708
 Muñoz, Patricia, 1200
 Muñoz, Victoria, 859
 Murakami, Kimihiro, 2412
 Murakawa, Yohko, 810
 Murphy, Noel B., 1163, 1167
 Murray, Barbara E., 1203,
 1966

Murray, Gilles, 1373
 Murray, Henry W., 1504
 Murray, P. R., 1696
 Muth, Peter, 1518
 Muthiani, Anthony M., 1167
 Myers, Dorothea E., 835
 Myers, Roy A. M., 120
 Mylvaganam, Haima, 2024

Naas, Thierry, 939, 962
 Nabeshima, Toshitaka, 1781
 Nadai, Masayuki, 1781
 Nadelmann, Lynda, 2550
 Naesens, L., 332
 Nagamuta, Masahiro, 2217
 Nagano, Hiroyuki, 2217
 Nagase, Mitsumasa, 229
 Nagata, Kumiko, 769
 Nagatake, Tsuyoshi, 164
 Nagrajan, K., 183
 Nahata, Milap C., 314
 Naidu, A. Satyanarayan, 240
 Naidu, Smita S., 240
 Naiman, N. A., 1713
 Naiman, Noreen A., 2668
 Nakada, Naoki, 2656
 Nakae, Taji, 2385
 Nakagawa, Susumu, 2756
 Nakamura, Mika, 839
 Nakamura, Shinichi, 839
 Nakamura, Yumiko, 2662
 Nakano, Shigeyuki, 2042
 Nakaya, Rintaro, 2486
 Nakayama, Noboru, 2662
 Namavar, F., 1184
 Narayan, O., 360
 Narayanan, Ven L., 754
 Narita, Hirokazu, 384
 Narita, Teruo, 322
 Nash, Donald R., 1850
 Nasr, Mohamed, 2166
 Nateghpour, M., 2337
 Nau, Roland, 1518
 Ndifor, Anthony M., 1318
 Ndoutamia, Guelmbye, 1163
 Nelson, Donald J., 2285
 Nelson, Jeffrey A., 1444
 Nelson, Kenrad E., 2407
 Nerhood, Lynda, 429
 Nervetti, G., 2545
 Neu, Harold C., 566
 Neumann, Theresa, 2244
 Neumann, Theresa M., 1670
 Neyfakh, Alexander A., 128
 Ng, Eva Y., 2588
 Ngoma, Michel, 901
 Ngu, Jacob L., 1318
 Nguyen, Hieu, 729
 Nguyen, Minh-Hong, 875
 Nicastri, Emanuele, 1190
 Nicastro, G., 2545
 Nicolas, Marie-Helene, 939
 Nicolas, M. H., 1406
 Nicolle, L. E., 574
 Nightingale, Charles H., 234
 Nightingale, Stephen D., 1869
 Niikido, Hiroshi, 322, 1393
 Niki, Yoshihito, 801
 Nimmo, G., 1924
 Nishikawa, Sae, 2042
 Nishikawa, T., 1043
 Nishiki, Katsuyuki, 199
 Nishimoto, Mitsunobu, 287

Niu, Wei Wei, 667
 Nix, David E., 371, 523, 775, 1065, 1073
 Nochy, Dominique, 1790
 Nolte, Frederick B., 39
 Nomizu, Motoyoshi, 810
 Noordergraaf, J. H., 317
 Nord, Carl Erik, 1665
 Norden, C. W., 1580
 Nordlander, E., 1977
 Nordmann, P., 1406
 Nordmann, Patrice, 939, 962
 Noriega, A. R., 2490
 Norman, Allyn, 775
 Normark, S., 224
 Norwegian Yeast Study Group, 2443
 Noskin, Gary A., 2470
 Novelli, Andrea, 2693

Öberg, Bo, 1370
 O'Brien, Julie A., 947
 O'Callaghan, Richard J., 1856
 Odds, Frank C., 39, 685
 Odenholt-Tornqvist, Inga, 2200
 Offensperger, Silke, 1539
 Offensperger, Wolf-Bernhard, 1539
 Ogawa, Nobuya, 2042
 Oguma, T., 1043
 Ohashi, Masayuki, 2412
 Ohdo, Shigehiro, 2042
 Ohmichi, M., 1043
 Ohno, Akira, 675
 Ohshima, Yumi, 2173
 Ohshita, Yoshihiro, 2278
 Ohta, Michio, 984
 Ohya, Satoshi, 322
 Oishi, Kazunori, 164
 Oizumi, Kotaro, 287
 Okamoto, Osamu, 2756
 Okamura, Noboru, 2486
 Okazaki, Osamu, 2173
 Okonogi, Kenji, 100
 Oleske, James, 532
 Oliary, J., 2674
 Ollert, Markus W., 2064
 Olsen, Kurt, 1630
 Onuki, Youichi, 2327
 Opravil, Milos, 1056
 Osada, Yasuaki, 2112
 Osborne, A. J., 2069
 Oseko, Fumimaro, 270, 2684
 Osheroff, Neil, 646, 2179, 2599
 Osmon, D. R., 554
 Ossi, Michael J., 159
 Otabe, Yohko, 2217
 Otero, J. R., 2490
 Otteni, Jean-Claude, 1873
 Otto, Michael J., 2606
 Ou, Ching-Nan, 2401

Paccaly-Moulin, Anne, 407
 Pacheco, Nancy D., 2688
 Pachucki, Constance T., 339
 Paessens, Arno, 1659
 Pagan, Joseph S., 144
 Pahissa, A., 1587
 Painter, Barbara, 1756
 Painter, George, 1720
 Painter, George R., 2285
 Pal, Koliol, 1693

Pangon, B., 737
 Pankuch, G. A., 1649
 Paradiso, Linda, 474
 Pares, Marta, 868
 Paris, Maria, 1630
 Park, Matthew K., 120
 Parker, Anita C., 1028, 2391
 Parker, William B., 1004
 Parniak, Michael A., 1390
 Paschalides, Panagiotis, 495
 Pascual, Alvaro, 187
 Pasculle, A. William, 1238
 Passariello, C., 2618
 Patchen, M. L., 1882
 Patel, Jayesh A., 339
 Patel, S., 2493
 Patterson, Jan Evans, 134
 Patterson, Thomas F., 2307
 Patton, Dorothy L., 8
 Patton, Melissa, 2244
 Paulfeuerborn, Wolfgang, 1835
 Paulsen, Ian T., 761
 Pav, Joseph W., 178
 Pavičić, M. J. A. M. P., 1184
 Payares, Gilberto, 580, 1353
 Pearson, Bridget A., 1473
 Pedemonte, Ronald, 754
 Pefanis, Angelos, 308, 507
 Peláez, Teresa, 1200
 Pellizzetti, Giampietro, 2693
 Peng, Tao, 2126
 Penn, Charles R., 1473
 Pennell, Andrew T., 1343
 Penni, Adriio, 1190
 Perea, Evelio J., 187
 Peregrine, Andrew S., 1050, 1163, 1167
 Perfect, John R., 903, 2449
 Periti, Piero, 2693
 Perri, Mary Beth, 134, 1187, 2474
 Perronne, Christian, 692, 1690
 Perry, Caroline R., 32
 Perry, Greg, 637
 Peter, Jean-Daniel, 501
 Petersen, Peter J., 2270
 Petitjean, O., 737, 2674
 Petteway, Stephen R., Jr., 71
 Pettinger, Mary B., 1360
 Petty, Brent G., 429
 Pfaff, Eberhard, 2612
 Pfaller, M. A., 893
 Pfaller, Michael A., 14, 39
 Pfiefferkorn, Elmer R., 2358
 Pfleiger, Philippe, 2599
 Phan, Lienhanh, 2241
 Philippon, Alain, 2020
 Phillips, Ian, 746
 Phillips, Robert, 1373
 Picazo, Juan J., 1717
 Pichichero, Michael E., 159
 Piddock, L. J. V., 662
 Piliewicz, Frank G., 1869
 Piperacillin-Tazobactam Skin and Skin Structure Study Group, 1580
 Piras, Marta M., 580
 Piras, Romano, 580
 Piret, Jacqueline, 84
 Pitha, P., 360
 Pitsakis, P. G., 2069
 Pitzurra, Lucia, 2422
 Pizzo, Philip A., 495

Pocidalo, Jean-Jacques, 692, 1599, 1690
 Pocidalo, J. J., 633
 Pohl, Jan, 2710
 Poiesz, Bernard, 512
 Polk, Ronald, 2193
 Polk, Ron E., 2139
 Pollack, Jay R., 1171
 Pollack, Matthew, 164
 Poncioni, Bernard, 2087
 Ponglerntapagorn, Preecha, 164
 Poppe, Susan M., 1127
 Porro, Gabriele Bianchi, 2212
 Portmann, R., 293, 2132
 Potgieter, Elsa, 2740
 Pottetier, Thierry, 501
 Pourtois, M., 142
 Powell, Francoise, 1227
 Powell, Marie, 1264
 Pozzi, Luann M., 19
 Pradier, C., 921
 Pramanik, A. J., 1264
 Prange, Hilmar W., 1518
 Prichard, Lynn E., 540
 Prichard, Mark N., 540
 Prince, Alice, 667
 Prince, Randall A., 1414
 Privitera, G., 2545
 Proenca, Rui, 667
 Progulske-Fox, Ann, 2037
 Prosser, Barbara L., 2144
 Pryka, Randy D., 2106
 Pudney, Mary, 2371
 Puel, J., 1232
 Pulverer, Gerhard, 750
 Pussard, Eric, 970
 Pye, G. W., 1962
 Quale, John M., 1904
 Queener, Sherry F., 1543, 1914, 2166
 Quemard, Annaik, 1536
 Quinn, John P., 1989
 Quinquis, Valérie, 54
 Quint, W. G. V., 595
 Quintero, Julio C., 1576
 Quintiliani, Richard, 234
 Rådström, Peter, 761
 Raffi, Francois, 1777
 Ragual, Rhonda J., 1334
 Rainey, Petrie M., 1842
 Ralph, Ray, 403, 991
 Ramiliarisoa, Olivao, 924
 Rand, Kenneth H., 613
 Rankin, Catherine D., 144
 Ransijn, Adriana, 991
 Raoult, D., 491, 1410, 2633
 Raoult, Didier, 1214, 1733
 Raponi, Giamarco, 1958
 Rasaily, R., 1197
 Rasmussen, Beth A., 851, 1989
 Rastogi, Nalin, 652, 1560
 Rather, Philip N., 2074
 Rather, P. N., 708
 Rathod, Pradipshin K., 1102
 Ravens, U., 1010
 Ray, Stephen, 1270
 Rayner, Marlene M., 2606
 Reardon, John E., 918
 Reboli, Annette C., 1334
 Reichtart, Cindy, 2244

Reichelderfer, Patricia S., 1095
 Reid, Carol D., 2606
 Reig, Roser, 138
 Reilly, J., 1180
 Renard, S., 1432
 Rende-Fournier, Rosanna, 2119
 Resconi, Anna, 741
 Resnick, Lionel, 1127
 Reuhl, Kenneth R., 419
 Reusser, Fritz, 1127
 Reynoldson, J. A., 328
 Rhodes, Audrey, 1576
 Ribera, E., 1587
 Ribner, Bruce S., 1334
 Rice, Louis B., 610, 1061, 2760
 Rice, Roselyn J., 1552
 Rich, Josiah, 2187
 Richardson, Judith F., 1219
 Richman, Douglas D., 1207
 Ricketts, Anthony P., 2358
 Riess, Günther, 1659
 Rigon, Antonio, 2693
 Rimland, David, 1334
 Rinaldi, Michael G., 39, 1383, 1847, 2307
 Ringwald, Pascal, 924
 Ripamonti, Franca, 741
 Risse, Gisa, 1367
 Rittel, Werner, 183
 Robbins, Brian L., 2247
 Robert, Alexandre, 1510
 Robert, Marta, 868
 Roberts, Glenn D., 39
 Roberts, William L., 1842
 Robillard, Norman J., 1756
 Rodríguez-Créixems, Marta, 1200
 Rodvold, Keith A., 436, 2106
 Roesel, Johannes L., 2087
 Rogers, Marc B., 2391
 Rogge, Mark C., 1468
 Roilides, Emmanuel, 495
 Roland, Gregory E., 2563
 Rollwagen, Florence M., 2688
 Rolston, Kenneth, 882
 Rolston, Kenneth V., 2584
 Rolston, Kenneth V. I., 2504
 Romand, Stéphane, 2371
 Romero, Donna L., 1127
 Ronco, Esthel, 962
 Rondel, Richard K., 2298
 Rose, Lucy M., 1004
 Rosen, Mark, 483
 Rosenbaum, Beverly, 729, 882, 2584
 Rosenberg, Ivan, 2540
 Roser, Roberto, 868
 Rosner, Judah L., 2251
 Rösner, Manfred, 1659
 Roth, Elizabeth, 1576
 Roth, Richard S., 1543
 Rothstein, David M., 191, 1624
 Rotschafer, John C., 436, 1377, 2454
 Rotstein, Coleman, 896
 Rouse, M. S., 554
 Rouse, Philippa, 2231
 Rouveau, Martine, 2020
 Roy, Tapon, 178
 Rozenberg-Ariska, Maja, 885
 Rubeglio, Etelvina A., 1728
 Rubin, Robert H., 619, 1270, 2144
 Rubinstein, E., 2333
 Ruble, Cheryl A., 1086
 Ruffing, Thomas L., 947
 Ruhnke, Markus, 2153
 RV-43 Study Group, The, 1095
 Ryan, D. Michael, 1473
 Rybak, Michael J., 605, 1931
 Ryzlak, Maria T., 419
 Saari, Herkko, 592
 Sacks, Steven, 637
 Safrin, Sharon, 975, 2241
 Sagiv, R., 293
 Saha, M. R., 1197
 Saissi, Gilbert, 464
 Saito, A., 1043
 Saito, H., 67, 1259
 Saito, Hajime, 722
 Saleh-Mghir, A., 633
 Saletan, Stephen L., 1869
 Samonis, George, 51
 Samuels, D. Scott, 46
 Sanada, Minoru, 2756
 Sanchez, Ana, 1717
 Sanders, Christine C., 251, 260, 1375, 2578
 Sanders, Paula L., 448
 Sanders, W. Eugene, Jr., 260
 Sands, Michael, 1
 Sandven, Per, 2443
 Sangaletti, Ornella, 2212
 Sannerud, Kim J., 835
 Sansano, Sebastiano, 2622
 Santander, Celina, 1728
 Santora, Julie, 512
 Saral, Rein, 1847
 Sardana, Vinod V., 947, 1576
 Saric, Muhamed, 1082
 Sato, K., 67, 1259
 Sato, Katsumasa, 722
 Sato, Kenichi, 2112
 Satoh, Hiroshi, 769
 Satta, Giuseppe, 1324
 Savani, Dora V., 903
 Sawada, Masashi, 2684
 Scaglia, Massimo, 1492
 Scarnati, Helen, 2606
 Scavone, Joseph M., 2187
 Schaberg, Dennis R., 2003
 Schachter, Julius, 1746
 Schacker, Tim, 975
 Schaeverbeke, Jean, 1510
 Schaeverbeke, Madeleine, 1510
 Schäfer-Körting, Monika, 2064
 Schaffner, Carl P., 419
 Schalm, S. W., 595
 Schedletzky, Holger, 696
 Schell, Wiley A., 2449
 Schentag, Jerome J., 371, 523, 1065, 1073
 Schiefer, Hans Gerd, 846
 Schinazi, Raymond F., 875, 1707, 2206
 Schindler, Jay J., 2716
 Schipper, Pauline, 1525, 2231
 Schlabach, Abner J., 1576
 Schleif, William A., 947, 1576
 Schloegel, M., 1488
 Schmidheini, Tobias, 2054
 Schmidt, Hans-Ludwig, 846
 Schneider, Christine L., 1576
 Schneider, Peter, 2087
 Schols, D., 332
 Schrenzel, J., 2132
 Schulman, Marvin, 1737
 Schultz, Robert J., 754
 Schulze, Andrea, 750
 Schuurman, Rob, 2231
 Scotti, Roberto, 741
 Sedman, Allen J., 775
 See, Darryl M., 1593
 Segal, Jack L., 93
 Segatore, Bernardetta, 1324
 Segreti, John, 1444
 Seifert, Harald, 750
 Seifert, Michael, 2153
 Seilheimer, Dan K., 1414
 Selan, L., 2618
 Selsted, Michael E., 2628
 Semmel, Marianne, 26
 Seo, Susan M., 1086
 Seta, Nathalie, 1790
 Setacci, Domenico, 1324
 Setogawa, Tomiochi, 722
 Shaddix, Sue C., 1004
 Shafer, William M., 2710
 Shafran, S. D., 574
 Shaharabany, Miriam, 1037
 Shannon, William M., 1004
 Shapiro, Theresa A., 1193
 Shasha, B., 2333
 Shaw, Karen J., 2074
 Shaw, K. J., 708
 Shawar, Ribhi, 882
 Shimada, Hideyo, 2042, 2327
 Shimada, Hisao, 2656
 Shimada, J., 1043
 Shimada, K., 1043
 Shimizu, K., 1043
 Shimomoura, Yuko, 2534
 Shimomura, Masahiko, 229
 Shimoyama, Takashi, 769
 Shinnick, Thomas M., 1348
 Shipkowitz, N. L., 864
 Shipman, Charles, Jr., 540
 Shirasaki, Takuma, 810
 Shlaes, David M., 610, 1061, 1238
 Shlaes, D. M., 2432
 Shlaes, J. H., 2432
 Shyu, W. C., 1180
 Siadak, Anthony, 164
 Siegert, Wolfgang, 1367
 Sijbesma, Rint, 1707
 Silve, Gaby, 1536
 Silver, Lynn L., 377
 Silverman, Edward G., 1869
 Simon, Sanford, 592
 Sinclair, Ian, 1270
 Singh, Kavindra B., 1203
 Singlas, Eric, 1777
 Sirisanthana, Thira, 2407
 Sironi, Marina, 2527
 Sjöstedt, Svante, 1665
 Sköld, Ola, 761
 Skurnik, Mikael, 1297
 Skurray, Ronald A., 761
 Slavin, Monica A., 1360
 Slocombe, Brian, 32

Sluchak, Julia A., 1927
 Smaoui, Hatem, 1510
 Smith, Anthony M., 1938
 Smith, C. Jeffrey, 1028, 2391
 Smith, Colin, 1243
 Smith, James W., 2166
 Smith, Marilyn S., 144
 Smithuis, F. M., 1977
 Snoeck, R., 332
 Snydman, David R., 1655
 So, Antero G., 1127
 Soejima, Rinzo, 801
 Soike, Kenneth F., 1370
 Soler, Paul, 281
 Sommadossi, Jean-Pierre, 1816
 Sonke, R. Lee, 532
 Sonoda, Fuminari, 164
 Soong, Seng-jaw, 1771
 Sörgel, F., 1860
 Sörgel, Fritz, 1518
 Sorsa, Timo, 592
 Soussy, Claude J., 2588
 Spector, Thomas, 602, 918
 Sperber, Steven J., 106
 Spicer, W. John, 914
 Spitzer, Eric D., 1383
 Spratt, Brian G., 1938
 Springer, Timothy A., 1278
 Srdanov, Gordana, 1707
 Srinivas, Ranga V., 2247
 Stair, Thomas O., 2754
 Stals, Frans S., 218
 Stanat, Sylvia C., 19
 Standiford, Harold C., 483, 1334
 Stanislawski, Lena, 26
 Stanislawski, Marc, 26
 Stark, Christina A., 1665
 Staszewski, Schlomo, 1576
 Staunton, Donald E., 1278
 Stecca, Clara, 2693
 Steckelberg, J. M., 554
 Steele, Lorraine C., 1850
 Steele, Paul, 1436
 Steib, Annick, 1873
 Steide, Jean-Alex, 1264
 Stein, Andreas, 1214
 Stein, Daniel S., 448
 Stein, Gary E., 89
 Steingrube, Vincent A., 1850
 Stephens, L. Clifton, 729
 Stevens, David A., 1177, 1334, 2224
 Stevens, Robert C., 448
 St. John, Lisa, 2285
 Stoeckel, Klaus, 2706
 Stotka, Jennifer, 2139
 St-Pierre, Claude, 1373
 Strauss, H. William, 1270, 2144
 Strle, Franc, 1444
 Strosberg, A. Donny, 26
 Stüber, Dietrich, 1400
 Sugar, Alan M., 39
 Sugiyama, Takashi, 2042
 Sullivan, John L., 178
 Sullivan, Maureen C., 234
 Sullivan, Veronica, 19
 Sum, Phaik-Eng, 2270
 Sumita, Yoshihiro, 2743
 Summanen, P., 2638
 Summers, Anne O., 825

Sun, He, 1132
 Sundström, Lars, 761, 1297
 Suomalainen, Kimmo, 592
 Supp, Andrew P., 1890
 Supparatpinyo, Khuanchai, 2407
 Sutton, David, 642
 Sutton, Lorraine, 2760
 Suzuki, Eiko, 1219
 Suzuki, Yasuyuki, 229
 Svensson, Ulla, 240
 Swan, S. K., 347
 Swaney, Steven M., 1127
 Swanson, Keith A., 778
 Swedberg, Göte, 761
 Swenson, Christine E., 1869
 Swenson, Jana M., 2311

Taburet, Anne-Marie, 1777
 Tagliabue, G., 2545
 Taira, Kazushige, 1877
 Takada, Kanji, 810
 Takahata, Masahiro, 384
 Takashima, Ikuo, 901
 Takatsuki, Akira, 980
 Takayama, Satoshi, 1764
 Takeda, Katsuo, 287
 Tal, Ruth, 1037
 Talan, D. A., 1580
 Talarico, Christine, 19
 Talbot, George H., 474
 Tallan, B. M., 554
 Tally, Francis P., 2270
 Tamura, Toshihide, 769
 Tan, J. S., 1580
 Tan, Tina Q., 2401
 Tanaka, Koji, 1945
 Tanaka, Kouichi, 2217
 Tanaka, Makoto, 2173
 Tanaka, Mayumi, 2112
 Tanaka, Nobuo, 2756
 Tanaka, Yasunori, 957
 Tanimura, M., 1043
 Taniyama, Yumi, 1547
 Tankovic, Jacques, 789
 Tarasi, Agapito, 1190
 Tardif, Carole, 2571
 Tardif, Manon, 2727
 Tarpley, W. Gary, 1127
 Tarrand, Jeffrey J., 2584
 Tateda, Kazuhiro, 675
 Taylor, David, 1552
 Taylor, Diane E., 457, 2645
 Taylor, Lester C., 2285
 Teggi, Antonella, 1679
 Teitz, Yael, 2483
 Teixeira, M., 1232
 Telenti, Amalio, 2054
 Tenorio, Carmen, 2427
 Tenover, Fred C., 2311
 Tenovuo, Jorma, 1158
 ter Kuile, F. O., 1977
 ter Laak, E. A., 317
 Terpenning, Margaret S., 2003
 Testa, Raymond T., 2270
 Thadepalli, Haragopal, 1711
 Thadepalli, Harini D., 1711
 Thal, Lee Ann, 134, 1187, 2474
 Thaller, M. C., 2618
 Thanassi, David G., 1393
 Thauvin-Eliopoulos, C., 1604

Thauvin-Eliopoulos, Claudie, 507
 Thayer, Walter R., 1645
 Theander, Thor G., 2550
 Then, Rudolf L., 1400
 Thom, Edna, 2144
 Thomas, Richard C., 1127
 Thompson, R. C. A., 328
 Thomson, Kenneth S., 1375
 Thormar, Halldor, 2540
 Thornsberry, Clyde, 1122
 Ticehurst, Julia, 1473
 Tidwell, Richard R., 2668
 Tidwell, R. R., 1713
 Tijnagel, Jolanda, 1525
 Tilles, Jeremiah G., 1593
 Tilling, Janet, 1473
 Ting, Windsor, 2106
 Titus, Donna L., 1576
 Tiwari, M., 2418
 Tod, M., 737, 2674
 Todo, Yozo, 384
 Tokuda, Yoshiko, 2228
 Tolokoff-Rubin, Nina E., 619
 Toltzis, Philip, 1610
 Tomasz, Alexander, 342
 Tomazić, J., 1786
 Tomioka, H., 67, 1259
 Tomioka, Haruaki, 722
 Tomonaga, Fumiya, 2042
 Tomono, Kazunori, 2762
 Tong, William, 398
 Torres, Carmen, 2427
 Torres, H., 491
 Tournay, C., 142
 Towle, Michelle, 2193
 Toyosawa, Toshio, 60
 Trautmann, Matthias, 2153
 Trias, Joaquim, 322
 Trieu-Cuot, Patrick, 2593
 Trifillis, A. L., 2496
 Troke, P. F., 1962
 Truffot-Pernot, Chantal, 407
 Trujillano, I., 911
 Tselenitis, Yannis, 51
 Tseng, Cheng-Chuang, 1826
 Ts'o, Paul O. P., 429
 Tsuda, Toshihiko, 2412
 Tsuda, Yasuyuki, 2327
 Tsui, S. Y. T., 1001
 Tsuji, Akiyoshi, 60
 Tsuji, Miho, 2228
 Tudela, Encarna, 868
 Turgeon, Fernand, 1174
 Turik, Michael, 2193
 Turner, Ronald B., 297
 Tzeng, Jausheng, 1909

Uckun, Fatih M., 835
 Ueda, Yasushi, 2217
 Ueno, Kazue, 957
 Ünal, S., 1604
 Ünal, Serhat, 1831
 Urbina, Julio A., 580, 1353
 Ussery, Michael A., 71
 Utsui, Yukio, 2278
 Uzun, Ömrüm, 1831

Vaara, Martti, 354, 2255
 Valdivia, Eva, 148
 Valero-Guillen, Pedro, 1536
 Valette, M., 2239
 Vallee, E., 633
 Vallois, J. M., 633

Vance-Bryan, Kyle, 436, 2454
 Vanden Bossche, Hugo, 2101
 van den Broek, P. J., 2318
 Van Den Ende, Jan, 2733
 Van der Auwera, P., 1015, 1860
 Vanderkolk, Julie, 2364
 van der Meer, Jos W. M., 276, 2527
 Van De Velde, Vera, 778
 van Leeuwen, Remko, 1525
 Vantha, Wanta Sok, 1977
 van Winkelhoff, A. J., 1184
 van Woensel, J. B. M., 1977
 Vapiwala, Manisha, 419
 Varela, Manuel F., 1253
 Vaudaux, Pierre, 625
 Vazquez, Jose A., 2474
 Venditti, Mario, 1190
 Venitz, Jürgen, 2139
 Venuti, Elaine, 2736
 Verboom, T., 1184
 Verdier, Francoise, 970
 Vergara, Yolanda, 138
 Verhoeft, Jan, 885
 Verschure, M. H., 317
 Videler, Joseph, 1480
 Vieler, Elke, 846
 Vila, Jordi, 138
 Vilde, Jean-Louis, 692, 1690
 Villareal, Kara, 39
 Vimy, Murray J., 825
 Vince, Robert, 1004
 Vincent, S., 2432
 Viola, Renato, 2693
 Visbal, Gonzalo, 580
 Visconti, M., 2545
 Vishvanathan, N., 183
 Visser, Maarten R., 885
 Voeller, Donna, 1227
 Vogels, Maria T. E., 276, 2527
 Von Bandel, Marc, 1873
 Vorachit, M., 2000
 Vrenzlos, George, 51

Wacharotayankun, Rochaporn, 984
 Wainberg, Mark A., 130, 1305, 1390, 2231
 Walcott, Sarah M., 1473
 Waldvogel, Francis A., 625
 Walker, Clay B., 2037
 Walker, Karla J., 1377, 2454
 Walker, Maja, 2087
 Walker, Sheila, 1558
 Wallace, Richard J., Jr., 1850
 Walsh, Thomas J., 1334
 Walter, Eike, 1539
 Walzer, Peter D., 1436
 Wang, Julie, 2139
 Wang, Li, 1781
 Wang, Shaomeng, 1799, 1807
 Wang, Ying, 457
 Ward, S. A., 2337
 Ward, Stephen A., 1318
 Warden, Glenn D., 1890
 Warnock, D. W., 1962
 Warren, John R., 2470
 Warren, Reed P., 2716
 Wasan, Kishor M., 246
 Washington, J. A., 1696
 Washington, John A., II, 1375

Waskin, Hetty A., 2449
 Wassmundt, Frederick W., 754
 Watanabe, Junko, 2656
 Watanabe, Kiwao, 164
 Watanabe, Kunitomo, 957
 Watanabe, Taiji, 2412
 Waterbury, Julie A., 1576
 Watson, Durward A., 1869
 Watts, J. L., 1122
 Waysbort, A., 1232
 Wear, Douglas J., 2500
 Webb, Douglas, 1270, 1383
 Webb, Vera, 2379
 Weickmann, Joachim, 1614
 Weidekamm, E., 293, 2132
 Weidner, Wolfgang, 846
 Weinstein, Melvin P., 106
 Weinstein, Robert A., 1989
 Weislow, Owen S., 754
 Wennensten, C. B., 1604
 Wennensten, Christine, 2009
 Wennensten, Christine B., 598, 1364
 Were, Joab B. O., 1193
 Westphal, J. F., 1488
 Wexler, Hannah M., 2509
 Wexler, H. M., 2638
 Weyler, Claudia, 1367
 Whiley, R. A., 2493
 Whitby, M., 1924
 White, E. Lucile, 754
 White, John, 1137
 White, Michael, 1436
 Whitman, M. S., 2069
 Wiedemann, B., 224
 Wiener, Janis, 1989
 Wilairat, Prapon, 403
 Wilber, R. B., 1180
 Wilcox, Gary, 1614
 Williams, Denise S., 1447
 Williams, G., 1924
 Willmott, Christopher J. R., 126
 Wilson, Jeanne E., 1720
 Wilson, W. R., 554
 Wingard, John R., 1847
 Winkler, Irvin, 1659
 Winslow, Dean L., 2606
 Wireman, Joy, 825
 Wise, Richard, 637
 Wise, W. Curtis, 393
 Wishnow, R. M., 1580
 Witt, Mallory D., 2030
 Witzig, Richard S., 1997
 Woestenborghs, Robert, 2224
 Wojcik, Stan, 991
 Wolanski, Bohdan S., 1576
 Wolfgang, Jill A., 1576
 Wolfson, John S., 2588
 Wong, Edward S., 1447
 Woodcock, Jocelyn, 637
 Woodford, Neil, 681
 Woods, Jacqueline M., 1473
 Woods-Cook, Kathie, 2087
 Wraber, B., 1786
 Wright, Esther L., 652
 Wright, Susan C., 2534
 Wrighton, Steven A., 265
 Wudl, Fred, 1707

Xiao, Xinfia, 84
 Xicoté, M. Angels, 868

Yamada, Hidehiko, 2412
Yamada, Hideo, 2327
Yamaguchi, Hideyo, 785, 2228
Yamaguchi, Keizo, 60, 675
Yamaguchi, Titaro, 287
Yamaguchi, Yoshiyuki, 26
Yamamoto, Naoki, 2486
Yamamoto, S., 1043
Yamashiro, Yoshiko, 384
Yamazaki, Masatoshi, 2228
Yamazaki, Toshiyuki, 100
Yancey, R. J., Jr., 1122
Yang, Ying-Zi, 1108
Yang, Youjun, 851
Yano, Takafumi, 287

Yao, Gang-qing, 1420
Yasuda, Hiroshi, 322, 1749
Yazawa, Katsukiyo, 1313
Yeaman, Michael R., 546
Yew, W. W., 1001
Yoder, Steven L., 2563
Yokoo, Mamoru, 363
Yokota, Takeshi, 1749, 2217
Yoneyama, Hiroshi, 2385
Yoshida, Hiroaki, 839
Yoshida, Masao, 2534
Yoshida, Takuji, 793
Yoshihara, Fumie, 2662
Yoshiyama, Yuji, 2042
Young, Glenda, 1850
Young, Robert D., 1102
Yuthavong, Yongyuth, 1108
Zabinski, Richard A., 1377, 2454
Zaccardi, Joe, 1624
Zakut, H., 293
Zannier, Arnold, 1214
Zappala, M., 1497
Zarins, Lidija T., 2003
Zausner, A., 2069
Zenilman, Jonathan M., 2244
Zervos, Marcus J., 134, 1187, 2474
Zeytinoglu, Aysin, 218
Zhanel, George G., 1154
Zhang, Ruiwen, 1771
Zhang, Yansheng, 1850
Zheng, Hui, 2534
Zhong, Jian, 2534
Zhou, Xiang Yang, 1387
Zhou, Zhu, 1816
Zienicke, Helga, 2064
Zieroth, Shelley R., 1154
Zimmerli, Werner, 2622
Zimmerman, Stephen W., 2650
Zinner, Stephen H., 1756
Zon, Gerald, 171
Zscheck, Karen K., 1966

SUBJECT INDEX

VOLUME 37

A77003

- human immunodeficiency virus type 1
 - preclinical evaluation, 115
 - toxicity
 - preclinical evaluation, 115
- aac(6')-Ii*
 - characterization, 1896
 - E. faecium*
 - specificity for, 1896
- aac(3)-VIIa*
 - E. cloacae*
 - biochemical analysis, 2074
- Abelson murine leukemia virus
 - thiosemicarbazones
 - v-*abl* protein, suppression of, 2483
- Abscesses
 - ampicillin-sulbactam
 - comparative evaluation, 610
 - cefotixin
 - comparative evaluation, 610
 - E. coli*
 - ampicillin-sulbactam, comparative evaluation, 610
 - cefotixin, comparative evaluation, 610
- 2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone
 - cytomegalovirus
 - potent inhibition of replication, 602
 - ganciclovir
 - potentiation of antiviral effects, 602
- 3-N-Acetyltransferase
 - E. cloacae*
 - aac(3)-VIIa* gene, biochemical analysis of, 2074
- Acetyltransferases
 - P. aeruginosa*
 - aac(6')-Ib*, characterization of, 1456
- Acinetobacter baumannii*
 - aminoglycoside-modifying enzymes
 - production of, 138
 - β-lactamase production, 138
 - chloramphenicol acetyltransferase
 - production of, 138
 - in vitro susceptibilities, 138
- Acinetobacter haemolyticus*
 - aac(6')-Ig* gene
 - 6'-N-acetyltransferase, 2093
- Acinetobacter* spp.
 - antimicrobial susceptibility, 750
- Actinobacillus actinomycetemcomitans*
 - HPQYNQR
 - in vitro activity, 2710
 - IIIGR
 - in vitro activity, 2710
- Acyclic nucleoside phosphonates
 - bis(pivaloyloxymethyl) prodrugs
 - metabolism and in vitro antiretroviral activities, 2247
- herpesviruses
 - (S) and (R) enantiomers, 332
 - (S) and (R) enantiomers
 - herpesviruses, 332
 - retroviruses, 332
 - retroviruses
 - (S) and (R) enantiomers, 332
 - vimsa virus
 - inhibition of replication, 2540
- Acyclovir
 - combinations
 - 348-U87, 975
 - herpes simplex virus, acyclovir resistance
 - tant, 975
 - ribonucleotide reductase inhibitor, 975
 - herpes simplex virus resistance
 - peniclovir, 2241
 - herpes simplex virus susceptibility
 - strains from organ transplant recipients after acyclovir or ganciclovir prophylaxis, 357
 - herpes simplex virus type 1
 - comparative evaluation, 642
 - salmonella
 - in vitro activities, 106
- Aeromonas hydrophila*
 - β-lactamase
 - β-lactam resistance, contribution to, 1324
 - carbapenems, high specificity for, 1324
- Aeromonas* spp.
 - in vitro susceptibilities
 - tropical isolates from Queensland, Australia, 905
- Afipia felis*
 - antibiotic susceptibilities
 - axenic medium and cells, 1410
- AG-2000
 - H. pylori*
 - urease activity, inhibition of, 769
- Agar dilution
 - G. vaginalis*
 - susceptibilities to 25 antimicrobial agents, 2733
- Albendazole
 - hydatid disease
 - treatment of, 1679
- N-n-Alkyl-3,4-dihydroxybenzamide
 - T. brucei brucei*
 - in vitro and in vivo activities, 1082
- Allopurinol riboside
 - pharmacokinetics
 - probenecid, effects of, 1193
- Alpha-1-antitrypsin
 - doxycycline
 - protection from human neutrophil collagenase and gelatinase, 592
- Alpha interferon
 - pharmacokinetics
 - transplacental passage, two assay techniques, 1232
- Aluminum hydroxide
 - levofloxacin
 - inhibition of absorption of, 2173
- AM-1155
 - Mycobacterium* spp.
 - in vitro activity, comparative evaluation, 1259
- Ames *Salmonella* TA102 assay
 - quinolones
 - bacterial mutagenicity, 213
- Amikacin
 - A. haemolyticus* resistance
 - aac(6')-Ig* gene, characterization of, 2093
 - combinations
 - aztreonam, 308
 - ceftazidime, 308
 - endocarditis, 308
 - imipenem, 1931
 - P. aeruginosa*, 308, 1931
- E. coli* resistance
 - bleomycin, increase of, 1982
- M. fortuitum*
 - postantibiotic effect, 1001
 - M. haemophilum*
 - in vitro activities, 2323
 - pharmacokinetics
 - attachment to collagen for local delivery in wounds, 1890
 - patients with septic multiple-organ failure during intermittent hemofiltration, 464
 - postantibiotic effect
 - M. fortuitum*, 1001
 - synergy
 - ethambutol, 1285
 - M. malmoense*, 1285
 - Aminoglycosides
 - 6'-N-acetyltransferase
 - aac(6')-Ig* gene, characterization of, 2093
 - combinations
 - inhibitors of glycosylation and fatty acid and peptide biosynthesis, 652
 - M. avium*, 652
 - F. oryzihabitans*
 - in vitro activities against clinical isolates from patients with cancer, 2504
 - P. aeruginosa* resistance
 - ant(4')-Ia*, nucleotide sequence analysis and DNA hybridization studies, 708
 - population pharmacokinetics
 - oncology patients, 1025
 - resistance gene nomenclature
 - letter to the editor, 927
 - T. brucei brucei* resistance phenotype
 - in vivo system to select for blood-stream-form transfectants, 1167
 - 8-Aminoquinolones
 - P. carinii*
 - in vivo and in vitro studies, 2166
 - Amopyroquin
 - malaria
 - P. falciparum*, 970
 - P. falciparum* malaria treatment, 970
 - Amorolfine
 - Candida* spp.
 - temperature, effect on activity, 685
 - Amoxicillin
 - B. burgdorferi*
 - in vitro susceptibility, 1444
 - combinations
 - clavulanic acid, 14
 - H. influenzae*, β-lactamase producing and nonproducing, ampicillin resistant, 14
 - comparative evaluation
 - chronic bronchitis, 2298
 - rufloxacin, 2298
 - otitis media
 - S. pneumoniae*, penicillin resistant, 1599
 - pharmacokinetics
 - local gastric and serum concentrations after different oral applications, 1506
 - S. mutans*
 - in vitro susceptibility, 1158
 - synergy
 - H. pylori*, 1184
 - metronidazole, 1184

metronidazole, hydroxymetabolite of, 1184

ampD

C. freundii sequences of wild-type and mutant genes, comparison with those in *E. coli*, 224

E. coli sequences of wild-type and mutant genes, comparison with those in *C. freundii*, 224

Amphotericin B aspergillosis, 2307 invasive pulmonary, prophylactic inhalations, 1367

C. albicans comparative evaluation, 729 disseminated infection in normal and granulocytopenic mice, 729 interleukin-6, reduction in release, 1958 tumor necrosis factor alpha, reduction in release, 1958

C. neoformans in vitro susceptibility, 1383 recurrent meningitis, isolates from patients with, 1383

Candida spp. temperature, effect on activity, 685 comparative evaluation fluconazole, 2030 itraconazole, 2307 endocarditis *C. parapsilosis*, 2030 *C. tropicalis*, 2030 immunological effects on splenocytes from immune-normal and immune-compromised mice, 2716 in vitro and in vivo studies, 2228

L. donovani T-cell-deficient mice, 1504 leishmaniasis, visceral T-cell-deficient mice, 1504 liposomal immunological effects on splenocytes from immune-normal and immune-compromised mice, 2716 liposome composition role in distribution of drug in serum lipoproteins, 246 mono-methyl ester derivative neurotoxicity, comparative evaluation, 419 murine tumor necrosis factor augmentation of production, 2228 neurotoxicity mono-methyl ester derivative, comparative evaluation, 419 rats, comparative evaluation, 419

P. marneffei response of human immunodeficiency virus-infected patients, 2407 temperature role in distribution of drug in serum lipoproteins, 246

Ampicillin combinations ciprofloxacin, 1904 comparative evaluation, 610 *E. coli* intra-abdominal abscess model, 610 *E. faecalis*, β -lactamase producing, highly gentamicin resistant, 1447

E. faecium, 1904 endocarditis, 507, 1447 *S. aureus*, β -lactamase hyperproducing, 507 sulbactam, 251, 507, 610, 1447 susceptibility testing with a predictor panel, 251

E. faecium resistance, 1904 endocarditis, 2069

H. influenzae distribution in patients with lower respiratory tract infections, effect on, 804

H. parainfluenzae distribution in patients with lower respiratory tract infections, effect on, 804 oxidant-scavenging activities neutrophil functions, effect on, 950

Amsacrine *P. carinii* activity in vitro and in a mouse model, 1543

Anaerobic organisms Bay Y3118 in vitro activity, 2509 FK037 in vitro activity, 957 MDL 62,879, 746

9-Anilinoacridines *Leishmania* spp. in vitro activity, 991 structure-activity relationships, 991

P. falciparum chloroquine resistant, 403 mode of action, 403 structure-activity relationship, 403

Antibiotic carryover quinolones antibiotic-removal beads, elimination with, 1377

Antibodies AS-48 immunocytological studies, 148 neutralizing simian immunodeficiency virus-infected macrophages, 360

P. aeruginosa flagella therapeutic effects in a murine model, 164

Antifungal agents susceptibility testing broth macrodilution, 39 yeasts, pathogenic, 39 triazino[5,6-*b*]indoles GR99060, 1243 GR99062, 1243

ant(4')-IIa *P. aeruginosa* nucleotide sequence analysis and DNA hybridization studies, 708

Antipneumocystis agents screening assay development and characterization, 1674

Antiviral agents combinations strategic design and three-dimensional analysis, 540 hepatitis B virus selectivity, high-capacity in vitro assessment, 441 selectivity high-capacity in vitro assessment, 441

Artemisinin iron-dependent free radical generation, 1108 mechanism of action iron dependence, 1108

AS-48 antibodies, neutralizing immunocytological studies, 148

Aspergillosis amphotericin B aerosol, prophylaxis, 1367 comparative evaluation itraconazole-cyclodextrin versus amphotericin B in a rabbit model, 2307 pulmonary, invasive amphotericin B, aerosol, for prophylaxis, 1367

Aspergillus fumigatus aspergillosis itraconazole-cyclodextrin versus amphotericin B in a rabbit model, comparative evaluation, 2307

D0870 in vivo and in vitro activities, 2412 itraconazole efficacy in a rat model, 2762

Atovaquone combinations clarithromycin, 2371 minocycline, 2371 pyrimethamine, 2371 sulfadiazine, 2371

T. gondii in vitro and in vivo activities, 2371

Avermectins *S. erythraea* glycosylation, microbial conversion by, 1737

3'-Azido-2',3'-deoxythymidine synergy carbovir, 144 human immunodeficiency virus type 1, 144

3'-Azido-3'-deoxythymidine toxicity thymidine kinase activity, correlation with circadian variation in, 1771 time of administration, effect on, 1771

3'-Azido-3'-deoxythymidine human immunodeficiency virus type 1 replication in human fetal brain macrophages, effect on, 1305

3'-Azido-3'-deoxythymidine monophosphate exonucleolytic repair of AZT-terminated DNA inhibition of, 918

3'-Azidothymidine simian immunodeficiency virus macrophages, comparative evaluation, 360

Azithromycin *B. burgdorferi* in vitro activity, comparative evaluation, 1704

Brucella spp. in vitro activity, comparative evaluation, 911

C. pneumoniae in vitro activity, 1746

C. trachomatis

in vitro activity, 1746
 combinations
 pyrimethamine, 1993
T. gondii, 1993
 cross-resistance
 frequency distribution curves, scattergrams, and regression analyses, 2080
 enteric bacterial pathogens
 in vitro activity, 1203
 gram-negative organisms
 outer membrane permeability barrier, 354
 in vitro activities
 frequency distribution curves, scattergrams, and regression analyses, 2080
L. micdadei
 inhibition of intracellular strains, 2261
 lymphocyte response
 in vivo activities, 1786
M. avium
 cross-resistance, 2364
M. avium complex
 rats treated with cyclosporine, 398
M. haemophilum
 in vitro activities, 2323
M. kansasi
 susceptibility testing, 1997
 pharmacokinetics
 pediatric patients, multiple oral doses of suspension, 314
S. aureus
 uptake by human monocytes, 2318
T. gondii
 protein synthesis, inhibition of, 1701
 Aztreonam
C. albicans
 colonization of the human gastrointestinal tract, effect on, 51
 combinations
 amikacin, 308
 endocarditis, 308
P. aeruginosa, 308
 endocarditis
P. aeruginosa, 308
P. aeruginosa
 endocarditis, 308
 yeast colonization of the human gastrointestinal tract, effect on, 51

Bacteroides fragilis
 Bay Y3118
 in vitro activity, 2509
cepA
 cloning and characterization reveal a new subgroup of β -lactamases, 2391
 ciprofloxacin
 T-cell subsets and tumor necrosis factor production in infected mice, effect on, 1711
 clindamycin
 in vivo efficacy, correlation with in vitro susceptibility, 997
 mice, 997
E. coli, polymicrobial infection
 mice, 1531
 quinolones
 in vivo efficacy, correlation with in vitro susceptibility, 997
 mice, 997

rufloxacin
 T-cell subsets and tumor necrosis factor production in infected mice, effect on, 1711
S. aureus, polymicrobial infection
 mice, 1531
 temafloxacin
 evaluation of activity by an in vitro pharmacodynamic system, 2454
tet(Q)
 nucleotide and deduced amino acid sequences, 2037
Bacteroides gracilis
 Bay Y3118
 in vitro activity, 2509
Bacteroides spp.
 Bay Y3118
 in vitro activity, 2509
 β -lactamase
 cefoxitin resistance, 1028
 novel Ambler class A, 1028
 cefoxitin resistance
 β -lactamase, 1028
Bacteroides thetaiotaomicron
E. coli, polymicrobial infection
 mice, 1531
S. aureus, polymicrobial infection
 mice, 1531
 Bay Y3118
 broth macrodilution assays
 in vitro activity and comparative evaluation, 2348
 Bay Y3118
 gram-negative organisms
 anaerobic, 1649
 comparative susceptibilities, 1649
 gram-positive organisms
 anaerobic, 1649
 comparative susceptibilities, 1649
 in vitro activities
 gram-negative organisms, 2017
 gram-positive organisms, 2017
 Benzimidazoles
Giardia spp.
 in vitro activity, 328
 Bis-benzimidazoles
P. carinii
 pneumonia, treatment of, 1713
 Benzoxazinorifamycin
M. avium complex
 radiometric method, determination by, 67
 Benzoxazinorifamycins
 KRM-1648
M. avium, 722
 Benzylpenicillin
Pneumococcus spp.
 postantibiotic effect, 2200
Streptococcus spp.
 postantibiotic effect, 2200
 β -Lactamase inhibitors
 combinations
 β -lactams, 702
S. aureus, borderline methicillin susceptible, 702
S. aureus, methicillin resistant, 702
 β -Lactamases
A. baumannii
 production by, 138
A. hydrophila
 β -lactam resistance, contribution to, 1324
 carbapenems, high specificity for, 1324

B. fragilis
 cloning and characterization of *cepA* reveal new subgroup, 2391
Bacteroides spp.
 cefoxitin resistance, 1028
 novel Ambler class A, 1028
C. coli
 β -lactam susceptibilities, 1174
 carbapenem hydrolyzing
E. cloacae, biochemical properties, 939
 CP-70,429
 stability to, 1547
E. cloacae
 biochemical properties, 939
 cloning of gene into *E. coli*, 939
E. coli
 clavulanate, 2059
 sulbactam, 2059
 tazobactam, 2059
E. faecalis
 mobilization of gene, 1187
 production by, 1966
 fecal activity
 healthy volunteers after cefixime treatment, 1432
 FK-037
 stability to, 566
H. alvei
 ceftazidime resistant, 1375
K. pneumoniae
 β -lactams, broad spectrum, resistance to, 984
 β -lactams, extended spectrum, resistance to, 2020
 MGH-1, 2760
 plasmid encoded, TEM derived, 2020
 plasmid mediated, AmpC type, transferable, 984
 YOU-1, 2760
 YOU-2, 2760
 MGH-1
 gene sequences for, 2760
 minireview
 induction of, molecular basis for, 153
N. farcinica
 characterization, 1850
P. aeruginosa
 carbapenem resistance, role in, 1387
 extended spectrum, characterization of, 962
 OXA-11, extended-spectrum variant of OXA-10, 1637
P. cepacia, 249
 chromosomal penicillinase, member of AmpC family, 667
 plasmid mediated
 β -lactams, broad spectrum, resistance to, 984
E. coli, 1989
K. pneumoniae, 984, 1989
S. aureus
bla and *blaRI*, regulation by, 1144
 cefazolin, inactivation and efficacy of, 203
 cefmetazole, inactivation and efficacy of, 203
 production by, 1966
Streptococcus spp., group A beta-hemolytic
 production of, role in infection management, 1452
 susceptibility testing

predictor panel for evaluating meth-
 ods, 2578
 tazobactam
 kinetic interactions, 851
 TEM-1
 hydrogen bonding by serine 235 for
 cephalosporinase activity, 2438
 YOU-1
 gene sequences for, 2760
 YOU-2
 gene sequences for, 2760
β-Lactams
A. hydrophila resistance
 metallo-β-lactamase, *cphA* encoded,
 1324
C. coli susceptibility
 β-lactamase-positive and -negative
 strains, 1174
 combinations
 β-lactamase inhibitors, 702
S. aureus, borderline methicillin sus-
 ceptible, 702
S. aureus, methicillin resistant, 702
E. faecium resistance
 synergistic combinations, resistance
 to, 1238
 minireviews
 penicillin-binding protein resistance,
 2045
 penicillin-binding protein resistance
 minireview, 2045
 synergy
 E. faecium resistance, 1238
Biapenem
 comparative evaluation
 imipenem, 2009
 gram-negative bacteria, 2009
 gram-positive bacteria, 2009
P. aeruginosa
 phenotypic resistance induced by sa-
 licylate, 2743
Bilobalide
P. carinii
 in vitro and in vivo activities, 1492
Bilophila wadsworthia
 Bay Y3118
 in vitro activity, 2509
 imipenem
 morphological response, 2638
 penicillin-binding protein patterns,
 2638
Bioavailability
 cefetamet pivoxil
 syrup and tablet formulations to
 healthy male volunteers, 2706
 $(-)$ -*cis*-5-fluoro-1-[2-(hydroxymethyl)-
 1,3-oxathiolan-5-yl] cytosine
 studies with rats, 2285
 clindamycin
 healthy volunteers and AIDS patients,
 1137
 fluconazole
 patients with AIDS, 2187
Biofilms
S. epidermidis
 diffusion of rifampin, 2522
 diffusion of vancomycin, 2522
Bioscreen C
 benzylpenicillin
 postantibiotic effect, 2200
Bis(pivaloyloxymethyl) prodrugs
 metabolism and in vitro antiretroviral
 activities, 2247

Bis-benzimidazoles
G. lamblia
 correlation of anti-giardial activity,
 DNA binding affinity, and giardial
 topoisomerase II inhibition, 2668
 structure-activity studies, 2668
Blastomyces dermatitidis
 D0870
 murine blastomycosis, 1177
Blastomycosis
 D0870
 murine, 1177
Bleomycin
E. coli
 amikacin and streptomycin resistance,
 1982
S. cerevisiae
 cell wall anchorage of mannoproteins,
 disruption of, 1264
Boric acid
Candida spp.
 temperature, effect on activity, 685
Borrelia burgdorferi
 azithromycin
 in vitro activity, comparative evalua-
 tion, 1704
 clarithromycin
 hamsters, 1329
 in vitro activity, comparative evalua-
 tion, 1704
 coumermycin A₁
 growth inhibition and induction of re-
 laxation of supercoiled plasmids,
 46
Erythromycin
 in vitro activity, comparative evalua-
 tion, 1704
 in vitro susceptibilities, 1444
 vancomycin
 in vitro activity, 1115
Bronchitis
 chronic
 rifloxacin and amoxicillin, compara-
 tive evaluation, 2298
Broth macrodilution assay
 Bay Y3118
 in vitro activity and comparative eval-
 uation, 2348
Yeasts
 susceptibility testing, 39
Brucella melitensis
 experimental murine brucellosis
 streptomycin alone and in combination
 with ciprofloxacin, doxycycline,
 and rifampin, 2333
Brucella spp.
 azithromycin
 in vitro activity, comparative evalua-
 tion, 911
 clarithromycin
 in vitro activity, comparative evalua-
 tion, 911
 dirithromycin
 in vitro activity, comparative evalua-
 tion, 911
 doxycycline-rifampin
 comparative evaluation, 1831
 ofloxacin-rifampin
 comparative evaluation, 1831
 rifapentine
 in vitro activity, comparative evalua-
 tion, 911
 roxithromycin

in vitro activity, comparative evalua-
 tion, 911
**in vitro activity, comparative evalua-
 tion, 911**
Butenafine
C. albicans
 mechanisms of action, 785
 percutaneous permeation, 363
T. mentagrophytes
 guinea pigs, 363

Camptothecin
P. carinii
 activity in vitro and in a mouse model,
 1543
Campylobacter coli
 β-lactamase-positive and -negative
 strains
 β-lactam susceptibilities, 1174

Campylobacter jejuni
 cytokines
 effect of oral recombinant interleukin
 on mucosal immunity in mice,
 2688

DNA gyrase
gyrA, cloning and nucleotide se-
 quence, 457
gyrA
 cloning and nucleotide sequence, 457
 quinolone resistance
 DNA gyrase mutations, characteriza-
 tion of, 457

Tet(O)
 effect of mutational alteration of Asn-
 128, 2645
tetracycline resistance
 effect of mutational alteration of Asn-
 128, 2645

Campylobacter spp.
 azithromycin
 in vitro activity, 1203

Candida albicans
 amphotericin B
 comparative evaluation, 729
 disseminated infection in normal and
 granulocytopenic mice, 729
 tumor necrosis factor alpha, reduction
 in release, 1958

aztreonam
 colonization of the human gastrointes-
 tinal tract, effect on, 51

butenafine
 mechanisms of action, 785

ceftazidime
 colonization of the human gastrointes-
 tinal tract, effect on, 51

ceftriaxone
 colonization of the human gastrointes-
 tinal tract, effect on, 51

cilofungin
 comparative evaluation, 729
 disseminated infection in normal and
 granulocytopenic mice, 729

D0870
 in vitro activities, 2126
 in vivo and in vitro activities, 2412

fluconazole resistance
 patients infected with human immuno-
 deficiency virus type 1, correla-
 tion to therapy and symptoms,
 2449

fluconazole susceptibility
 emergence of resistance of Norwegian
 strains, 2443

imipenem-cilastatin
colonization of the human gastrointestinal tract, effect on, 51

itraconazole
placebo-controlled trial, 89

myeloperoxidase, human recombinant
candidid activity, 142

picolinic acid
protective effect on mice, 2422

Ro 09-1470
inhibition of P-450 lanosterol C-14 demethylase, 2662

ticarcillin-clavulanic acid
colonization of the human gastrointestinal tract, effect on, 51

Candida glabrata
fluconazole resistance, 1962

Candida parapsilosis
amphotericin B, 2030

endocarditis, 2030

fluconazole, 2030

Candida spp.
amorolfine
temperature, effect on activity, 685

amphotericin B
temperature, effect on activity, 685

boric acid
temperature, effect on activity, 685

flucytosine
temperature, effect on activity, 685

platelet microbicidal protein
fungalid activity, 546

susceptibility testing
current status of the standardization process, minireview, 2517

terbinafine
temperature, effect on activity, 685

terconazole
temperature, effect on activity, 685

Candida tropicalis
amphotericin B, 2030

endocarditis, 2030

fluconazole, 2030

Candidiasis
itraconazole
placebo-controlled trial, 89

CAP18
gram-negative organisms
in vitro activity, 2534

gram-positive organisms
in vitro activity, 2534

Capnocytophaga spp.
antimicrobial susceptibilities
letter to the editor, 1206

Capnocytophaga sputigena
HPQYNR
in vitro activity, 2710

IIIGR
in vitro activity, 2710

Carbapenems
β-lactamase hydrolysis
E. cloacae, 939

biapenem
P. aeruginosa resistance induced by salicylate, 2743

BO-2727
in vitro activity, 2756

F. oryzihabitans
in vitro activities against clinical isolates from patients with cancer, 2504

imipenem
P. aeruginosa resistance induced by salicylate, 2743

LJC 10,627
neurotoxicity in rats, low levels of, 199

P. aeruginosa resistance
cephalosporinase, role in, 1387

panipenem
P. aeruginosa resistance induced by salicylate, 2743

Carbenicillin
epimers
stereoselective renal tubular secretion in human volunteers, 2327

Carbovir
cellular metabolism
effects on, 1004

metabolism, 1004

synergy
3'-azido-2',3'-deoxythymidine, 144

human immunodeficiency virus type 1, 144

Carboxyquinolones
Q-35
L. interrogans, 901

Cecropin
C terminus, modification of
broad-spectrum antimicrobial activity, essential for, 1614

Cefaclor
H. influenzae
β-lactamase producing and nonproducing, ampicillin resistant, 14

Cefazolin
abscesses
β-lactamase-mediated inactivation and efficacy, 203

pharmacokinetics
protein binding in rats, 1781

proconvulsant effects
DBA/2 and Swiss mice, 1497

S. aureus
β-lactamase-mediated inactivation and efficacy, 203

seizures
DBA/2 and Swiss mice, 1497

Cefepime
in vitro activity
multicenter comparison, 1696

pharmacokinetics
cystic fibrosis patients, 1414

Cefetamet pivoxil
bioavailability
syrup and tablet formulations to healthy male volunteers, 2706

Cefixime
β-lactamase activity, fecal
healthy volunteers after drug treatment, 1432

C. difficile shedding
healthy volunteers after drug treatment, 1432

gastrointestinal symptoms
effect on in healthy volunteers after drug treatment, 1432

H. influenzae
β-lactamase producing and nonproducing, ampicillin resistant, 14

pharmacokinetics
biliary excretion in patients with T-tube drainage, 1488

Cefmetazole
abscesses
β-lactamase-mediated inactivation and efficacy, 203

S. aureus
β-lactamase-mediated inactivation and efficacy, 203

β-lactamase-mediated inactivation and efficacy, 203

Cefonidic
peritonitis, spontaneous bacterial comparative evaluation, 1587

pharmacokinetics
protein binding in adult and neonatal sera, 1343

protein binding
adult and neonatal sera, 1343

Cefoperazone
combinations
E. coli, 1927

K. pneumoniae resistance, 1061

P. aeruginosa, 1927

sulbactam, 1061, 1927

Cefotaxime
B. burgdorferi
in vitro susceptibility, 1444

E. coli
comparative evaluation, 846

epididymitis, 846

postantibiotic effect in pooled cerebrospinal fluid and Mueller-Hinton broth, 1154

epididymitis
comparative evaluation, 846

E. coli, 846

H. influenzae
β-lactamase producing and nonproducing, ampicillin resistant, 14

pharmacokinetics
cerebrospinal fluid of patients with uninflamed meninges, passage into, 1518

postantibiotic effect
E. coli, in pooled cerebrospinal fluid and Mueller-Hinton broth, 1154

S. pneumoniae breakpoint
letter to the editor, 616

Cefoxitin
abscesses, intra-abdominal
comparative evaluation, 610

Bacteroides resistance
β-lactamase, 1028

E. coli
comparative evaluation, 610

Cefozopran
K. pneumoniae
respiratory tract infection, 100

P. aeruginosa
urinary tract infection, 100

S. aureus
thigh muscle infection, 100

Cefpodoxime proxetil
ex vivo susceptibility
studies with patients receiving continuous ambulatory peritoneal dialysis, 2650

pharmacokinetics
studies with patients receiving continuous ambulatory peritoneal dialysis, 2650

Cefprozil
pharmacokinetics
tonsillar and adenoidal tissues, penetration into, 1180

tonsillopharyngitis, streptococcal comparative evaluation, 1620

Ceftazidime
C. albicans
 colonization of the human gastrointestinal tract, effect on, 51
 combinations
 amikacin, 308
 endocarditis, 308
P. aeruginosa, 308
E. coli resistance
 β -lactamase, 1989
 endocarditis
P. aeruginosa, 308
H. alvei resistance
 β -lactamase producing, 1375
 in vitro activity
 multicenter comparison, 1696
K. pneumoniae resistance
 β -lactamase, 1989
P. aeruginosa
 endocarditis, 308
P. cepacia
 comparative evaluation, 123
P. pseudomallei resistance
 biofilm cells, 2000
 pharmacokinetics
 healthy volunteers, 1835
 patients with septic multiple-organ failure during intermittent hemofiltration, 464
 serum bactericidal activities, 1835
 side effects, 1835
 yeast colonization of the human gastrointestinal tract, effect on, 51

Ceftibuten
H. influenzae
 β -lactamase producing and nonproducing, ampicillin resistant, 14

Ceftizoxime
B. burgdorferi
 in vitro susceptibility, 1444

Ceftriaxone
C. albicans
 colonization of the human gastrointestinal tract, effect on, 51
C. burnetii
 shell vial assay, 491
 combinations
 endocarditis, 1971
 netilmicin, 1971
 concentrations in plasma during liver transplantation, 1873
 gonorrhea, uncomplicated
 single-dose therapy, comparative evaluation, 1670
 in vitro activity
 multicenter comparison, 1696
 peritonitis, spontaneous bacterial comparative evaluation, 1587
 pharmacokinetics
 cerebrospinal fluid of patients with uninfamed meninges, passage into, 1518
 elimination, effect of plasmapheresis, 1171
 pregnant women, 54
 protein binding during pregnancy, 54
S. typhi
 5 days, comparative evaluation, 1572
 synergy
 netilmicin, 207
 streptococcal endocarditis, 207
 tissue penetration during liver transplantation, 1873

typhoid fever
 5 days, comparative evaluation, 1572
 yeast colonization of the human gastrointestinal tract, effect on, 51

Cefuroxime
H. influenzae
 β -lactamase producing and nonproducing, ampicillin resistant, 14
 in vitro activity
 multicenter comparison, 1696
 pharmacokinetics
 protein binding in adult and neonatal sera, 1343
 protein binding
 adult and neonatal sera, 1343
S. mutans
 in vitro susceptibility, 1158

Cefuroxime axetil
 pharyngitis
 comparative evaluation, 159
Streptococcus spp.
 comparative evaluation, 159
 group A, 159
 pharyngitis, 159
 suspension
 comparative evaluation, 159
 group A streptococcal pharyngitis, 159

Cephalosporin 7 α -hydroxylase
S. claviger
 cloning and expression in *S. lividans*, 84

Cephalosporinases
P. aeruginosa
 carbapenem resistance, role in, 1387

Cephalosporins
B. fragilis and *E. coli* infection
 mice, 1531
B. fragilis and *S. aureus* infection
 mice, 1531
B. thetaiotaomicron and *E. coli* infection
 mice, 1531
B. thetaiotaomicron and *S. aureus* infection
 mice, 1531
 cefozopran
K. pneumoniae, 100
P. aeruginosa, 100
 respiratory tract infections, 100
S. aureus, 100
 urinary tract infections, 100
 cefpodoxime proxetil
 ex vivo susceptibility, 2650
 pharmacokinetics, 2650

E1077
 in vitro and in vivo activities, 60

F. oryzihabitans
 in vitro activities against clinical isolates from patients with cancer, 2504

FK037
 anaerobic organisms, 957
 β -lactamase stability, 566
 in vitro activity, 566
 in vitro and in vivo activities, 301
 polymicrobial infection
 mice, 1531
 3'-quinolone carbamates
E. coli, mechanism of action, 559
 3'-quinolone esters
E. coli, mechanism of action, 559
 3'-quinolone tertiary amines
E. coli, mechanism of action, 559
 Ro 40-6890

antibiotic activity and host defense mechanisms, 2622
 pharmacodynamic activity in human skin blister fluid, 2622

S. aureus
 endocarditis, 554
 methicillin susceptible, 554

Cephems
 S-1108
 pharmacokinetics, 1043
 safety of and carnitine status of patients, 1043

CGI 17341
M. tuberculosis
 in vitro and in vivo activities, 183

CGP 53437
 antiviral activity
 human immunodeficiency virus type 1 protease, 2087

Chagas' disease
 ICI 195,739-terbinafine
 murine model, 1353
 ketoconazole-terbinafine
 murine model, 1353

Chancroid
 agents for treatment of, currently recommended and newer
H. ducreyi from the United States and Thailand, 1552
 in vitro susceptibilities, 1552

Chlamydia pneumoniae
 azithromycin
 in vitro activity, 1746
 OPC-17116
 in vitro and in vivo activities, 801
 sparfloxacin
 in vitro and in vivo activities, 801
 tosufloxacin
 in vitro and in vivo activities, 801
 tosufloxacin
 in vitro and in vivo activities, 801

Chlamydia psittaci
 OPC-17116
 in vitro and in vivo activities, 801
 sparfloxacin
 in vitro and in vivo activities, 801
 tosufloxacin
 in vitro and in vivo activities, 801

Chlamydia trachomatis
 azithromycin
 in vitro activity, 1746
 CI-960
 salpingitis, 8
 doxycycline
 comparative evaluation, 1373
 genital infections, treatment of, 1373
 genital infections
 doxycycline, comparative evaluation, 1373
 spiramycin, comparative evaluation, 1373

OPC-17116
 in vitro and in vivo activities, 801
 sparfloxacin
 in vitro and in vivo activities, 801
 spiramycin
 comparative evaluation, 1373
 genital infections, treatment of, 1373

tosufloxacin
in vitro and in vivo activities, 801

Chloramphenicol
P. cepacia
comparative evaluation, 123

S. typhi
14 days, comparative evaluation, 1572
typhoid fever
14 days, comparative evaluation, 1572

Chloramphenicol acetyltransferases
A. baumannii
production by, 138

Chlorhexidine
S. mutans
in vitro susceptibility, 1158

Chloroquine
P. falciparum
clonal viability measurements to assess in vitro activity, 1102

CI-960
C. trachomatis
salpingitis, monkey model, 8

Cilastatin
combinations
imipenem, 51
yeast colonization of the human gastrointestinal tract, effect on, 51

Cilofungin
C. albicans
comparative evaluation, 729
disseminated infection in normal and granulocytopenic mice, 729

Ciprofloxacin
adverse effects
convulsions in mice, 1764

B. burgdorferi
in vitro susceptibility, 1444
combinations
ampicillin, 1904
E. faecium, 1904
novobiocin, 1904
comparative evaluation
DU-6859a, 2747
ofloxacin, 2193
disk elution
M. avium complex susceptibility testing, 1556
M. tuberculosis susceptibility testing, 1556

E. coli
postantibiotic effect in pooled cerebrospinal fluid and Mueller-Hinton broth, 1154

gonorrhea, uncomplicated
single-dose therapy, comparative evaluation, 1670

H. influenzae
adherence changes induced by subinhibitory concentrations, 885

in vitro activities
gram-negative organisms, 2017
gram-positive organisms, 2017

K. pneumoniae
adherence changes induced by subinhibitory concentrations, 885

keratitis
age and therapeutic outcome, 1856

liposome incorporated
treatment of murine salmonellosis, 2293

M. catarrhalis
adherence changes induced by subinhibitory concentrations, 885

M. haemophilum
in vitro activities, 2323

M. pneumoniae
hamsters, 287

N. gonorrhoeae
antibacterial activities, 2244

P. aeruginosa
age and therapeutic outcome, 1856
dose-ranging and fractionation, 1756
in vitro model of infection, 1756
increased susceptibility in the presence of vancomycin, 2506
resistance to unrelated antibiotics, effects on, 1289

P. cepacia
comparative evaluation, 123

pharmacokinetics
effects of cardiopulmonary bypass surgery on disposition, 2106
multiple oral doses to healthy volunteers, 2193
seriously ill patients, 1073

population pharmacokinetics
optimal sampling strategies, 1065

postantibiotic effect
E. coli in pooled cerebrospinal fluid and Mueller-Hinton broth, 1154

S. aureus
dose-ranging and fractionation, 1756
in vitro model of infection, 1756
resistance to unrelated antibiotics, effects on, 1289

S. pneumoniae
mouse protection model, 234

S. typhimurium resistance
isolates from two patients, 662

serum bactericidal titers
multiple oral doses to healthy volunteers, 2193

synergy
ethambutol, 1285
M. malmoense, 1285

T-cell subsets and tumor necrosis factor production
mice infected with *B. fragilis*, effect on, 1711

typhoid fever
severe, in children, 1197

vancomycin
increased susceptibility of *P. aeruginosa*, 2506

Citrobacter freundii
ampD
sequences of wild-type and mutant genes, comparison with those of *E. coli*, 224

Clarithromycin
B. burgdorferi
hamsters, 1329
in vitro activity, comparative evaluation, 1704
in vitro susceptibility, 1444
bite wound isolates
aerobic and anaerobic, 1150

Brucella spp.
in vitro activity, comparative evaluation, 911

C. burnetii
in vitro susceptibilities, 2633
combinations
granulocyte colony-stimulating factor, 692

M. avium complex, 692

M. avium, prophylaxis in mice, 1690
minocycline, 1690
RU-4055, 692

cross-resistance
frequency distribution curves, scattergrams, and regression analyses, 2080

gram-negative organisms
outer membrane permeability barrier, 354

in vitro activities
frequency distribution curves, scattergrams, and regression analyses, 2080

Lyme disease
hamsters, 1329

M. avium
cross-resistance, 2364
erratum, 2515
human macrophages, 111
macrophages, inhibition of intracellular growth, 1380
prophylaxis in C57BL/6 mice, 1690

M. avium complex, 692

M. haemophilum
in vitro activities, 2323

M. kansasi
susceptibility testing, 1997

metabolite
B. burgdorferi, susceptibility in vitro, 1444

P. aeruginosa
biofilms, interaction with, 1749

S. pneumoniae resistance
cultures from Providence, R.I., 1742

T. pallidum
hamsters, 864

Clavulanate
combinations
E. coli, 2059
sulbactam, 2059
tazobactam, 2059

E. coli
β-lactamase, TEM type, resistant, 2059

Clavulanic acid
combinations
amoxicillin, 14
H. influenzae, β-lactamase producing and nonproducing, ampicillin resistant, 14
ticarcillin, 51
yeast colonization of the human gastrointestinal tract, effect on, 51

Clindamycin
B. fragilis
in vivo efficacy, correlation with in vitro susceptibility, 997

mice, 997

bioavailability
healthy volunteers and AIDS patients, 1137

E. coli
in vivo efficacy, correlation with in vitro susceptibility, 997

mice, 997

peptidyl-RNA
dissociation from ribosomes, 2027

pharmacokinetics
bioavailability, 1137
healthy volunteers and AIDS patients, 1137

T. gondii

infectivity, 2571
intracellular replication, 2571
protein synthesis, 2571

Clofazamine
M. haemophilum
in vitro activities, 2323

Clofazimine
M. avium-M. intracellulare complex
in vitro activities, 2584

M. tuberculosis
in vitro activities, 2584

Clonal viability measurements
P. falciparum
leupeptin, chloroquine, and 5-fluoroorotate, in vitro activity, 1102

Clostridium difficile
cefixime
effect on shedding in healthy volunteers, 1432

Clostridium spp.
Bay Y3118
in vitro activity, 2509

Co-trimoxazole
P. cepacia
comparative evaluation, 123

P. pseudomallei resistance
biofilm cells, 2000

Coumermycin A₁
B. burgdorferi
growth inhibition and induction of relaxation of supercoiled plasmids, 46

Coxiella burnetii
ceftriaxone
shell vial assay, 491

clarithromycin
in vitro susceptibilities, 2633

Q fever
minireview, 1733
treatment of, 1733

Coxsackievirus
WIN 54954
group B diabetogenic strain in mice, 1593

CP-70,429
in vitro antibacterial activity, 1547
β-lactamase stability, 1547

CP-99,219
gram-positive organisms
in vitro activity, 366

in vitro activity, 349

Cryptococcus neoformans
amphotericin B
in vitro susceptibility, 1383

recurrent meningitis, isolates from patients with, 1383

D0870
in vitro activities, 2126
in vivo and in vitro activities, 2412

fluconazole
in vitro susceptibility, 1383

recurrent meningitis, isolates from patients with, 1383

itraconazole
effects on cytochrome P-450-dependent sterol 14α-demethylation and reduction of 3-ketosteroids, 2101

NP-1
in vitro activity, 2628

platelet microbicidal protein
fungicidal activity, 546

susceptibility testing
current status of the standardization

process, minireview, 2517

Cryptosporidium parvum
sinefungin
curative and preventive activities, 889
immunosuppressed rat model, 889

Cycloguanil
P. falciparum
African isolates, 924

Cyclothialidine
Eubacterium spp.
inhibition, 2656

Cytochrome P-450
dirithromycin
type I binding spectrum, 265

macrolides
type I binding spectrum, 265

Cytokines
C. jejuni
effect of oral recombinant interleukin on mucosal immunity in mice, 2688

interleukin-8
nonspecific resistance to infection in neutropenic and normal mice, 276

Cytomegalovirus
1110U81
ganciclovir, potentiation of antiviral effects, 602

potent inhibition of replication, 602

ganciclovir
decrease in frequency and severity of disease in liver transplant recipients treated with OKT3 monoclonal antibodies, 2490

sensitivity at diagnosis and during treatment, 1360

ganciclovir resistance
point mutation in DNA polymerase gene, 19

(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine
interstitial pneumonitis after bone marrow transplantation, 218

phosphonylmethoxyalkyl derivatives, resistance to
point mutation in DNA polymerase gene, 19

phosphorothioate oligonucleotides
ISIS 2922, in vitro activity of, 1945

D0870

A. fumigatus
in vivo and in vitro activities, 2412

B. dermatitidis
murine blastomycosis, 1177

blastomycosis
murine, 1177

C. albicans
in vitro activities, 2126
in vivo and in vitro activities, 2412

C. neoformans
in vitro activities, 2126
in vivo and in vitro activities, 2412

comparative evaluation
fluconazole, 2412

pathogenic yeasts
in vitro activities, 2126

Dapsone
synergy
dihydrofolate reductase inhibitors, 1436

P. carinii, 1436

Ro 11-8958, 1436

Daptomycin
bactericidal activity
albumin or serum, presence of, controlled pH and calcium, 605

Decimal assay for additivity
synergy and antagonism
delineation of, 260

Deglucotiecoplanin amides
E. coli
uptake, mechanism of, 453

P. aeruginosa
uptake, mechanism of, 453

Dental amalgam
mercury
bacterial resistance, 825
bacterial resistance, letter to the editor, 1730

3'-Deoxy-2',3'-didehydrothymidine
pharmacokinetics
disposition and metabolism in hepatocytes and nonhuman primates, 1816

2'-Deoxy-3'-thiacytidine
human immunodeficiency virus type 1 resistance
due to amino acid substitution at catalytic site of reverse transcriptase, 2231

Diarylsulfones
human immunodeficiency virus type 1 mechanism of action, 754
reverse transcriptase inhibitor, 754

Didanosine
human immunodeficiency virus resistance
pol mutations, multiple resistance, 1480

salmonellae
in vitro activities, 106

2',3'-Dideoxy-3'-thiacytidine
(-) enantiomer
human immunodeficiency virus, resistance, characterization of, 875

human immunodeficiency virus resistance
characterization of, 875

confferred by the same mutation that confers resistance to ddI and ddC, 1390

generation of variants, 130

2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(+) enantiomer
human immunodeficiency virus, resistance, characterization of, 875

human immunodeficiency virus resistance
characterization of, 875

2',3'-Dideoxycytidine
human immunodeficiency virus resistance
generation of variants, 130

salmonellae
in vitro activities, 106

2',3'-Dideoxyinosine
salmonellae
in vitro activities, 106

2',3'-Dideoxynucleosides
visna virus
inhibition of replication, 2540

Dihydrofolate reductase
T. gondii
inhibitors, identification of, 1914

trimethoprim resistance
integron on a Tn27-like element, 1297

Dihydrofolate reductase inhibitors
synergy
dapsone, 1436
P. carinii, 1436
sulfamethoxazole, 1436

Dihydrofolate reductases
S. aureus
characterization of gene for, 1400
trimethoprim sensitive
S. aureus, characterization of gene for, 1400

Diltiazem
nefimicin
nephrotoxicity in rabbits, induction by, 1790

Diminazine
pharmacokinetics
Boran cattle, noninfected and infected with *T. congolense*, 1050

Dinitroanilines
L. mexicana
structure-function analysis, 1909
trifluralin, 1909

Dirithromycin
B. burgdorferi
in vitro susceptibility, 1444

Brucella spp.
in vitro activity, comparative evaluation, 911

cytochrome P-450 complex formation
rat and human livers, 265

polymorphonuclear leukocytes
interactions may promote killing of infecting organisms, 2557

Disk elution
ciprofloxacin susceptibility testing
M. avium complex, 1556
M. tuberculosis, 1556

DNA gyrases
E. coli
quinolones, mechanism of action, 839
quinolones
E. coli, mechanism of action, 839

DNA gyrases
C. jejuni
gyrA, cloning and nucleotide sequence, 457

Eubacterium spp.
cyclothialidine, characterization of, 2656

fluoroquinolones
single point mutation in *E. coli* A protein reduces binding, 126

Doxycycline
alpha-1-antitrypsin
protection from human neutrophil collagenase and gelatinase, 592

B. burgdorferi
in vitro susceptibility, 1444

C. trachomatis
comparative evaluation, 1373
genital infections, treatment of, 1373

combinations
Brucella spp., 1831
rifampin, 1831

E. coli
comparative evaluation, 846
epididymitis, 846

epididymitis
comparative evaluation, 846

E. coli, 846

DR-3354
comparative evaluation
accumulation by human polymorphonuclear leukocytes, 1882

Drosophila melanogaster
pyrimido[1,6- α]benzimidazoles
effects on topoisomerase II and Kc cells, 2599

Ro 46-7864
effects on topoisomerase II and Kc cells, 2599

Ro 47-3359
effects on topoisomerase II and Kc cells, 2599

Drug combination testing
fractional maximal effect method, 523

DU-6859a
comparative evaluation
ciprofloxacin, 2747
floxacin, 2747
levofloxacin, 2747
lomefloxacin, 2747
ofloxacin, 2747

Duck hepatitis B virus
suramin
prevention of infection in vivo, 1539

DV-7751a
fluoroquinolones
in vitro antibacterial activity, 2112

E1077
in vitro and in vivo activities, 60

E-4868
in vitro and in vivo activities, 868

Efflux pump inhibitors
screening assay, 1624

Encephalitis
foscarnet
blood-brain barrier, penetration of, 1010

Endocarditis
amphotericin B, 2030
ampicillin-sulbactam
S. aureus, β -lactamase hyperproducing, 507

aztreonam, 308

aztreonam-amilacacin, 308

C. parapsilosis, 2030

C. tropicalis, 2030

ceftazidime, 308

ceftazidime-amilacacin, 308

ceftriaxone-netilmicin
Streptococcus spp., 1971
synergy, 207

cephalosporins
broad spectrum, 554

E. faecalis, β -lactamase producing, highly gentamicin resistant
ampicillin-sulbactam, comparative evaluation, 1447

vancomycin, comparative evaluation, 1447

fluconazole, 2030

oxacillin
S. aureus, β -lactamase hyperproducing, 507

S. aureus, methicillin susceptible
cephalosporins, broad spectrum, 554

Streptococcus spp.
ceftriaxone-netilmicin synergy, 207

Endotoxic shock
magainins
eicosanoid release by rat peritoneal macrophages, effect on, 393

Enoxacin
infection prevention
adults with acute nonlymphocytic leukemia, 474

pharmacokinetics
oral antacids, effect on disposition, 775

urinary tract infections, recurrent
cefuroxime axetil, more rapid than, 1558
rapid symptom alleviation, 1558

Enterobacter cloacae
3-N-acetyltransferase
aac(3)-Vla gene, biochemical analysis of, 2074

β -lactamase
carbapenem hydrolyzing, biochemical properties, 939

Enterococcus faecalis
 β -lactamase
mobilization of gene, 1187
production, genes involved in regulation, 1966

β -lactamase producing, highly gentamicin resistant
ampicillin-sulbactam, comparative evaluation, 1447

vancomycin, comparative evaluation, 1447

endocarditis
ampicillin-sulbactam, comparative evaluation, 1447

vancomycin, comparative evaluation, 1447

virulence in a rabbit model conferred by plasmid-associated hemolysin and aggregation substance production, 2474

highly gentamicin resistant
molecular characterization of isolates lacking high-level streptomycin resistance, 134

penicillinase gene
mobilization of, 1187

polymerase chain reaction
heterogeneity of chloramphenicol acetyltransferase genes, 2593

vancomycin resistance gene
homology with *vanB*, *vanA*, and *vanC*, 1604

WIN 57273
activity against high-level gentamicin-resistant strains, 2470

Enterococcus faecium
aac(6')-li
specificity for, 1896

ampicillin resistance, 1904

ampicillin resistant, 2069

endocarditis, 2069

gentamicin resistance, 1904

gentamicin resistant, high level isolates from different continents, comparison of, 681

novobiocin
in vitro activity against multiresistant strains, 2736

penicillin resistance
time-kill studies, 2427

polymerase chain reaction

heterogeneity of chloramphenicol acetyltransferase genes, 2593
streptogramin A acetyltransferase
 identification of *satA*, 2119
 synergy
 penicillin-gentamicin, 2427
 vancomycin resistance, 1904
 vancomycin resistance gene
 homology with *vanB*, *vanA*, and
vanC, 1604
 vancomycin resistant, 2069
 resistance to synergistic β -lactam
 combinations, 1238

Enterococcus spp.
 antimicrobial susceptibilities
 isolates from hospitalized patients,
 1190
 glycopeptide resistance
 genetics and mechanisms of, minireview, 1563
 glycopeptide resistant
 characterization of isolates from U.S.
 hospitals, 2311
 pulsed-field gel electrophoresis, 2311

Epididymitis
 cefotaxime
 comparative evaluation, 846
 doxycycline
 comparative evaluation, 846
E. coli
 cefotaxime, comparative evaluation,
 846
 doxycycline, comparative evaluation,
 846
 ofloxacin, comparative evaluation, 846
 ofloxacin
 comparative evaluation, 846

Epipolyphyllotoxins
P. carinii
 activity in vitro and in a mouse model,
 1543

Epstein-Barr virus
 phosphorothioate oligodeoxynucleotides
 inhibition of replication, 1420

Equine herpesvirus 1
 phosphonylmethoxyalkyl derivatives
 murine model for abortion, 2478

Errata
M. avium
 activities of quinolones, 2766
 clarithromycin, minocycline, and rifabutin treatments of C57BL/6
 mice, 2515
 quinolones
 anti-*M. avium* activities, 2766

Erythromycin
B. burgdorferi
 in vitro activity, comparative evaluation, 1704
 in vitro susceptibility, 1444
 cross-resistance
 frequency distribution curves, scattergrams, and regression analyses, 2080
H. influenzae
 distribution in patients with lower respiratory tract infections, effect on, 804
H. parainfluenzae
 distribution in patients with lower respiratory tract infections, effect on, 804
 in vitro activities

frequency distribution curves, scattergrams, and regression analyses, 2080
M. haemophilum
 in vitro activities, 2323
P. aeruginosa
 serum sensitivity, effect of sub-MICs on, 675
 peptidyl-RNA
 accumulation, 2027
S. mutans
 in vitro susceptibility, 1158
S. pneumoniae resistance
 cultures from Providence, R.I., 1742
Escherichia coli
 amikacin resistance
 bleomycin, increase of, 1982
ampD
 sequences of wild-type and mutant genes, comparison with those of *C. freundii*, 224
 ampicillin-sulbactam
 comparative evaluation, 610
 azithromycin
 in vitro activity, 1203
B. fragilis, polymicrobial infection
 mice, 1531
B. thetaiotaomicron, polymicrobial infection
 mice, 1531
 β -lactamase
 ceftazidime resistance, 1989
 β -lactamase, TEM type, resistant
 clavulanate, 2059
 sulbactam, 2059
 tazobactam, 2059
 β -lactamases
 TEM-1, cephalosporinase activity of, 2438
 cefoperazone-sulbactam
 granulocytopenic mice, disseminated infections in, 1927
 cefotaxime
 comparative evaluation, 846
 postantibiotic effect in cerebrospinal fluid and Mueller-Hinton broth, 1154
 cefoxitin
 comparative evaluation, 610
 ceftazidime resistance
 β -lactamase, 1989
 cephalosporins
 3'-quinolone esters, carbamates, and tertiary amines, mechanism of action, 559
 ciprofloxacin
 postantibiotic effect in cerebrospinal fluid and Mueller-Hinton broth, 1154
 clindamycin
 in vivo efficacy, correlation with in vitro susceptibility, 997
 mice, 997
 deglucotetralin amide derivatives
 uptake, mechanism of, 453
 DNA gyrase
 quinolones, mechanism of action, 839
 DNA gyrase A protein
 fluoroquinolones, single point mutation reduces binding, 126
 doxycycline
 comparative evaluation, 846
 epididymitis

cefotaxime, comparative evaluation, 846
 doxycycline, comparative evaluation, 846
 ofloxacin, comparative evaluation, 846
 fluoroquinolone resistant
gyrA, mutations in, 696
 fluoroquinolone resistant, nalidixic acid susceptible
gyrA point mutation, novel, 1247
 gentamicin
 kill kinetics and regrowth patterns after exposure, 914
 postantibiotic effect in cerebrospinal fluid and Mueller-Hinton broth, 1154
 isoniazid
 susceptibilities of *oxyR* regulon mutants, 2251
 lactoferrin-porin interaction
 antibacterial activity, effect on, 240
 mutants
 supersusceptibility to antibiotics, 2255
 ofloxacin
 comparative evaluation, 846
 pefloxacin
 one 800-mg versus two 400-mg doses, 737
 plasmid complementation test
 quinolone resistance, 2588
 postantibiotic effect
 correlation of tobramycin-induced inhibition of protein synthesis, 2678
 quinolone resistance
 plasmid complementation test, 2588
 quinolones
 DNA gyrase, mechanism of action, 839
 in vivo efficacy, correlation with in vitro susceptibility, 997
 mice, 997
S. aureus *tetK*
 expression in, 191
 streptomycin resistance
 bleomycin, increase of, 1982
 tobramycin resistance
 3'-aminoglycoside phosphotransferase type I, overproduction of, 78

Ethambutol
Mycobacterium spp.
 glucose metabolism, inhibition of, 1536
 synergy
 amikacin, 1285
 ciprofloxacin, 1285
M. malmoense, 1285
 rifampin, 1285

Eubacterium spp.
 DNA gyrases
 cyclothialidine, characterization of, 2656

FDA approvals
 anti-infective agents, biologics, and vaccines approved in 1992, 926

FK037
 anaerobic organisms
 in vitro activity, 957
B. burgdorferi
 in vitro susceptibility, 1444
 β -lactamase stability, 566
 in vitro activity, 566

multicenter comparison, 1696
in vitro and in vivo activities
comparative evaluation, 301

Flavimonas oryzihabitans
aminoglycosides
in vitro activities against clinical isolates from patients with cancer, 2504

carbapenems
in vitro activities against clinical isolates from patients with cancer, 2504

extended-spectrum cephalosporins
in vitro activities against clinical isolates from patients with cancer, 2504

monobactams
in vitro activities against clinical isolates from patients with cancer, 2504

ureidopenicillins
in vitro activities against clinical isolates from patients with cancer, 2504

Fleroxacin
breast milk
penetration into, 293
combinations
rifampin, 2132
comparative evaluation
DU-6859a, 2747
in vitro activities
gram-negative organisms, 2017
gram-positive organisms, 2017
pharmacokinetics
breast milk, penetration into, 293
effects in healthy volunteers by
positron emission tomography,
¹⁸F labeled, 2144
lactating women, 293
rifampin, influence of, 2132
S. aureus, 2132

Fluconazole
bioavailability
patients with AIDS, 2187
C. albicans
emergence of resistance of Norwegian strains, 2443
patients infected with human immunodeficiency virus type 1, correlation to therapy and symptoms, 2449

C. glabrata resistance, 1962
C. neoformans
in vitro susceptibility, 1383
recurrent meningitis, isolates from patients with, 1383
comparative evaluation
amphotericin B, 2030
endocarditis
C. parapsilosis, 2030
C. tropicalis, 2030
intracellular activity
human polymorphonuclear leukocytes, 187

P. marneffei
response of human immunodeficiency virus-infected patients, 2407
pharmacokinetics
healthy human subjects, 1270
influence of radiotherapy on penetration into human saliva, 2674
patients with AIDS, 2187

positron emission tomography, ¹⁸F labeled, 1270
uptake in human polymorphonuclear leukocytes, 187

T. glabrata
prophylaxis in neutropenic bone marrow transplant patients, 1847

Flucytosine
Candida spp.
temperature, effect on activity, 685
cis-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolane-5-yl]cytosine
(-) and (+) enantiomers, 5'-triphosphates
human immunodeficiency virus, 1720
human immunodeficiency virus
(-) and (+) enantiomers, 5' triphosphates, 1720

5-Fluorocytosine
P. marneffei
response of human immunodeficiency virus-infected patients, 2407

5-Fluoroorotate
P. falciparum
clonal viability measurements to assess in vitro activity, 1102

Fluoroquinolones
ciprofloxacin
reduced susceptibilities of *S. sonnei* strains, 2486
combinations
inhibitors of glycosylation and fatty acid and peptide biosynthesis, 652
M. avium, 652

CP-99,219
gram-positive organisms, in vitro activity, 366
in vitro activity, 349

DNA gyrase
E. coli A protein, single point mutation reduces binding, 126

DV-7751a
in vitro antibacterial activity, 2112

E-4868
in vitro and in vivo activities, 868

E. coli DNA gyrase A protein
single point mutation reduces binding, 126

E. coli resistance
gyrA, mutations in, 696

E. coli resistance, nalidixic acid susceptible
gyrA, novel point mutation, 1247

gram-positive cocci
bloodstream isolates, 896
in vitro activity, 896

M. pneumoniae, 1826

ofloxacin
reduced susceptibilities of *S. sonnei* strains, 2486

OPC-17116
accumulation by human polymorphonuclear leukocytes, 1882
penetration into bacterial cells
minireview, 1393

Q-35
in vitro and in vivo activities, 1826
reduced phototoxicity in mice irradiated with long-wavelength UV, 2217

S. aureus resistance
efflux mediated, 1086
NorA, multidrug efflux transporter, 128

sparfloxacin
reduced susceptibilities of *S. sonnei* strains, 2486

WIN 57273
E. faecalis, 2470

Flurbiprofen
keratitis
age and therapeutic outcome, 1856

P. aeruginosa
age and therapeutic outcome, 1856

Foscarnet
human immunodeficiency virus
cerebrospinal fluid of patients with AIDS, penetration of, 1777
human renal proximal tubule cells
nephrotoxicity, 2496
nephrotoxicity
human renal proximal tubule cells, 2496

pharmacokinetics
blood-brain barrier, penetration of, 1010
cerebrospinal fluid of patients with AIDS, penetration of, 1777

Fosfomycin
B-lymphocyte function
immunomodulatory effect, 270

T cells
immunosuppressive effect, 2684

Fractional maximal effect method
antibiotic combinations
effect, characterization of, 523
nonlinear pharmacodynamics
characterization of, 523

Fullerenes
human immunodeficiency virus
activity against, 1707

Fusidic acid
combinations
S. aureus, 2466
vancomycin, 2466

M. kansasii
susceptibility testing, 1997

pharmacokinetics
intravenous, cholestatic patients, 501

Fusobacterium spp.
Bay Y3118
in vitro activity, 2509

G418
T. brucei brucei resistance phenotype
in vivo system to select for blood-stream-form transfectants, 1167

Gamma interferon
receptors
relation to therapy of typhoid fever, 2418

Ganciclovir
cytomegalovirus
1110U81, potentiation of antiviral effects, 602

prophylaxis decreases frequency and severity in liver transplant recipients treated with OKT3 monoclonal antibodies, 2490

sensitivity at diagnosis and during treatment, 1360

cytomegalovirus resistance
point mutation in DNA polymerase gene, 19

Gardnerella vaginalis
agar dilution
susceptibilities to 25 antimicrobial agents, 2733

Gentamicin
E. coli
kill kinetics and regrowth patterns after exposure, 914
postantibiotic effect in pooled cerebrospinal fluid and Mueller-Hinton broth, 1154

E. faecalis resistance, high level
molecular characterization of isolates lacking high-level streptomycin resistance, 134

E. faecium resistance, 1904

E. faecium resistance, high level
isolates from different continents, comparison of, 681

glomerular basement membrane
alteration of development after administration during gestation, 1510

M. avium complex
AIDS patients with bacteremia, 1869

nephrotoxicity
neonates, drug-treated pregnant Wistar rats, 1510
polyaspartic acid, protective effects, pharmacologic limits of, 347

P. aeruginosa
A band and B band lipopolysaccharides, interaction with, 715

pharmacokinetics
increased renal uptake in endotoxemic rats receiving thromboxane A₂ therapy, 2727
population pharmacokinetic models, comparison of, 93

postantibiotic effect
E. coli, in pooled cerebrospinal fluid and Mueller-Hinton broth, 1154

S. mitis
chromosomally mediated high-level resistance, 2740

TLC G-65, 1869

Giardia lamblia
bis-benzimidazoles
correlation of antigiardial activity, DNA binding affinity, and giardial topoisomerase II inhibition, 2668
structure-activity studies, 2668

Giardia spp.
benzimidazoles
in vitro activity, 328

tubulin inhibitors
in vitro activity, 328

Glucan
irradiated mice, therapy for after adverse effects from pefloxacin, 1877

Glucose oxidase
human immunodeficiency virus type 1 virucidal effects, 26

Glucose peroxidase
human immunodeficiency virus type 1 virucidal effects, 26

Glycopeptides
Enterococcus resistance
genetics and mechanisms of, minireview, 1563

gram-positive cocci
bloodstream isolates, 896
in vitro activity, 896

Glycylcyclines
comparative evaluation
in vitro and in vivo activities, 2270
minocycline and tetracycline, 2270

Gonorrhea
ceftriaxone
single-dose therapy for women, comparative evaluation, 1670

ciprofloxacin
single-dose therapy for women, comparative evaluation, 1670

GR99060
antifungal activity, 1243

GR99062
antifungal activity, 1243

Gram-negative organisms
anaerobic
Bay y3118, comparative susceptibilities, 1649

azithromycin
outer membrane permeability barrier, 354

Bay y3118
comparative susceptibilities, 1649

biapenem
in vitro activity, 2009

CAP18
in vitro activity, 2534

clarithromycin
outer membrane permeability barrier, 354

CP-70,429
in vitro activity, 1547

imipenem
in vitro activity, 2009

outer membrane permeability barrier
azithromycin, clarithromycin, and roxithromycin, 354

roxithromycin
outer membrane permeability barrier, 354

Gram-positive organisms
aerobic
MDL 62,879, 746

anaerobic
Bay y3118, comparative susceptibilities, 1649

Bay y3118
comparative susceptibilities, 1649

biapenem
in vitro activity, 2009

bloodstream isolates
fluoroquinolones, 896
glycopeptides, 896
ramoplanin, 896

CAP18
in vitro activity, 2534

CP-70,429
in vitro activity, 1547

CP-99,219
in vitro activity, 366

fluoroquinolones
in vitro activity, 896

glycopeptides
in vitro activity, 896

imipenem
in vitro activity, 2009

MDL 62,879
aerobic, 746

PD 138312
in vitro activities, 2563

PD 140248
in vitro activities, 2563

ramoplanin
in vitro activity, 896

RP59500
in vitro activity, 598

vancomycin resistant ramoplanin, 1364

RP59500, 598

Granulocyte colony-stimulating factor combinations
clarithromycin, 692

M. avium complex, 692

M. avium complex, 692

Granulocyte-macrophage colony-stimulating factor
pharmacokinetics
zidovudine, administration with, 512

Griseofulvin
comparative evaluation
itraconazole, 2064
tinea unguium, 2064

4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneurameric acid
influenza viruses
growth inhibition, 1473
sialidase, inhibition of, 1473

gyrA
E. coli
fluoroquinolone resistance, 696
mutations in, 696

E. coli, fluoroquinolone resistant, nalidixic acid susceptible point mutation, novel, 1247

Haemophilus ducreyi
chancroid, currently recommended and newer agents for
in vitro susceptibilities, 1552

isolates from the United States and Thailand, 1552

parenteral and oral antimicrobial agents
in vitro activities, 1986

Haemophilus influenzae
ampicillin
distribution in patients with lower respiratory tract infections, effect on, 804

β -lactamase producing and nonproducing, ampicillin resistant amoxicillin-clavulanic acid, susceptibility to, 14

cefaclor, susceptibility to, 14

cefixime, susceptibility to, 14

cefotaxime, susceptibility to, 14

ceftibuten, susceptibility to, 14

cefuroxime, susceptibility to, 14

ciprofloxacin
adherence changes induced by subinhibitory concentrations, 885

ecology in sputum and saliva, 804

erythromycin
distribution in patients with lower respiratory tract infections, effect on, 804

macrolides
subinhibitory concentrations, influence on human neutrophil chemiluminescence, 1015

sparfloxacin
adherence changes induced by subinhibitory concentrations, 885

trimethoprim
adherence changes induced by subin-

hibitory concentrations, 885
Haemophilus parainfluenzae
 ampicillin
 distribution in patients with lower respiratory tract infections, effect on, 804
 ecology in sputum and saliva, 804
erythromycin
 distribution in patients with lower respiratory tract infections, effect on, 804
Hafnia alvei
 ceftazidime resistant
 β -lactamase producing, 1375
Halofantrine
P. falciparum, 1955
 efficacy in semi-immune patients in Cameroon, 1955
P. falciparum resistance, 2337
Helicobacter pylori
 AG-2000
 urease activity, inhibition of, 769
lansoprazole
 urease activity, inhibition of, 769
 metronidazole and its hydroxymetabolite synergy, 1184
 metronidazole's hydroxymetabolite-tetracycline-HCl
 synergy, 1184
 metronidazole's hydroxymetabolite-amoxicillin
 synergy, 1184
 metronidazole-tetracycline-HCl
 synergy, 1184
 metronidazole-amoxicillin
 synergy, 1184
omeprazole
 urease activity, inhibition of, 769
Hepatitis B virus
 antiviral agents
 assessment in vitro, high capacity, 441
 duck
 suramin, prevention of infection in vivo, 1539
Hepatitis C virus
 alpha interferon treatment
 HCV RNA levels in patients with chronic infections, 595
 RNA levels
 patients with chronic infections receiving interferon treatment, 595
Herpes simplex virus
 acyclovir and foscarnet resistant
 pencyclovir, 2241
 acyclovir resistant
 348-U87-acyclovir, 975
 ribonucleotide reductase inhibitor-acyclovir, 975
 acyclovir susceptibility
 strains from organ transplant recipients after acyclovir or ganciclovir prophylaxis, 357
 acyclovir-5-fluorodeoxyuridine-2'-acetylpyridine thiosemicarbazone
 three-dimensional analysis of, 540
 pencyclovir
 in vitro activities, 2241
Herpes simplex virus type 1
 acyclovir
 comparative evaluation, 642
 pencyclovir
 comparative evaluation, 642

Herpesviruses
 acyclic nucleoside phosphonates
 (S) and (R) enantiomers, 332
 (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine, 332
 High-performance liquid chromatography
 carbicillin epimers
 analysis in biological fluids, 2327
Human immunodeficiency virus
 antiretroviral agents
 resistance to, minireview, 1207
 (-)-2',3'-dideoxy-5-fluoro-3'-thiacytidine
 characterization of, 875
 (-)-2',3'-dideoxy-3'-thiacytidine
 characterization of, 875
 foscarnet
 cerebrospinal fluid of patients with AIDS, penetration of, 1777
 fullerene, derivatized C₆₀
 activity of, 1707
 protease inhibitors
 allophenylnorstatine containing, in vitro activities, 810
 XM323
 in vitro activity, 2606
Human immunodeficiency virus type 1
 3TC resistance
 conferred by same mutation that confers resistance to ddI and ddC, 1390
 A77003
 preclinical evaluation, 115
 protease inhibitor, 115
 anti-CD4-pokeweed antiviral protein immunocconjugate
 in vitro activity, 835
 3'-azido-3'-deoxythymidine
 replication in human fetal brain macrophages, effect on, 1305
C. albicans
 fluconazole resistance, 2449
 carbovir
 cellular metabolism, effects on, 1004
 metabolism, 1004
 carbovir-3'-azido-2',3'-deoxythymidine
 synergy, 144
 CGP 53437
 protease, inhibition of, 2087
 chimeric enzymes, inhibition of
 nonnucleoside inhibitors, 1037
 2'-deoxy-3'-thiacytidine resistance
 due to amino acid substitution at catalytic site of reverse transcriptase, 2231
 diarylsulfones
 mechanism of action, 754
 reverse transcriptase inhibitor, 754
 2',3'-dideoxy-3'-thiacytidine resistance
 generation of variants, 130
 2',3'-dideoxycytidine resistance
 generation of variants, 130
 drug susceptibility
 peripheral blood mononuclear cell culture assay, 1095
 fluconazole
C. albicans resistance, 2449
 FTC
 5'-triphosphates of (-) and (+) enantiomers, 1720
 glucose oxidase and peroxidase
 virucidal effects, 26
 peripheral blood mononuclear cell culture assay
 drug susceptibility, determination of, 1095
 protease inhibitors
 A77003, 115
 reverse transcriptase inhibition
 nonnucleoside inhibitors, 1037
 reverse transcriptase inhibitor
 isolates resistant to related inhibitors, activity against, 947
 reverse transcriptase inhibitor resistance
 mutant enzyme and viral variant assessment, 1576
 reverse transcriptase inhibitors
 FTC, 5'-triphosphates of (-) and (+) enantiomers, 1720
 infectious amplification from lymphocytes and modulation, 2206
 S-2720, activity of, 1659
 S-2720
 inhibition of reverse transcriptase and viral replication, 1659
 thiazolo-iso-indolinones
 resistance, 2612
 U-90152
 replication, inhibition of, 1127
 zidovudine and didanosine resistant *pol* mutations, 1480
 zidovudine sensitivity
 discontinuation of zidovudine treatment, effects on, 1525
Human immunodeficiency virus type 2
 chimeric enzymes, inhibition of
 nonnucleoside inhibitors, 1037
Human renal proximal tubule cells
 nephrotoxicity
 in vitro studies, 2496
Hydatid disease
 albendazole
 treatment of, 1679
 mebendazole
 treatment of, 1679
 (-)-9-[4-Hydroxy-2-(hydroxymethyl)butyl]guanine
 simian varicella virus
 African green monkeys, 1370
 (S)-1-(3-Hydroxy-2-phosphonyl-methoxypropyl)cytosine
 cytomegalovirus
 interstitial pneumonitis after bone marrow transplantation, 218
Hydroxylitraconazole
 bioassay and chromatography, effect on, 2224
 itraconazole, metabolism of, 2224
 ICI 195,739
 combinations
Chagas' disease, murine, 1353
T. cruzi, 1353
 terbinafine, 1353
Imipenem
B. wadsworthia
 morphological response, 2638
 penicillin-binding protein patterns, 2638
 combinations
 amikacin, 1931
 cilastatin, 51
P. aeruginosa, 1931
 yeast colonization of the human gastrointestinal tract, effect on, 51
P. aeruginosa

phenotypic resistance induced by salicylate, 2743

pharmacodynamics
P. aeruginosa, 1931

postantibiotic effect
 repeated exposures, 1723

R. equi resistance
 penicillin-binding proteins, potential role in, 1406

Imipenem resistance
P. aeruginosa
 mechanism of efficient elimination of protein D2, 2385

Immune globulin
 respiratory syncytial virus
 prophylaxis for high-risk infants, evaluation of, 1655

Influenza viruses
E. coli, expression in
 rimantadine
 susceptibilities of subtypes A/H1N1 and A/H3N2, 2239

Influenza viruses
 4-guanidino-2,4-dideoxy-2,3-dehydro-*N*-acetylneuraminic acid
 growth inhibition, 1473
 sialidase, inhibition of, 1473

Intercellular adhesion molecule 1
E. coli, expression in
 functional studies, 1278
 soluble
 function studies of, 1278

Interleukin-6
 amphotericin B, 1958
C. albicans, 1958
 receptors
 relation to therapy of typhoid fever, 2418

Interleukin-8
 nonspecific resistance to infection
 neutropenic and normal mice, 276

Intestinal microflora
 anaerobic
 resistance patterns, 1665

Isepamicin
 pharmacokinetics
 nephrotoxicity, influence on in rats, 2042

ISIS 2922
 cytomegalovirus
 in vitro activity, 1945

Isoniazid
E. coli
 susceptibilities of *oxyR* regulon mutants, 2251

S. typhimurium
 susceptibilities of *oxyR* regulon mutants, 2251

Isoprinosine
P. carinii
 dihydropteroate synthetase inhibition, 1227

Itraconazole
A. fumigatus
 efficacy in a rat model, 2762
 alveolar macrophages, uptake by, 903
 aspergillosis, 2307
 bioassay and chromatography, discrepancies in
 hydroxyitraconazole, metabolism to, 2224

C. albicans
 placebo-controlled trial, 89

C. neoformans

effects on cytochrome P-450-dependent sterol 14 α -demethylation and reduction of 3-ketosteroids, 2101

candidiasis, acute vaginal
 placebo-controlled trial, 89

comparative evaluation
 amphotericin B, 2307
 griseofulvin, 2064

interpatient variations in concentration, 2224

P. marneffei
 response of human immunodeficiency virus-infected patients, 2407

pharmacokinetics
 food interaction, 778
 steady state, 778

tinea unguium, 2064

Ivermectins
S. erythraea
 glycosylation, microbial conversion by, 1737

Keratitis
 ciprofloxacin
 age and therapeutic outcome, 1856

flurbiprofen
 age and therapeutic outcome, 1856

P. aeruginosa
 age and therapeutic outcome, 1856

prednisolone
 age and therapeutic outcome, 1856

Ketoconazole
 combinations
Chagas' disease, murine, 1353

T. cruzi, 1353

terbinafine, 1353

mevinolin
T. cruzi, potentiation of antiproliferative effects, 580

P. marneffei
 response of human immunodeficiency virus-infected patients, 2407

Klebsiella pneumoniae
 β -lactamase
 β -lactams, broad spectrum, resistance to, 984

β -lactams, extended spectrum, resistance to, 2020

ceftazidime resistance, 1989

plasmid encoded, TEM derived, 2020

plasmid mediated, AmpC type, transferable, 984

cefoperazone-sulbactam resistance
 coexistence of two different resistance mechanisms, 1061

cefotazopran
 respiratory tract infection, 100

ceftazidime resistance
 β -lactamase, 1989

ciprofloxacin
 adherence changes induced by subinhibitory concentrations, 885

interleukin-1-induced nonspecific resistance
 role of acute-phase proteins in studies with mice, 2527

sparfloxacin
 adherence changes induced by subinhibitory concentrations, 885

trimethoprim
 adherence changes induced by subinhibitory concentrations, 885

KNI-227
 human immunodeficiency virus
 protease inhibitor, allophenylnorstatine containing, 810

KNI-272
 human immunodeficiency virus
 protease inhibitor, allophenylnorstatine containing, 810

KRM-1648
M. avium, 722

L-696,229
 analogs
 human immunodeficiency virus isolates resistant to related inhibitors, 947

human immunodeficiency virus isolates resistant to related inhibitors, activity against, 947

Lactoferrin
 porin binding
E. coli antibacterial activity, relationship with, 240

S. typhimurium antibacterial activity, relationship with, 240

Lansoprazole
H. pylori
 urease activity, inhibition of, 769

Legionella micadai
 azithromycin
 inhibition of intracellular strains, 2261

intracellular
 azithromycin inhibition, 2261

Legionella spp.
 RP 74501-RP 74502
 in vitro activity, 908

Leishmania amazonensis
 quinoline alkaloids
 2 substituted, 859

Leishmania donovani
 amphotericin B
 T-cell-deficient mice, 1504

leishmaniasis
 trans-aconitic acid in combined chemotherapy, 2459

licoachalcone A
 inhibition of growth, 2550

pentamidine
 T-cell-deficient mice, 1504

trans-aconitic acid
 role in combined chemotherapy for experimentally infected hamsters, 2459

Leishmania major
 licoachalcone A
 inhibition of growth, 2550

Leishmania mexicana
 dinitroanilines
 structure-function analysis, 1909

trifluralin, 1909

Leishmania panamensis
 sodium stibogluconate
 in vitro activities of fractions, 1842

Leishmania spp.
 9-anilinoacridines
 in vitro activity, 991
 structure-activity relationships, 991

quinoline alkaloids
 2 substituted, 859

Leishmania venezuelensis
 quinoline alkaloids
 2 substituted, 859

Leishmaniasis
 cutaneous
 quinolone alkaloids, 2 substitut. J, 859
 quinoline alkaloids
 2 substituted, 859
visceral
 amphotericin B, T-cell-deficient mice, 1504
 pentamidine, T-cell-deficient mice, 1504

Leptospira interrogans
Q-35
 five serogroups, 901

Letters to the editor
 aminoglycoside resistance genes
 nomenclature, 927

Capnocytophaga spp.
 antimicrobial susceptibilities, 1206

cefotaxime
 S. pneumoniae breakpoint, 616

dental amalgam
 multiple antibiotic resistance, 1730

Nocardia spp.
 susceptibility testing, 2514

S. pneumoniae
 cefotaxime breakpoint, 616
 susceptibility data
 multidimensional analysis, 929

Leukemia
 enoxacin
 infection prevention in adults with nonlymphocytic leukemia, 474

Leupeptin
 P. falciparum
 clonal viability measurements to assess in vitro activity, 1102

Levofloxacin
 adverse effects
 convulsions in mice, 1764
 aluminum hydroxide
 inhibition of absorption by, 2173
 comparative evaluation
 accumulation by human polymorphonuclear leukocytes, 1882
 DU-6859a, 2747
 synergy
 oxacillin, 339
 S. aureus, quinolone resistant, 339

Licochalcone A
 L. donovani
 inhibition of growth, 2550
 L. major
 inhibition of growth, 2550

Lincomycin
 peptidyl-RNA
 accumulation, 2027
 dissociation from ribosomes, 2027

Lipophilic agents
 penetration into bacterial cells
 minireview, 1393

Liposomes
 ciprofloxacin, liposome incorporated
 treatment of murine salmonellosis, 2293

LJC 10,627
 toxicity
 central nervous systems of rats, low levels of, 199

Lomefloxacin
 comparative evaluation
 DU-6859a, 2747
 pharmacodynamics
 concentration in plasma-time profile, relation to survival, 483

neutropenic rat model of *Pseudomonas* sepsis, 483

urinary tract infections
 3-day treatment, 574
 acute uncomplicated, 574
 comparative evaluation, 574

Luciferase
 M. tuberculosis
 antimicrobial activity against, method for screening for, 1348

Lyme disease
 clarithromycin
 hamsters, 1329

Macrolides
 combinations
 inhibitors of glycosylation and fatty acid and peptide biosynthesis, 652
 M. avium, 652

cytochrome P-450 complex formation
 rat and human livers, 265

dirithromycin
 interactions with polymorphonuclear leukocytes, 2557

H. influenzae
 subinhibitory concentrations, influence on human neutrophil chemiluminescence, 1015

P. acidilactici resistance
 genetic basis for, 789

P. aeruginosa
 serum sensitivity, effect of sub-MICs on, 675

Magainins
 eicosanoid release
 rat peritoneal macrophages, effect on, 393

Magnesium-aluminum hydroxide
 rifloxacin
 effects on absorption, 2212

Malaria
 amopyroquin
 intramuscular, 970
 halofantrine
 efficacy in semi-immune patients in Cameroon, 1955

mefloquine
 P. falciparum, 1977

P. falciparum, 1955
 amopyroquin, 970
 mefloquine, 1977

Mastitis
 bovine
 pirlimycin, activity and disk diffusion breakpoints, 1122

pirlimycin
 activity against bovine pathogens, 1122
 disk diffusion breakpoints, 1122

MDL 62,879
 anaerobic bacteria, 746
 gram-positive organisms
 aerobic, 746
 in vitro activity, 741

Mebendazole
 hydatid disease
 treatment of, 1679

mec
 Staphylococcus spp., methicillin resistant
 distribution of regulator genes in, 1219

Mefloquine
 malaria
 comparison of two regimens, 1977

P. falciparum
 comparative evaluation of two regimens, 1977

Meningitis
 pneumococcal, penicillin and cephalosporin resistant
 treatment regimens, evaluation of, 1630

recurrent cryptococcal
 susceptibility of *C. neoformans* isolates to amphotericin B and fluconazole, 1383

Mercury
 bacterial resistance
 letter to the editor, 1730
 mercury from dental fillings provokes increased occurrence, 825

Meropenem
 P. cepacia
 comparative evaluation, 123

pharmacokinetics
 patients with various degrees of renal function, 229

Metabolic disposition
 (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine studies with rats, 2285

Methicillin
 S. aureus resistance
 abnormal peptidoglycan, 342
 β-lactam-β-lactam inhibitor combinations, 702
 β-lactams, 702
 penicillin-binding protein 2A, role in cell wall synthesis, 342

S. aureus resistance and susceptibility
 sequential acquisition of norfloxacin and ofloxacin resistance in isolates, 2278

Staphylococcus resistance
 mec regulator genes, distribution of, 1219

Metronidazole
 synergy
 amoxicillin, 1184
 H. pylori, 1184
 hydroxymetabolite of metronidazole, 1184
 tetracycline-HCl, 1184

Mevinolin
 T. cruzi
 ketoconazole and terbinafine, potentiation of antiproliferative effects, 580

Miconazole
 P. marneffei
 response of human immunodeficiency virus-infected patients, 2407

Microdilution checkerboard method
 synergy measurement
 reproducibility, 613

Minireviews
 β-lactamases
 induction of, molecular basis for, 153
 β-lactams
 penicillin-binding protein resistance, 2045

C. neoformans
 susceptibility testing, status of the standardization process, 2517

Candida spp.
susceptibility testing, status of the standardization process, 2517

Enterococcus spp.
glycopeptide resistance, genetics and mechanisms of, 1563
glycopeptides
Enterococcus resistance, genetics and mechanisms of, 1563
human immunodeficiency virus
antiretroviral agents, resistance to, 1207
lipophilic agents with multiple protonation sites
penetration into bacterial cells, 1393
new antibiotics
discovery and development, problem of resistance, 377
nosocomial pneumonia
critically ill patients, prevention of, 931
organ transplant recipients
antimicrobial strategies, 619
penicillin-binding proteins
β-lactam resistance, 2045
Q fever
treatment of, 1733
rifampin
nonstaphylococcal, nonmycobacterial disease, 1

Minocycline
combinations
clarithromycin, 1690
M. avium, prophylaxis in mice, 1690
rifabutin, 1690

M. avium
erratum, 2515

Monobactams
F. oxytropis
in vitro activities against clinical isolates from patients with cancer, 2504

Moraxella catarrhalis
ciprofloxacin
adherence changes induced by subinhibitory concentrations, 885
sparfloxacin
adherence changes induced by subinhibitory concentrations, 885
trimethoprim
adherence changes induced by subinhibitory concentrations, 885

Mupirocin
S. aureus resistance, high level
isoleucyl-tRNA synthetases, evidence for two distinct, 32

Mupirocin resistance
S. aureus
detection and characterization, 2003

Mureidomycins
bacterial translocase reaction in peptidoglycan synthesis, inhibition of, 980

Murine leukemia virus
protease inhibitors
antiretroviral activity, 71

Mutagenicity
quinolones
Ames *Salmonella* TA102 assay, 213

Mycobacterium avium
activities of quinolones
erratum, 2766
aminoglycosides

combination with inhibitors of glycosylation and fatty acid and peptide biosynthesis, 652
azithromycin resistance
clarithromycin, 2364
cross-resistance, 2364
clarithromycin
erratum, 2515
human macrophages, 111
macrophages, inhibition of intracellular growth, 1380
prophylaxis in C57BL/6 mice, 1690

clarithromycin resistance
azithromycin, 2364
cross-resistance, 2364
clarithromycin-minocycline
prophylaxis in C57BL/6 mice, 1690
fluoroquinolones
combination with inhibitors of glycosylation and fatty acid and peptide biosynthesis, 652

KRM-1648, 722

macrolides
combination with inhibitors of glycosylation and fatty acid and peptide biosynthesis, 652

minocycline
erratum, 2515

quinolones
in vitro activities, 1799
structure-activity relationship studies, 1807

rifabutin
erratum, 2515
prophylaxis in C57BL/6 mice, 1690

rifabutin-minocycline
prophylaxis in C57BL/6 mice, 1690

Mycobacterium avium complex
azithromycin
rats treated with cyclosporine, 398
benzoxazinorifampicin
radiometric method, determination by, 67

clarithromycin, 692

gentamicin
AIDS patients with bacteremia, 1869
TLC G-65, 1869

granulocyte colony-stimulating factor, 692

granulocyte colony-stimulating factor-clarithromycin, 692

rifabutin
rats treated with cyclosporine, 398

rifapentine
rats treated with cyclosporine, 398

RU-40555, 692

RU-40555-clarithromycin, 692

Mycobacterium avium-M. intracellulare complex
clofazimine
in vitro activities, 2584
resorcinomycin
in vitro activities, 2584

Mycobacterium fortuitum
amikacin
postantibiotic effect, 1001
ofloxacin
postantibiotic effect, 1001

Mycobacterium haemophilum
amikacin
in vitro activities, 2323
azithromycin
in vitro activities, 2323

ciprofloxacin
in vitro activities, 2323
clarithromycin
in vitro activities, 2323
clofazamine
in vitro activities, 2323
erythromycin
in vitro activities, 2323
ofloxacin
in vitro activities, 2323
rifabutin
in vitro activities, 2323
rifampin
in vitro activities, 2323
sparfloxacin
in vitro activities, 2323

Mycobacterium kansasi
susceptibility testing
azithromycin, 1997
clarithromycin, 1997
fusidic acid, 1997
ofloxacin, 1997
sparfloxacin, 1997

Mycobacterium leprae
rifampin resistance
molecular basis, 414

Mycobacterium malmoense
ethambutol
ciprofloxacin, amikacin, rifampin, synergy with, 1285
susceptibility to antibacterial drugs and drug combinations, 1285

Mycobacterium paratuberculosis
rifabutin
systemic infection in mice, 1645

Mycobacterium spp.
AM-1155
in vitro activity, comparative evaluation, 1259
ethambutol
glucose metabolism, inhibition of, 1536

roxithromycin
in vitro activity, 1560
pH, effect on radiometric MICs, 1560

Mycobacterium tuberculosis
antimicrobial activity
method for screening for, 1348
CGI 17341
in vitro and in vivo activities, 183

clofazimine
in vitro activities, 2584

luciferase expressing
antimicrobial activity against, method for screening for, 1348

multidrug resistant
studies with mice, 2344

polymerase chain reaction
detection, 2054

resorcinomycin
in vitro activities, 2584

rifampin resistant
detection, 2054

single-strand conformation polymorphism analysis
detection, 2054

sparfloxacin, 407

Mycoplasma bovis
antimicrobial susceptibilities, 317

Mycoplasma dispar
antimicrobial susceptibilities, 317

Mycoplasma fermentans
susceptibility testing
in vitro strains from AIDS patients, 2500
in vitro strains from non-AIDS patients with acute respiratory disease, 2500
tissue culture, 2500

Mycoplasma hominis
OPC 17116
susceptibility in vitro, 1726

Mycoplasma pneumoniae
ciprofloxacin
hamsters, 287
ofloxacin
hamsters, 287
OPC 17116
susceptibility in vitro, 1726

Q-35
in vitro and in vivo activities, 1826

temafloxacin
hamsters, 287

Myeloperoxidase
C. albicans
human recombinant, candididial activity, 142
human recombinant
C. albicans, candididial activity, 142

Neisseria gonorrhoeae
ciprofloxacin
antibacterial activities, 2244
ofloxacin
antibacterial activities, 2244
in vitro susceptibilities, 2007
OPC-17116
antibacterial activities, 2244

Neisseria meningitidis
ofloxacin
single doses to eradicate tonsillopharyngeal carriage in Norway, 2024
penicillin susceptible, moderately isolated in Argentina, 1728

Nephrotoxicity
gentamicin
neonates, drug-treated pregnant Wistar rats, 1510

Netilmicin
combinations
ceftriaxone, 1971
endocarditis, 1971

Diltiazem
nephrotoxicity in rabbits, effects on, 1790

Synergy
ceftriaxone, 207
streptococcal endocarditis, 207

Nevirapine
pharmacokinetics
single-rising-dose study in humans, 178

Nitrofurazone
urinary tract infections
catheter associated, 2033

Nitroimidazoles
CGI 17341
M. tuberculosis, 183

M. tuberculosis
CGI 17341, 183

NM394
antibacterial activity, 793

Nocardia brasiliensis
rifampin
inactivation of, 1313

Nocardia farcinica
β-lactamases
characterization, 1850

Nocardia spp.
antimicrobial susceptibilities
in vitro, 882
susceptibility testing
letter to the editor, 2514

Norfloxacin
urinary tract infections
3-day treatment, 574
acute uncomplicated, 574
comparative evaluation, 574

Northern (RNA) blot analysis
C. albicans
picolinic acid, protective effect on mice, 2422

Novobiocin
combinations
ciprofloxacin, 1904
E. faecium, 1904
rifampin, 1334
S. aureus, methicillin resistant, eradication of, 1334

E. faecium
in vitro activity against multiresistant strains, 2736

NP-1
C. neoformans
fungicidal properties, 2628
in vitro activity, 2628

Ofloxacin
B. burgdorferi
in vitro susceptibility, 1444

combinations
Brucella spp., 1831
rifampin, 1214, 1831

Staphylococcus-infected orthopedic implants, 1214

comparative evaluation
accumulation by human polymorphonuclear leukocytes, 1882
ciprofloxacin, 2193
DU-6859a, 2747

E. coli
comparative evaluation, 846
epididymitis, 846

epididymitis
comparative evaluation, 846
E. coli, 846

in vitro activities
gram-negative organisms, 2017
gram-positive organisms, 2017

M. fortuitum
postantibiotic effect, 1001

M. haemophilum
in vitro activities, 2323

M. kansasi
susceptibility testing, 1997

M. pneumoniae
hamsters, 287

N. gonorrhoeae
antibacterial activities, 2244
in vitro susceptibilities, 2007

N. meningitidis
single doses to eradicate tonsillopharyngeal carriage in Norway, 2024

pharmacokinetics
bioequivalence after multiple doses to healthy volunteers, 1468
multiple oral doses to healthy volunteers, 2193

postantibiotic effect
M. fortuitum, 1001

serum bactericidal titers
multiple oral doses to healthy volunteers, 2193

Omeprazole
H. pylori
urease activity, inhibition of, 769

OPC 17116
M. hominis
susceptibility in vitro, 1726

M. pneumoniae
susceptibility in vitro, 1726

U. urealyticum
susceptibility in vitro, 1726

OPC-17116
C. pneumoniae
in vitro and in vivo activities, 801

C. psittaci
in vitro and in vivo activities, 801

C. trachomatis
in vitro and in vivo activities, 801

comparative evaluation
accumulation by human polymorphonuclear leukocytes, 1882

N. gonorrhoeae
antibacterial activities, 2244

Ophthalmritis
sparfloxacin
rabbit model, efficacy in, 633

Oral flora
mercury resistant
mercury from dental fillings provokes increased occurrence, 825

Oral microflora
anaerobic
resistance patterns, 1665

Organ transplant patients
antimicrobial strategies
minireview, 619

Ornidazole
concentrations in plasma during liver transplantation, 1873

tissue penetration during liver transplantation, 1873

Orthopedic implants
Staphylococcus infections
rifampin-ofloxacin, 1214

Otitis media
S. pneumoniae, penicillin resistant amoxicillin, increased dosages of, 1599

Oxacillin
endocarditis
S. aureus, β-lactamase hyperproducing, 507

S. aureus
β-lactamase hyperproducing, 507

Synergy
levofloxacin, 339

S. aureus, quinolone resistant, 339

Oxidase inhibitors
P. berghei
drug susceptibility, enhancement of, 1318

P. falciparum
drug susceptibility, enhancement of, 1318

Panipenem
P. aeruginosa, 322
 diffusion through outer membrane, 322
 role of OprD protein, 322
 phenotypic resistance induced by salicylate, 2743

Papillomavirus
 E2 mRNA
 phosphorothioate oligonucleotides, potential treatment for genital warts, 171
 phosphorothioate oligonucleotides
 E2 mRNA, potential treatment for genital warts, 171

Pasteurella multocida
 Tet H
 active efflux of tetracycline, 2699

PBP 2a
S. aureus
blaI and *blaRI*, regulation by, 1144

PD 127391
P. cepacia
 comparative evaluation, 123

PD 131628
P. cepacia
 comparative evaluation, 123

PD 138312
 gram-positive organisms
 in vitro activities, 2563

PD 140248
 gram-positive organisms
 in vitro activities, 2563

Pediococcus acidilactici
 macrolide resistance
 genetic basis for, 789

Pediococcus spp.
 antimicrobial susceptibilities, 789

Penfloxacin
 bactericidal activities
 one 800-mg versus two 400-mg doses, 737
 irradiated mice, adverse effects on and
 glucan therapy for, 1877
 pharmacokinetics
 one 800-mg versus two 400-mg doses, 737

Penciclovir
 herpes simplex virus type 1
 comparative evaluation, 642

Pencyclovir
 herpes simplex virus
acyclovir and *foscarnet* resistant, 2241
 in vitro activities, 2241
 herpes simplex virus resistance
pencyclovir, 2241

Penems
 CP-70,429
 β -lactamase stability and in vitro activity, 1547

Penicillin
E. faecium resistance
 time-kill studies, 2427
 haptenation
 serum proteins, facilitation of, 1463
N. meningitidis, moderately susceptible
 isolation in Argentina, 1728
S. mutans
 in vitro susceptibility, 1158
 synergy
gentamicin, 2427

Penicillin V
 tonsillopharyngitis, streptococcal
 comparative evaluation, 1620

Penicillin-binding proteins
B. wadsworthia
 inhibition by imipenem, 2638
 β -lactam resistance
 minireview, 2045
 expression of a novel membrane protein and increased expression of penicillin-binding protein 2 complex, 2432
 minireviews
 β -lactam resistance, 2045

R. equi
 imipenem resistance, potential role in, 1406

S. aureus
blaI and *blaRI*, regulation by, 1144
 cell wall synthesis, role in, 342

S. pneumoniae
 2B and 2X, genetic diversity of, 1938

Penicillium marneffei
 human immunodeficiency virus
 response of patients to antifungal therapy, 2407

Pentamidine
L. donovani
 T-cell-deficient mice, 1504
 leishmaniasis, visceral
 T-cell-deficient mice, 1504

Peptide antibiotics
 AS-48
 neutralizing antibodies, immunological studies, 148
 MDL 62,879
 in vitro activity, 741

Peptidoglycan synthesis inhibitors
 mureidomycins
 bacterial translocase reaction, inhibition of, 980

Peptostreptococcus spp.
 Bay Y3118
 in vitro activity, 2509

Peripheral blood mononuclear cell culture assay
 human immunodeficiency virus
 drug susceptibility, determination of, 1095

Peritonitis
 bacterial, spontaneous
ceftriaxone versus *cefonicid*, 1587

Cefonicid
 comparative evaluation, 1587

Ceftriaxone
 comparative evaluation, 1587

Pharmacokinetics
 3'-deoxy-2',3'-didehydrothymidine
 disposition and metabolism in hepatocytes and nonhuman primates, 1816

Allopurinol riboside
probencid, effects of, 1193

Alpha interferon
 transplacental passage, two assay techniques, 1232

Amikacin
 attachment to collagen for local delivery in wounds, 1890

Patients with septic multiple-organ failure during intermittent hemofiltration, 464

Amoxycillin
 local gastric and serum concentrations after different oral applications, 1506

azithromycin
 pediatric patients, multiple oral doses of suspension, 314

carbenicillin epimers
 stereoselective renal tubular secretion, 2327

Cefazolin
 protein binding in rats, 1781

Cefepime
 cystic fibrosis patients, 1414

Cefixime
 biliary excretion in patients with T-tube drainage, 1488

Cefonicid
 protein binding in adult and neonatal sera, 1343

Cefotaxime
 cerebrospinal fluid of patients with uninfamed meninges, passage into, 1518

Cefpodoxime proxetil
 studies with patients receiving continuous ambulatory peritoneal dialysis, 2650

Cefprozil
 tonsillar and adenoidal tissues, penetration into, 1180

Ceftazidime
 patients with septic multiple-organ failure during intermittent hemofiltration, 464

Serum bactericidal activities, 1835

Side effects, 1835

Ceftriaxone
 cerebrospinal fluid of patients with uninfamed meninges, passage into, 1518

Elimination, effect of plasmapheresis, 1171

Liver transplantation, 1873

Pregnant women, 54

Protein binding during pregnancy, 54

Cefuroxime
 protein binding in adult and neonatal sera, 1343

Ciprofloxacin
 effects of cardiopulmonary bypass surgery on disposition, 2106

Healthy volunteers, multiple oral doses, 2193

Seriously ill patients, 1073

(-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine
 studies with rats, 2285

Clindamycin
 bioavailability, 1137

Healthy volunteers and AIDS patients, 1137

Diminazene
 Boran cattle, noninfected and infected with *T. congolense*, 1050

Enoxacin
 oral antacids, effect on disposition, 775

Fleroxacin
 breast milk, penetration into, 293

Effects in healthy volunteers by positron emission tomography, ^{18}F labeled, 2144

Lactating women, 293

Rifampin, influence of, 2132

Fluconazole
 healthy human subjects, 1270

influence of radiotherapy on penetration into human saliva, 2674
 patients with AIDS, 2187
 positron emission tomography, ^{18}F -labeled, 1270
 uptake in human polymorphonuclear leukocytes, 187

foscarnet
 blood-brain barrier, penetration of, 1010

fusidic acid
 intravenous, cholestatic patients, 501

gentamicin
 increased renal uptake in endotoxemic rats receiving thromboxane A₂ therapy, 2727

population pharmacokinetic models, comparison of, 93

patients with AIDS and severe AIDS-related complex, 512

isepamicin
 nephrotoxicity, influence on in rats, 2042

itraconazole
 alveolar macrophages, uptake by, 903
 food interaction, 778
 steady state, 778

lomefloxacin
 concentration in plasma-time profile, relation to survival, 483

neutropenic rat model of *Pseudomonas* sepsis, 483

meropenem
 patients with various degrees of renal function, 229

nevirapine
 single-rising-dose study in humans, 178

nonparametric expectation maximization oncology patients receiving aminoglycoside therapy, 1025

ofloxacin
 bioequivalence after multiple doses to healthy volunteers, 1468
 healthy volunteers, multiple oral doses, 2193

ornidazole
 liver transplantation, 1873

pefloxacin
 one 800-mg versus two 400-mg doses, 737

piperacillin
 healthy volunteers, 1860

piperacillin-tazobactam
 healthy volunteers, 1860

population
 ciprofloxacin, optimal sampling strategies, 1065
 nonparametric approach, 1025

ribavirin
 children with human immunodeficiency virus infection, 532

rifampin
 fleroxacin, influence on, 2132
 zidovudine, interaction with, 1426

rifloxacin
 biliary excretion in humans, 2545
 patients with impaired renal function, 637

S-1108
 safety of and carnitine status of patients, 1043

S. aureus

fleroxacin-rifampin, 2132

SCE-2787
 serum bactericidal activities, 1835
 side effects, 1835

sparfloxacin
 ocular penetration in rabbits with ophthalmitis, 633

stavudine
 cynomolgus monkeys, 1160

teicoplanin
 evaluation of a fluorescence polarization immunoassay, 1924

prophylaxis in monolateral and bilateral total knee replacement procedures, 2693

ticarcillin-clavulanic acid
 healthy volunteers, 1860

trimethoprim-sulfamethoxazole
 12/60 mg/kg/day, multiple dose, 448
 healthy volunteers, 448

vancomycin
 obesity, effect on, 436
 pulmonary lining fluid, penetration into, 281

serum protein-binding characteristics, 1132

zidovudine
 effects of standard breakfast in patients with AIDS, 2153
 prodrugs, enhanced levels in brain tissue, 818
 rifampin, interaction with, 1426

zidovudine-granulocyte-macrophage colony-stimulating factor
 patients with AIDS and severe AIDS-related complex, 512

Pharyngitis
 cefuroxime axetil suspension
 comparative evaluation, 159

***Streptococcus* spp., group A**
 cefuroxime axetil suspension, comparative evaluation, 159

(R)-9-(2-Phosphonomethoxypropyl)-2,6-diaminopurine

herpesviruses, 332

retroviruses, 332

Phosphonylmethoxyalkyl derivatives
 cytomegalovirus resistance
 point mutation in DNA polymerase gene, 19

Phosphorothioate oligodeoxynucleotides
 Epstein-Barr virus
 inhibition of replication, 1420

Picolinic acid
C. albicans
 protective effect on mice, 2422

Picornavirus
 capsid binders
 detection with soluble intercellular adhesion molecule 1, 1693

Piperacillin
 combinations
 comparative evaluation, 1580
 skin and skin structure infections, 1580
 tazobactam, 1580, 2578

pharmacokinetics
 healthy volunteers, 1860

Piperacillin-tazobactam
 pharmacokinetics
 healthy volunteers, 1860

Pirlimycin
 bovine mastitis, isolates from
 activity of, 1122
 disk diffusion breakpoints, 1122

Plasmids
 R751
 multidrug resistance to antiseptics and disinfectants, 761

resistance
S. aureus, 2003

Plasmodium berghei
 oxidase inhibitors
 drug susceptibility, enhancement of, 1318

Plasmodium falciparum
 5-fluoroorotate
 clonal viability measurements to assess in vitro activity, 1102

amopyroquin
 malaria treatment, 970

chloroquine
 clonal viability measurements to assess in vitro activity, 1102

chloroquine resistant
 9-anilinoacridines, 403

clonal viability measurements
 leupeptin, chloroquine, and 5-fluoroorotate, in vitro activity, 1102

cross-resistance patterns, 2337

cycloguanil
 African isolates, 924
 halofantrine resistance, 2337

leupeptin
 clonal viability measurements to assess in vitro activity, 1102

malaria
 amopyroquin, 970
 halofantrine, 1955
 mefloquine, 1977

mefloquine
 malaria treatment, 1977

oxidase inhibitors
 drug susceptibility, enhancement of, 1318

Platelet microbicidal protein
C. neoformans
 fungicidal activity, 546

Candida spp.
 fungicidal activity, 546

Pneumocystis carinii
 8-aminoquinolones
 in vivo and in vitro studies, 2166

amsacrine
 activity in vitro and in a mouse model, 1543

bis-benzimidazoles
 pneumonia, treatment of, 1713

biguanide folate antagonist
 PS-15, immunosuppressed rat model, 1417

bilobalide
 in vitro and in vivo activities, 1492

camptothecin
 activity in vitro and in a mouse model, 1543

dihydrofolate reductase inhibitors and dapsone
 synergy, 1436

dihydrofolate reductase inhibitors and sulfamethoxazole
 synergy, 1436

epipodophyllotoxins
 activity in vitro and in a mouse model,

1543
 isoprinosine
 dihydroporoate synthetase inhibition, 1227
 pneumonia
 bis-benzimidazoles, cationically substituted, activity of, 1713
PS-15
 folate antagonism, 1417
 immunosuppressed rat model, 1417
 quinolones
 activity in vitro and in a mouse model, 1543
 Ro 11-8958-dapsone
 synergy, 1436
 Ro 11-8958-sulfamethoxazole
 synergy, 1436
 topoisomerase inhibitors
 activity in vitro and in a mouse model, 1543
Pneumonia
 cytomegalovirus
 ganciclovir sensitivity at diagnosis and during treatment, 1360
 nosocomial
 critically ill patients, prevention of, 931
 minireview, 931
Pneumonitis
 cytomegalovirus
 (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine, 218
Poloxamers
T. gondii, 2265
 toxoplasmosis, 2265
Poly(I):poly(C₁₂U)
 biologic effects
 healthy volunteers, 429
Polyaspartic acid
 gentamicin
 nephrotoxicity, protective effects, pharmacologic limits of, 347
 nephrotoxicity
 gentamicin, protective effects, pharmacologic limits of, 347
Polymerase chain reaction
E. faecalis
 heterogeneity of chloramphenicol acetyltransferase genes, 2593
E. faecium
 heterogeneity of chloramphenicol acetyltransferase genes, 2593
M. tuberculosis
 rifampin resistant, 2054
S. pneumoniae
 heterogeneity of chloramphenicol acetyltransferase genes, 2593
Polymorphonuclear leukocytes
 dirithromycin
 interactions may promote killing of infecting organisms, 2557
 suramin
 suppression of bactericidal activity, 495
Porphyromonas spp.
 Bay Y3118
 in vitro activity, 2509
Positron emission tomography
 fleroxacin
 pharmacokinetics, ¹⁸F labeled, 2144
 pharmacokinetics
 fleroxacin, ¹⁸F labeled, 2144
 fluconazole, ¹⁸F labeled, 1270
Postantibiotic effect
 benzylpenicillin
Bioscreen C, 2200
Streptococcus and *Pneumococcus*
 spp., 2200
E. coli
 correlation of tobramycin-induced inhibition of protein synthesis, 2678
imipenem
 repeated exposure to, 1723
temafloxacin
 repeated exposure to, 1723
tobramycin
 hyperoxia, prolongation by, role of reactive oxygen species, 120
P. aeruginosa, 120
 repeated exposure to, 1723
Prednisolone
 keratitis
 age and therapeutic outcome, 1856
P. aeruginosa
 age and therapeutic outcome, 1856
Prevotella spp.
 Bay Y3118
 in vitro activity, 2509
Pristinamycin resistance
S. aureus
 isolates responsible for outbreak in Parisian hospital, 2159
Probencid
 allopurinol riboside
 pharmacokinetics, effects on, 1193
Protease inhibitors
 human immunodeficiency virus
 in vitro activity of XM323, 2606
 murine leukemia virus
 antiretroviral activity, 71
 simian immunodeficiency virus
 antiretroviral activity, 71
PS-15
P. carinii
 folate antagonism, 1417
 immunosuppressed rat model, 1417
Pseudomonas aeruginosa
 6'-N-acetyltransferase
aac(6')-Ib, characterization of, 1456
 antiflagella monoclonal antibodies
 therapeutic effects in a murine model, 164
ant(4')-IIa
 nucleotide sequence analysis and DNA hybridization studies, 708
 aztreonam, 308
 aztreonam-amikacin, 308
 β -lactamase
 extended spectrum, characterization of, 962
 OXA-11, extended-spectrum variant of OXA-10, 1637
 biapenem
 phenotypic resistance induced by sialic acid, 2743
 biofilms
 clarithromycin, interaction with, 1749
 inhibition of formation on prosthetic devices by proteolytic enzymes, 2618
BO-2727
 in vitro activity, 2756
 carbapenem resistance
 cephalosporinase, role in, 1387
 cefoperazone-sulbactam
 granulocytopenic mice, disseminated infections in, 1927
cefozopran
 urinary tract infection, 100
ceftazadime, 308
ceftazidime-amikacin, 308
ciprofloxacin
 age and therapeutic outcome, 1856
 dose-ranging and fractionation, 1756
 in vitro model of infection, 1756
 increased susceptibility in the presence of vancomycin, 2506
 resistance to unrelated antibiotics, effects on, 1289
clarithromycin
 biofilms, interaction with, 1749
 deglucotetrapeptidyl amide derivatives
 uptake, mechanism of, 453
erythromycin
 sub-MICs, effect on serum sensitivity, 675
flurbiprofen
 age and therapeutic outcome, 1856
gentamicin
 A band and B band lipopolysaccharides, interaction with, 715
imipenem
 phenotypic resistance induced by sialic acid, 2743
imipenem resistance
 mechanism of efficient elimination of protein D2, 2385
imipenem-amikacin
 in vitro pharmacodynamic effects, 1931
interleukin-1-induced nonspecific resistance
 role of acute-phase proteins in studies with mice, 2527
keratitis
 age and therapeutic outcome, 1856
macrolides
 sub-MICs, effect on serum sensitivity, 675
panipenem, 322
 diffusion through outer membrane, role of OprD protein, 322
 phenotypic resistance induced by sialic acid, 2743
postantibiotic effect
 tobramycin, prolongation by hyperoxia, role of reactive oxygen species, 120
prednisolone
 age and therapeutic outcome, 1856
tobramycin
 postantibiotic effect, prolongation by hyperoxia, role of reactive oxygen species, 120
vancomycin
 increased susceptibility to ciprofloxacin, 2506
Pseudomonas cepacia
 β -lactamase
 strain 249 chromosomal penicillinase, member of AmpC family, 667
ceftazidime
 comparative evaluation, 123
 chloramphenicol
 comparative evaluation, 123
ciprofloxacin
 comparative evaluation, 123
co-trimoxazole
 comparative evaluation, 123

meropenem
comparative evaluation, 123
PD 127391
comparative evaluation, 123
PD 131628
comparative evaluation, 123

Pseudomonas pseudomallei
ceftazidime resistance
biofilm cells, 2000
co-trimoxazole
biofilm cells, 2000

Pulsed-field gel electrophoresis
enterococci
characterization of glycopeptide-resistant isolates from U.S. hospitals, 2311

Pyrimethamine
combinations
azithromycin, 1993
T. gondii, 1993

creatinine secretion, renal
inhibition of, 1056

Pyrimido[1,6- α]benzimidazoles
D. melanogaster
effects on topoisomerase II and Kc cells, 2599

Q-35
L. interrogans
five serogroups, 901
M. pneumoniae
in vitro and in vivo activities, 1826
mice irradiated with long-wavelength UV
reduced phototoxicity, 2217

Q fever
C. burnetti
minireview, 1733
treatment of
minireview, 1733

Quinapyramine
T. congolense, resistant clone
derivation and characterization, 1163

Quinoline alkaloids
2 substituted
L. amazonensis, 859
L. venezuelensis, 859
leishmaniasis, cutaneous, 859
L. amazonensis, 859
L. venezuelensis, 859
leishmaniasis, 859

Quinolones
1-8 bridged
topoisomerase II, stereospecificity for the C-11 methyl group, 646

AM-1155
antimycobacterial activities, comparative evaluation, 1259

Ames *Salmonella* TA102 assay
bacterial mutagenicity, 213

antibiotic carryover
antibiotic-removal beads, elimination with, 1377

anti-*M. avium* activities
erratum, 2766

B. fragilis
in vivo efficacy, correlation with in vitro susceptibility, 997
mice, 997

Bay y 3118
broth macrodilution assays, 2348

C. jejuni resistance

DNA gyrase mutations, characterization of, 457

cefazolin-induced seizures
DBA/2 mice, potentiation of, 1497

CI-960
C. trachomatis salpingitis, 8

combinations
Brucella spp., 1831
comparative evaluation, 1831

CP-115, 953
activities against mammalian systems, comparative evaluation, 2179

DNA gyrases
E. coli, mechanism of action, 839

E. coli
DNA gyrase, mechanism of action, 839
in vivo efficacy, correlation with in vitro susceptibility, 997
mice, 997

E. coli resistance
plasmid complementation test, 2588

M. avium
in vitro activities, 1799
structure-activity relationship studies, 1807

M. pneumoniae
hamsters, 287

NM394
antibacterial activity, 793

OPC 17116
M. hominis, *M. pneumoniae*, and *U. urealyticum*, 1726

P. carinii
activity in vitro and in a mouse model, 1543

PD 138312
in vitro activities, 2563

PD 140248
in vitro activities, 2563

proconvulsant effects
DBA/2 mice, 1497

T-3761
in vitro and in vivo activities, 384

topoisomerase II
stereospecificity for the C-11 methyl group, 646

topoisomerase II and cultured cells, activities against, 2179

R751
integron
multidrug resistance to antiseptics and disinfectants, 761

Ramoplanin
gram-positive organisms
bloodstream isolates, 896
in vitro activity, 896
vancomycin resistant, 1364

"Red man syndrome"
vancomycin
skin tests to healthy volunteers, 2139

Renal function
creatinine secretion
pyrimethamine, inhibition of, 1056

Resorcinomycin
M. avium-*M. intracellulare* complex
in vitro activities, 2584

M. tuberculosis
in vitro activities, 2584

Respiratory pathogens
ciprofloxacin
adherence changes induced by subinhibitory concentrations, 885

sparfloxacin
adherence changes induced by subinhibitory concentrations, 885

trimethoprim
adherence changes induced by subinhibitory concentrations, 885

Respiratory syncytial virus
immune globulin
prophylaxis for high-risk infants, evaluation of, 1655

Respiratory tract infections
cefoxopran, 100

K. pneumoniae
cefoxopran, 100

Retroviruses
acyclic nucleoside phosphonates
(S) and (R) enantiomers, 332
(R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine, 332

Reverse transcriptase inhibitors
diarylsulfones
human immunodeficiency virus, 754

FTC
human immunodeficiency virus, 1720

human immunodeficiency virus
diarylsulfones, mechanism of action, 754

FTC, 5'-triphosphates of (-) and (+) enantiomers, 1720

L-696, 229, activity against isolates resistant to related inhibitors, 947

nonnucleoside inhibitors, 1037

S-2720, 1659

human immunodeficiency virus resistance
mutant enzyme and viral variant assessment, 1576

human immunodeficiency virus type 1
infectious amplification from lymphocytes and modulation, 2206

L-696, 229
human immunodeficiency virus isolates resistant to related inhibitors, 947

S-2720
human immunodeficiency virus, 1659

thiazolo-iso-indolines
human immunodeficiency virus type 1 resistance, 2612

U-90152
human immunodeficiency virus, 1127

Rhinovirus
WIN 54954
prophylaxis, efficacy of, 297

Rhodococcus equi
penicillin-binding proteins
imipenem resistance, potential role in, 1406

Ribavirin
pharmacokinetics
children with human immunodeficiency virus infection, 532

safety and tolerance
children with human immunodeficiency virus infection, 532

Rickettsia spp.
spotted fever group
in vitro susceptibilities to clarithromycin, 2633

Rifabutin
combinations
 M. avium, prophylaxis in mice, 1690
 minocycline, 1690
M. avium
 erratum, 2515
 prophylaxis in C57BL/6 mice, 1690
M. avium complex
 rats treated with cyclosporine, 398
M. haemophilum
 in vitro activities, 2323
M. paratuberculosis
 systemic infection in mice, 1645

Rifampin
combinations
 Brucella spp., 1831
 doxycycline, 1831
 floxacin, 2132
 novobiocin, 1334
 ofloxacin, 1214, 1831
 S. aureus, methicillin resistant, eradication of, 1334
 Staphylococcus-infected orthopedic implants, 1214
M. haemophilum
 in vitro activities, 2323
M. leprae resistance
 molecular basis, 414
minireview
 nonstaphylococcal, nonmycobacterial disease, 1
N. brasiliensis
 inactivation of drug by glycosylation, 1313
nonstaphylococcal, nonmycobacterial disease
 minireview, 1
pharmacokinetics
 floxacin, influence on, 2132
 S. aureus, 2132
 zidovudine, interaction with, 1426
S. epidermidis
 diffusion through a biofilm, 2522
staphylococcal bacteremia
 use with neonates, 2401
synergy
 ethambutol, 1285
 M. malmoense, 1285
zidovudine
 pharmacokinetic interaction with, 1426

Rifapentine
Brucella spp.
 in vitro activity, comparative evaluation, 911
M. avium complex
 rats treated with cyclosporine, 398

Rimantadine
influenza virus
 susceptibilities of subtypes A/H1N1 and A/H3N2, 2239

Ro 11-8958
synergy
 dapsone, 1436
 P. carinii, 1436
 sulfamethoxazole, 1436

Ro 40-6890
antimicrobial susceptibility, 893
disk diffusion susceptibility, 893
S. aureus
 antibiotic activity and host defense mechanisms, 2622
 pharmacodynamic activity in human skin blister fluid, 2622

Ro 41-3399
metabolite
 antimicrobial susceptibility, 893
 disk diffusion susceptibility, 893

Roxithromycin
Brucella spp.
 in vitro activity, comparative evaluation, 911
gram-negative organisms
 outer membrane permeability barrier, 354
Mycobacterium spp.
 in vitro activity, 1560
 pH, effect on radiometric MICs, 1560

RP 74501-RP 74502
Legionella spp.
 in vitro activity, 908

RP59500
gram-positive organisms
 vancomycin resistant, 598

RU-40555
combinations
 clarithromycin, 692
 M. avium complex, 692
M. avium complex, 692

Rufloxacin
comparative evaluation
 amoxicillin, 2298
 chronic bronchitis, 2298
magnesium-aluminum hydroxide
 effects on absorption, 2212
pharmacokinetics
 biliary excretion in humans, 2545
 patients with impaired renal function, 637

T-cell subsets and tumor necrosis factor production
 mice infected with *B. fragilis*, effect on, 1711

S-1108
pharmacokinetics, 1043
safety and carnitine status of patients, 1043

S-2720
human immunodeficiency virus
 inhibition of reverse transcriptase and viral replication, 1659

Saccharomyces cerevisiae
bleomycin
 cell wall anchorage of mannoproteins, disruption of, 1264

Ro 09-1470
inhibition of P-450 lanosterol C-14 demethylase, 2662

Saccharopolyspora erythraea
avermectins and ivermectins, glycosylation, microbial conversion by, 1737

Salmonella typhi
ceftriaxone
 5 days, comparative evaluation, 1572
 chloramphenicol
 14 days, comparative evaluation, 1572

Salmonella typhimurium
ciprofloxacin resistance
 isolates from two patients, 662
isoniazid
 susceptibilities of *oxyR* regulon mutants, 2251

lactoferrin-porin interaction
 antibacterial activity, effect on, 240

mutants

supersusceptibility to antibiotics, 2255

Salmonellae
 acyclovir, 106
antimicrobial resistance
 Spanish hospital, 1200
azithromycin
 in vitro activity, 1203
2',3'-dideoxycytidine, 106
2',3'-dideoxyinosine, 106
zidovudine, 106

Salmonellosis
 murine
 ciprofloxacin, 2293

Salpingitis
CI-960
 monkey model, 8

SCE-2787
pharmacokinetics
 healthy volunteers, 1835
 serum bactericidal activities, 1835
side effects, 1835

Screening assays
anti-*P. carinii* agents
 development and characterization, 1674

Shell vial assay
 C. burnetii susceptibility
 shell vial assay, 491

Shigella sonnei
dysentery
 fluoroquinolones, 2486
 fluoroquinolones
 reduced susceptibilities of strains from patients with dysentery, 2486

Shigella spp.
azithromycin
 in vitro activity, 1203

Simian immunodeficiency virus
 antibodies, neutralizing
 macrophages, comparative evaluation, 360

3'-azidothymidine
 macrophages, comparative evaluation, 360

protease inhibitors
 antiretroviral activity, 71

Simian varicella virus
 (-)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine
 African green monkeys, 1370

Sinefungin
Cryptosporidium parvum
 curative and preventive activities, 889
 immunosuppressed rat model, 889

Skin infections
 piperacillin-tazobactam
 comparative evaluation, 1580

Ticarcillin-clavulanate
 comparative evaluation, 1580

Sodium stibogluconate
L. panamensis
 in vitro activities of fractions, 1842

Soluble intercellular adhesion molecule 1
picornavirus capsid binders
 detection of, 1693

Sparfloxacin
bite wound isolates
 aerobic and anaerobic, 1150

C. pneumoniae
 in vitro and in vivo activities, 801

C. psittaci
 in vitro and in vivo activities, 801

C. trachomatis

in vitro and in vivo activities, 801

H. influenzae
adherence changes induced by subinhibitory concentrations, 885

K. pneumoniae
adherence changes induced by subinhibitory concentrations, 885

M. catarrhalis
adherence changes induced by subinhibitory concentrations, 885

M. haemophilum
in vitro activities, 2323

M. kansasi
susceptibility testing, 1997

M. tuberculosis, 407

ophthalmitis
rabbits with, efficacy in, 633

pharmacokinetics
ocular penetration in rabbits with ophthalmitis, 633

Spiramycin
C. trachomatis
comparative evaluation, 1373
genital infections, treatment of, 1373

Staphylococcus aureus
abscesses
cefazolin, β -lactamase-mediated inactivation and efficacy, 203
cefmetazole, β -lactamase-mediated inactivation and efficacy, 203

adherence
teicoplanin, effect of subinhibitory concentrations on, 921
vancomycin, effect of subinhibitory concentrations on, 921

ampicillin-sulbactam
 β -lactamase-hyperproducing strain, 507

antimicrobial susceptibility
fibronectin-coated surfaces, isolates on, 625

azithromycin
uptake by human monocytes, 2318

B. fragilis, polymicrobial infection
mice, 1531

B. thetaiotaomicron, polymicrobial infection
mice, 1531

bacteremia
use of intravenous rifampin with neonates, 2401

β -lactamase
production, genes involved in regulation, 1966

β -lactamases
blaI and *blaRI*, regulation of, 1144

blaI and *blaRI*
 β -lactamase and PBP 2a regulation, 1144

cefazolin
 β -lactamase-mediated inactivation and efficacy, 203

cefmetazole
 β -lactamase-mediated inactivation and efficacy, 203

cefozopran, 100

cephalosporins
broad spectrum, 554

ciprofloxacin
dose-ranging and fractionation, 1756
in vitro model of infection, 1756
resistance to unrelated antibiotics, effects on, 1289

dihydrofolate reductase, trimethoprim sensitive
characterization of gene for, 1400
enhanced intracellular antibacterial activity, 2318

fibronectin-coated surfaces, isolates on
antimicrobial susceptibility, 625

fleroxacin-rifampin
pharmacokinetics, 2132

fluoroquinolone resistance
efflux mediated, 1086

NorA, multidrug efflux transporter, 128

levofloxacin-oxacillin
synergy, 339

methicillin resistant
 β -lactam- β -lactamase inhibitor combinations, 702

β -lactams, 702

blaI and *blaRI* regulate β -lactamase and PBP 2a production, 1144

ciprofloxacin, resistance to unrelated antibiotics, effects on, 1289

endocarditis, 2466

fusidic acid, alone or in combination with vancomycin, 2466

penicillin-binding protein 2A, role in cell wall synthesis, 342

rifampin-novobiocin, 1334

methicillin resistant and susceptible
sequential acquisition of norfloxacin and ofloxacin resistance, 2278

methicillin susceptible
cephalosporins, broad spectrum, 554

methicillin susceptible, borderline
 β -lactam- β -lactamase inhibitor combinations, 702

β -lactams, 702

mupirocin resistance
detection and characterization, 2003

mupirocin resistance, high level
isoleucyl-tRNA synthetases, evidence for two distinct, 32

NorA
Bmr, comparison of substrate specificities, 128

multidrug efflux transporter, 128

oxacillin
 β -lactamase-hyperproducing strain, 507

pefloxacin
one 800-mg versus two 400-mg doses, 737

povidone iodine
irrigation, 2754

pristinamycin resistance
isolates responsible for outbreak in Parisian hospital, 2159

quinolone resistant
levofloxacin-oxacillin synergy, 339

rifampin
use with neonates, 2401

Ro 40-6890
antibiotic activity and host defense mechanisms, 2622

pharmacodynamic activity in human skin blister fluid, 2622

teicoplanin
adherence, effect of subinhibitory concentrations on, 921

teicoplanin resistance
expression of a novel membrane protein and increased expression of penicillin-binding protein 2 complex, 2432

E. coli, expression in, 191

TetK, TetA(B), and TetA(C)
substrate specificities, comparison of, 191

vancomycin
adherence, effect of subinhibitory concentrations on, 921

Staphylococcus epidermidis
adherence
teicoplanin, effect of subinhibitory concentrations on, 921

vancomycin
adherence, effect of subinhibitory concentrations on, 921

biofilms
diffusion of rifampin, 2522

diffusion of vancomycin, 2522

inhibition of formation on prosthetic devices by proteolytic enzymes, 2618

teicoplanin
adherence, effect of subinhibitory concentrations on, 921

vancomycin
adherence, effect of subinhibitory concentrations on, 921

Staphylococcus spp.
adherence
teicoplanin, effect of subinhibitory concentrations on, 921

vancomycin, effect of subinhibitory concentrations on, 921

mec regulator genes
distribution in methicillin-resistant strains, 1219

methicillin resistant
mec regulator genes, distribution of, 1219

orthopedic implant infections
rifampin-ofloxacin, 1214

rifampin-ofloxacin
infected orthopedic implants, 1214

teicoplanin
adherence, effect of subinhibitory concentrations on, 921

vancomycin
adherence, effect of subinhibitory concentrations on, 921

Stavudine
pharmacokinetics
cynomolgus monkeys, 1160

Streptococcus mitis
gentamicin
chromosomally mediated high-level resistance, 2740

Streptococcus mutans
amoxicillin
in vitro susceptibility, 1158

cefuroxime
in vitro susceptibility, 1158

chlorhexidine
in vitro susceptibility, 1158

erythromycin
in vitro susceptibility, 1158

penicillin
in vitro susceptibility, 1158

tetracycline
in vitro susceptibility, 1158

trimethoprim-sulfamethoxazole
in vitro susceptibility, 1158

Streptococcus pneumoniae
 cefotaxime breakpoint
 letter to the editor, 616
 ciprofloxacin
 mouse protection model, 234
 clarithromycin resistance
 cultures from Providence, R.I., 1742
 erythromycin resistance
 cultures from Providence, R.I., 1742
 meningitis
 penicillin and cephalosporin resistant, evaluation of treatment regimens, 1630
 penicillin and cephalosporin resistant meningitis, evaluation of treatment regimens, 1630
 penicillin resistant
 otitis media, treatment with amoxicillin, 1599
 penicillin-binding proteins 2B and 2X, genetic diversity of, 1938
 polymerase chain reaction
 heterogeneity of chloramphenicol acetyltransferase genes, 2593

Streptococcus pyogenes
 poloxamer 188
 effects of scrubbing, 2754

Streptococcus spp.
 ceftriaxone-netilmicin
 endocarditis, 207
 synergy, 207
 endocarditis
 ceftriaxone-netilmicin, 1971
 ceftriaxone-netilmicin synergy, 207
 group A
 antibiotic susceptibilities, hospital isolates, 1717
 cefuroxime axetil suspension, comparative evaluation, 159
 group A, beta-hemolytic
 bacterial interference, role in infection management, 1452
 beta-lactamase production, role in infection management, 1452
 tonsillopharyngitis
 cefprozil versus penicillin V, 1620
 viridans group
 activities of potential therapeutic and prophylactic antibiotics against blood culture isolates, 2493
 neutropenic patients receiving ciprofloxacin, 2493

Streptogramin A acetyltransferases
E. faecium
 identification of *satA*, 2119

Streptogramins
 RP 74501-RP 74502
Legionella spp., 908

RP59500
 gram-positive organisms, vancomycin resistant, 598

Streptomyces clavuligerus
 cephalosporin 7alpha-hydroxylase cloning and expression in *S. lividans*, 84

Streptomyces spp.
 chromosomal DNA
 role in multiple antibiotic resistance, 2379
 multiple antibiotic resistance
 chromosomal DNA in antibiotic preparations, 2379

Streptomycin
 combinations
B. melitensis, 2333
 ciprofloxacin, doxycycline, and rifampin, 2333

E. coli resistance
 bleomycin, increase of, 1982

Sulbactam
 combinations
 ampicillin, 251, 507, 610, 1447
 cefoperazone, 1927
 clavulanate, 2059
 comparative evaluation, 610
E. coli, 1927, 2059
E. coli intra-abdominal abscess model, 610
E. faecalis, beta-lactamase producing, highly gentamicin resistant, 1447
 endocarditis, 507, 1447
P. aeruginosa, 1927
S. aureus, beta-lactamase hyperproducing, 507
 susceptibility testing with a predictor panel, 251
 tazobactam, 2059

E. coli
 beta-lactamase, TEM type, resistant, 2059
 oxidant-scavenging activities
 neutrophil functions, effect on, 950

Sulfamethoxazole
 synergy
 dihydrofolate reductase inhibitors, 1436
P. carinii, 1436
 Ro 11-8958, 1436

Suramin
 duck hepatitis B virus
 prevention of infection in vivo, 1539
 polymorphonuclear leukocyte bactericidal activity
 suppression of, 495

Susceptibility testing
 agar dilution
G. vaginalis, 2733
 amoxicillin
 blood culture isolates of viridans group streptococci from neutropenic patients receiving ciprofloxacin, 2493
 ampicillin-sulbactam predictor panel, 251
 azlocillin
 blood culture isolates of viridans group streptococci from neutropenic patients receiving ciprofloxacin, 2493
 broth microdilution
 multicenter evaluation, 39
 yeasts, 39

C. neofmans
 current status of the standardization process, minireview, 2517

Candida spp.
 current status of the standardization process, minireview, 2517

clarithromycin
 blood culture isolates of viridans group streptococci from neutropenic patients receiving ciprofloxacin, 2493

co-amoxiclav
 blood culture isolates of viridans

group streptococci from neutropenic patients receiving ciprofloxacin, 2493

group streptococci from neutropenic patients receiving ciprofloxacin, 2493

dye uptake assay
 in vitro activity of clarithromycin against spotted fever group rickettsiae, 2633

erythromycin
 blood culture isolates of viridans group streptococci from neutropenic patients receiving ciprofloxacin, 2493

G. vaginalis
 agar dilution, 2733

M. fermentans
 in vitro strains from AIDS patients, 2500

in vitro strains from non-AIDS patients with acute respiratory disease, 2500

tissue culture, 2500

M. kansasi
 azithromycin, 1997
 clarithromycin, 1997
 fusidic acid, 1997
 ofloxacin, 1997
 sparfloxacin, 1997

***Nocardia* spp.**
 letter to the editor, 2514

piperacillin-tazobactam predictor panel for evaluating methods, 2578

plaque assay
 in vitro activity of clarithromycin against spotted fever group rickettsiae, 2633

roxithromycin
Mycobacterium spp., effect of pH on MICs, 1560

yeasts
 broth macrodilution, 39
 multicenter evaluation, 39

Synergy
 3'-azido-2',3'-deoxythymidine
 carbovir, 144
 human immunodeficiency virus type 1, 144

carbovir
 3'-azido-2',3'-deoxythymidine, 144
 human immunodeficiency virus type 1, 144

decimal assay for additivity, 260

E. faecium
 penicillin-gentamicin, 2427

ethambutol-amikacin
M. malmoense, 1285
 ethambutol-ciprofloxacin
M. malmoense, 1285
 ethambutol-rifampin
M. malmoense, 1285
 levofloxacin-oxacillin
S. aureus, quinolone resistant, 339

M. malmoense
 ethambutol-amikacin, 1285
 ethambutol-ciprofloxacin, 1285
 ethambutol-rifampin, 1285

microdilution checkerboard method
 measurement of, reproducibility of results, 613

penicillin-gentamicin
E. faecium, 2427

T-3761
in vitro and in vivo activities, 384

Tazobactam
β-lactamases
kinetic interactions, 851
combinations
clavulanate, 2059
E. coli, 2059
piperacillin, 2578
sulbactam, 2059

E. coli
β-lactamase, TEM type, resistant, 2059

Teicoplanin
adherence
Staphylococcus spp., effect of subinhibitory concentrations on, 921

bactericidal activity
albumin or serum, presence of, controlled pH and calcium, 605

pharmacokinetics
evaluation of a fluorescence polarization immunoassay, 1924
prophylaxis in monolateral and bilateral total knee replacement procedures, 2693

S. aureus resistance
expression of a novel membrane protein and increased expression of penicillin-binding protein 2 complex, 2432

Staphylococcus spp.
adherence, effect of subinhibitory concentrations on, 921

Temafloxacin
B. fragilis
evaluation of activity by an in vitro pharmacodynamic system, 2454

bite wound isolates
aerobic and anaerobic, 1150

M. pneumoniae
hamsters, 287

postantibiotic effect
repeated exposures, 1723

Terbinafine
Candida spp.
temperature, effect on activity, 685

combinations
Chagas' disease, murine, 1353
ICI 195,739, 1353
ketoconazole, 1353

T. cruzi, 1353

mevinolin
T. cruzi, potentiation of antiproliferative effects, 580

Terconazole
Candida spp.
temperature, effect on activity, 685

tet(Q)
B. fragilis
nucleotide and deduced amino acid sequences, 2037

TetA(D)
nucleotide and deduced protein sequences, 1253
relationship to other antimicrobial transport proteins, 1253

TetK
S. aureus
E. coli, expression in, 191
substrate specificities, comparison with those of TetA(B) and TetA(C), 191

Tetracycline
C. jejuni resistance
effect of mutational alteration of Asn-128, 2645
resistance determinants
TetA(D), nucleotide and deduced protein sequences, 1253

S. mutans
in vitro susceptibility, 1158

Tet(O)
effect of mutational alteration of Asn-128, 2645

TetA(D)
nucleotide and deduced protein sequences, 1253
relationship to other antimicrobial transport proteins, 1253

Tetracycline-HCl
synergy
H. pylori, 1184
metronidazole, 1184
metronidazole, hydroxymetabolite of, 1184

Tetracyclines
glycylcyclines
comparative evaluation, 2270
penetration into bacterial cells
minireview, 1393
screening assay, 1624

Thiazolo-iso-indolones
human immunodeficiency virus type 1 resistance, 2612

Thiosemicarbazones
Abelson murine leukemia virus *v-abl* protein, suppression of, 2483

Ticarcillin
combinations
clavulanate, 1580
clavulanate acid, 51
comparative evaluation, 1580
skin and skin structure infections, 1580
yeast colonization of the human gastrointestinal tract, effect on, 51

Ticarcillin-clavulanic acid
C. albicans
colonization of the human gastrointestinal tract, effect on, 51

pharmacokinetics
healthy volunteers, 1860
yeast colonization of the human gastrointestinal tract, effect on, 51

Time-kill curves
mathematical model for comparison of, 1685

Time-kill studies
turbidimetric assay
viable bacterial densities, quantitation of, 371

Tinea unguium
griseofulvin
ultramicrosize, 2064
itraconazole, 2064

Tobramycin
E. coli resistance
3'-aminoglycoside phosphotransferase type I, overproduction of, 78
postantibiotic effect
hyperoxia, prolongation by, role of reactive oxygen species, 120

P. aeruginosa, 120
repeated exposures, 1723

Tonsillopharyngitis
cefprozil
comparative evaluation, 1620

penicillin V
comparative evaluation, 1620

streptococcal
cefprozil versus penicillin V, 1620

Topoisomerase inhibitors
P. carinii
activity in vitro and in a mouse model, 1543

Topoisomerase quinolones
1-8 bridged, stereospecificity for the C-11 methyl group, 646
activities against mammalian systems, comparative evaluation, 2179

Torulopsis glabrata
fluconazole
prophylaxis in neutropenic bone marrow transplant patients, 1847

Tosufloxacin
C. pneumoniae
in vitro and in vivo activities, 801

C. psittaci
in vitro and in vivo activities, 801

C. trachomatis
in vitro and in vivo activities, 801

Toxicity
A77003
preclinical evaluation, 115

amphotericin B
mono-methyl ester derivative, 419
neurotoxicity, comparative evaluation, 419

3'-azido-3'-deoxythymidine
time of administration, effect on, 1771

gentamicin
polysapic acid, protective effects, pharmacologic limits of, 347
human renal proximal tubule cells
use in studying fosfarnet-induced nephrotoxicity in vitro, 2496

LJC 10,627
central nervous systems of rats, low levels of, 199

nephrotoxicity
isepmamicin, 2042

neurotoxicity
amphotericin B, 419
amphotericin B mono-methyl ester derivative, 419

Toxoplasma gondii
anticoccidial agents
susceptibility and resistance, 2358

atoxavquone-clarithromycin
in vitro and in vivo activities, 2371

atoxavquone-minocycline
in vitro and in vivo activities, 2371

atoxavquone-pyrimethamine
in vitro and in vivo activities, 2371

atoxavquone-sulfadiazine
in vitro and in vivo activities, 2371

azithromycin
combinations, in vitro activities of, 1993
protein synthesis, inhibition of, 1701

clindamycin
infectivity, 2571
intracellular replication, 2571
protein synthesis, 2571

dihydrofolate reductase
inhibitors, identification of, 1914

poloxamers
 toxoplasmosis, 2265

pyrimethamine
 combinations, in vitro activities of, 1993

toxoplasmosis
 poloxamers, 2265

Toxoplasmosis
 poloxamers, 2265
 T. gondii, 2265

Treponema pallidum
 clarithromycin
 hamsters, 864

Triazino[5,6-*b*]indoles
GR99060
 antifungal properties, 1243

GR99062
 antifungal properties, 1243

Triazoles
D0870
 blastomycosis, murine, 1177
 pathogenic yeasts, 2126

Trichophyton mentagrophytes
butenafine
 guinea pigs, 363

Trimethoprim
 dihydrofolate reductase cassette
 integron on a *Tn21*-like element, 1297

H. influenzae
 adherence changes induced by subinhibitory concentrations, 885

K. pneumoniae
 adherence changes induced by subinhibitory concentrations, 885

M. catarrhalis
 adherence changes induced by subinhibitory concentrations, 885

resistance
 dihydrofolate reductase cassette inserted on an integron on a *Tn21*-like element, 1297

Trimethoprim-sulfamethoxazole
pharmacokinetics
 12/60 mg/kg/day, multiple dose, 448
 healthy volunteers, 448

S. mutans
 in vitro susceptibility, 1158

Tritrichomonas foetus
zinc
 electron microscopic study, 2722

Trypanosoma brucei brucei
N-*n*-alkyl-3,4-dihydroxybenzamide
 in vitro and in vivo activities, 1082

G418 resistance phenotype
 in vivo system to select for blood-stream-form transfectants, 1167

Trypanosoma congolense
Boran cattle
 diminazene pharmacokinetics, effect of infection on, 1050

quinapyramine resistant
 derivation and characterization, 1163

Trypanosoma cruzi
N,N'-bis(benzyl)-substituted polyamine analogs
 inhibition of host cell invasion and intracellular replication, 2235

ICI 195,739-terbinafine
 murine model, 1353

ketoconazole-terbinafine
 murine model, 1353

Trypanosoma (Schizotrypanum) cruzi
mevinolin
 ketoconazole and terbinafine, potentiation of antiproliferative effects, 580

Tuberculosis
 multidrug resistant
 studies with mice, 2344

Tumor necrosis factor
 murine models
 amphotericin B, 2228

receptors
 relation to therapy of typhoid fever, 2418

Tumor necrosis factor alpha
 amphotericin B, 1958
 C. albicans, 1958

Turbidimetric assays
 viable bacterial densities, quantitation of *E. coli*, 371

Typhoid fever
 ceftriaxone
 5 days, comparative evaluation, 1572

chloramphenicol
 14 days, comparative evaluation, 1572

ciprofloxacin
 severe, in children, 1197

interleukin-6, gamma interferon, and tumor necrosis factor receptors
 relation to outcome of antimicrobial therapy, 2418

severe
 ciprofloxacin, 1197

U-90152
 human immunodeficiency virus type 1 replication, inhibition of, 1127

Ureaplasma diversum
antimicrobial susceptibilities, 317

Ureaplasma urealyticum
OPC 17116
 susceptibility in vitro, 1726

Ureidopenicillins
F. oxytropis
 in vitro activities against clinical isolates from patients with cancer, 2504

Urinary tract infections
 acute uncomplicated
 lomefloxacin, 3 days, comparative evaluation, 574

 norfloxacin, 3 days, comparative evaluation, 574

cefozopran, 100

enoxacin
 cefoxime axetil, more rapid than, 1558
 rapid symptom alleviation, 1558

lomefloxacin
 3 days, comparative evaluation, 574

nitrofurazone
 catheter associated, 2033

norfloxacin
 3 days, comparative evaluation, 574

recurrent
 enoxacin, rapid symptom alleviation, 1558
 rapid symptom alleviation, 1558

Vancomycin
adherence
Staphylococcus spp., effect of subinhibitory concentrations on, 921

B. burgdorferi
 in vitro activity, 1115

E. faecalis
 β-lactamase producing, highly gentamicin resistant, 1447

 endocarditis, 1447

E. faecalis resistance gene
homology with *vanB*, *vanA*, and *vanC*, 1604

E. faecium resistance, 1904

 endocarditis, 2069

E. faecium resistance gene
homology with *vanB*, *vanA*, and *vanC*, 1604

gram-positive organism resistance
ramoplanin, 1364

gram-positive organisms, resistance
RP59500, 598

pharmacokinetics
obesity, effect on, 436

pulmonary lining fluid, penetration into, 281

serum protein-binding characteristics, 1132

pulmonary lining fluid
 penetration into, 281

“red man syndrome”
 skin tests to healthy volunteers, 2139

S. epidermidis
 diffusion through a biofilm, 2522

Staphylococcus spp.
 adherence, effect of subinhibitory concentrations on, 921

Visna virus
acyclic nucleoside phosphonate analogs
 inhibition of replication, 2540

2',3'-dideoxynucleosides
 inhibition of replication, 2540

WIN 54954
coxsackievirus
 group B diabetogenic strain in mice, 1593

rhinovirus
 prophylaxis, efficacy of, 297

WIN 57273
E. faecalis
 activity against high-level gentamicin-resistant strains, 2470

Yeasts
D0870
 in vitro activities, 2126

susceptibility testing
 broth macrodilution, 39

multicenter evaluation, 39

Zalcitabine
salmonellae
 in vitro activities, 106

Zidovudine
embryos, implantation of
 prevention of, 1610

human immunodeficiency virus resistance
 pol mutations, multiple resistance, 1480

human immunodeficiency virus type 1 sensitivity
 discontinuation of zidovudine treatment, effects on, 1525

pharmacokinetics

effects of standard breakfast in patients with AIDS, 2153
 granulocyte-macrophage colony-stimulating factor, administration with, 512
 prodrugs, enhanced levels in brain tissue

sue, 818
 rifampin, interaction with, 1426
 prodrugs
 pharmacokinetics, enhanced levels in brain tissue, 818
 rifampin

pharmacokinetic interaction with, 1426
 salmonellae
 in vitro activities, 106
 Zinc
T. foetus
 electron microscopic study, 2722



**Statement of Ownership,
 Management and
 Circulation**
(Required by 39 U.S.C. 3685)

| | | | | | | | | | | | | |
|---|---|--|---|--|--|--|--|--|--|--|--|--|
| 1A. Title of Publication Antimicrobial Agents and Chemotherapy | 1B. PUBLICATION NO. 0 0 6 6 4 8 0 4 | 2. Date of Filing 10-12-93 | | | | | | | | | | |
| 3. Frequency of Issue Monthly | 3A. No. of Issues Published Annually 12 | 3B. Annual Subscription Price \$49 mbr, \$250 nonmbr | | | | | | | | | | |
| 4. Complete Mailing Address of Known Office of Publication (Street, City, County, State and ZIP+4 Code) (Not printer) American Society for Microbiology 1325 Massachusetts Ave., N.W., Washington, D.C. 20005-4171 | | | | | | | | | | | | |
| 5. Complete Mailing Address of the Headquarters of General Business Offices of the Publisher (Not printer) (Same as above) | | | | | | | | | | | | |
| 6. Full Names and Complete Mailing Address of Publisher, Editor, and Managing Editor (This item MUST NOT be blank) Publisher (Name and Complete Mailing Address) (Same as above) | | | | | | | | | | | | |
| Editor (Name and Complete Mailing Address) Robert C. Moellering, Jr. (Address same as above) | | | | | | | | | | | | |
| Managing Editor (Name and Complete Mailing Address) Linda M. Illig (Address same as above) | | | | | | | | | | | | |
| 7. Owners if owned by a corporation, its name and address must be stated and also immediately thereunder the names and addresses of stockholders owning or holding 1 percent or more of total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated firm, its name and address, as well as that of each individual must be given. If the publication is published by a nonprofit organization, its name and address must be stated. (Item must be completed.) | | | | | | | | | | | | |
| <table border="1"> <tr> <td>Full Name</td> <td>Complete Mailing Address</td> </tr> <tr> <td>American Society for Microbiology</td> <td>1325 Massachusetts Ave., N.W. Washington, D.C. 20005-4171</td> </tr> <tr> <td> </td> <td> </td> </tr> <tr> <td> </td> <td> </td> </tr> <tr> <td> </td> <td> </td> </tr> </table> | | | Full Name | Complete Mailing Address | American Society for Microbiology | 1325 Massachusetts Ave., N.W. Washington, D.C. 20005-4171 | | | | | | |
| Full Name | Complete Mailing Address | | | | | | | | | | | |
| American Society for Microbiology | 1325 Massachusetts Ave., N.W. Washington, D.C. 20005-4171 | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| 8. Known Bondholders, Mortgagors, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages or Other Securities (If there are none, so state) | | | | | | | | | | | | |
| <table border="1"> <tr> <td>Full Name</td> <td>Complete Mailing Address</td> </tr> <tr> <td>None</td> <td> </td> </tr> <tr> <td> </td> <td> </td> </tr> <tr> <td> </td> <td> </td> </tr> <tr> <td> </td> <td> </td> </tr> </table> | | | Full Name | Complete Mailing Address | None | | | | | | | |
| Full Name | Complete Mailing Address | | | | | | | | | | | |
| None | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| 9. For Completion by Nonprofit Organizations Authorized To Mail at Special Rates (DMR Section 424.12 only) The purpose, function, and nonprofit status of this organization and the exempt status for Federal income tax purposes (Check one) | | | | | | | | | | | | |
| <table border="1"> <tr> <td>(1) <input checked="" type="checkbox"/> Has Not Changed During Preceding 12 Months</td> <td>(2) <input type="checkbox"/> Has Changed During Preceding 12 Months</td> <td>(If changed, publisher must submit explanation of change with this statement.)</td> </tr> </table> | | | (1) <input checked="" type="checkbox"/> Has Not Changed During Preceding 12 Months | (2) <input type="checkbox"/> Has Changed During Preceding 12 Months | (If changed, publisher must submit explanation of change with this statement.) | | | | | | | |
| (1) <input checked="" type="checkbox"/> Has Not Changed During Preceding 12 Months | (2) <input type="checkbox"/> Has Changed During Preceding 12 Months | (If changed, publisher must submit explanation of change with this statement.) | | | | | | | | | | |
| 10. Extent and Nature of Circulation <i>(See instructions on reverse side)</i> | Average No. Copies Each Issue During Preceding 12 Months | Actual No. Copies of Single Issue Published Nearest to Filing Date | | | | | | | | | | |
| A. Total No. Copies (Net Press Run) | 8,775 | 8,800 | | | | | | | | | | |
| B. Paid and/or Requested Circulation | | | | | | | | | | | | |
| 1. Sales through dealers and carriers, street vendors and counter sales | | | | | | | | | | | | |
| 2. Mail Subscription <i>(Paid and/or requested)</i> | 7,171 | 7,751 | | | | | | | | | | |
| E. Total Paid and/or Requested Circulation <i>(Sum of 10B1 and 10B2)</i> | 7,171 | 7,751 | | | | | | | | | | |
| D. Free Distribution by Mail, Carrier or Other Means Samples, Complimentary, and Other Free Copies | 110 | 110 | | | | | | | | | | |
| E. Total Distribution (Sum of C and D) | 7,281 | 7,861 | | | | | | | | | | |
| F. Copies Not Distributed | | | | | | | | | | | | |
| 1. Office use, left over, unaccounted, spoiled after printing | 1,494 | 939 | | | | | | | | | | |
| 2. Return from News Agents | | | | | | | | | | | | |
| G. TOTAL (Sum of E, F1 and 2—should equal net press run shown in A) | 8,775 | 8,800 | | | | | | | | | | |
| 11. I certify that the statements made by me above are correct and complete | Signature and Title of Editor, Publisher, Business Manager, or Owner <i>Linda M. Illig</i> Director, Journals | | | | | | | | | | | |

